 
Document Type:  Study Protocol  
Official Title:  A Randomized, Double -Blind, Placebo -Controlled Phase II Study 
to Investigate the Efficacy and Safety of Riociguat  in Patients 
With Diffuse  Cutaneous Systemic Sclerosis (dcSSc)  
NCT N umber:  [STUDY_ID_REMOVED]  
Document D ate: 17 Apr 2018  
 
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  1of 167
A Randomized, Double -Blind, Placebo -Controlled Phase II Study to 
Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse 
Cutaneous Systemic Sclerosis (dcSSc)
This protocol version is an integration of the following documents / sections:
Original protocol, Version 1.0, dated 04 SEP 2014
Amendment no. 1 (described in Section 13.1)
forming integrated protocol Version 2.0, dated 04 FEB 2015
Amendment no. 4 (described in Section 13.2)
forming integrated protocol Version 3.0, dated 24 FEB 2016
Amendment no. 5 (described in Section 13.3)
forming integrated protocol Version 4.0, date
d 31 AUG 2016
Amendment no. 6 (described in Section 13.4)
forming integrated protocol Version 5.0, dated 02 MAY 2017
Amendment no. 7 (described in Section 13.5)
forming integrated protocol Version 6.0, dated 17 APR 2018
This protocol has also been amended for specific countries:
Amendment no 2 (UK), dated 29 JAN 2015 (not submitted) .
Amendment no 3 (UK), dated 12 MAR 2015
These local amendments do not form part of this integrated global protocol.
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  2of 167
Title page -amended
A Randomized, Double -Blind, Placebo- Controlled Phase II Study to Investigate the 
Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis 
(dcSSc)
Riociguat in diffuse cutaneous systemic sclerosis ( dcSSc)
Test drug: BAY63 -
2521 / Riociguat 
Study purpose: Safety and efficacy
Clinical study phase: II Date: 17APR 2018
EudraCT 
no.: 2014-001353-16 Version no.: 6.0
Study no.: BAY 63 -2521 / 16277
Sponsor1:Non-US:Bayer AG, D-51368 Leverkusen, Germany
US territory: Bayer Healthcare Pharmaceuticals Inc., 100 Bayer 
Boulevard, P.O. Box 915, Whippany NJ 07981 -
0915, USA
Sponsor’s medical expert2:
Bayer Healthcare Company Ltd
Bayer Center, 
No.27, Dong San Huan North Road, Chaoyang District, 
Beijing, 100020 , China
Tel: 
Fax:
The study  will be conducted in compliance with the protocol, ICH-GCP and any  applicable 
regulatory  requirements.
Confidential
The information provided in this document is strictly  confidential and is intended solely  for 
the guidance of the clinical investigation.  Reproduction or disclosure of this 
document - whet her in part or in full - to parties not associated with the clinical 
investigation, or its use for any other purpose, without the prior written consent of the 
sponsor is not permitted.
Throughout this document, symbols indicating proprietary names ( , TM) may not be displayed.  Hence, the 
appearance of product names without these symbols does not imply that these names are not protected.
                                                
1Per Amendment 5
2Per Amendment 1
PPD
PPD
PPD
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  3of 167
Signature of the s ponsor’ s medically responsible person
The signatory  agrees to the content of the final clinical study  protocol as presented.
Name: Role:  Global Clinical Lead
Date: Signature:
PPD
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  4of 167
Signature of principal investigator
The signatory  agrees to the content of the final clinical study  protocol as presented.
Name:
Date: Signature:
Signed copies of this signature page are stored in the sponsor’s study  file and in the respective 
center’s investigator site file.
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  5of 167
Synopsis -amended
TitleA Randomized, Double- Blind, Placebo -Controlled Phase II Study to 
Investigate the Efficacy and Safety of Riociguat  in Patients With Diffuse 
Cutaneous Systemic Sclerosis ( dcSSc)
Short titleRiociguat in diffuse cutaneous sy stem ic sclerosis ( dcSSc)
Clinical study phaseII
Study objective(s)To evaluate the efficacy and safety of 52 w eeks of treatment w ith riociguat 
versus placebo in patients with diffuse cutaneous systemic sclerosis ( dcSSc)
Test drug(s)BAY 63 -2521 / Riociguat
Nam e of active ingredientBAY 63 -2521 / Riociguat
Dose(s)0.5mg, 1mg, 1.5 mg, 2mgand 2.5 mgadministered 3times a day ( TID);
dose titration starting with 0.5 mg(planned up -titration every 2 w eeks)
Route of administrationOral
Duration of treatm entTotal of 52weeks, consisting of a 10 -week titration period and 42 w eeks of 
maintenance. 
Reference drug(s)Placebo
Nam e of active ingredientNot applicable
Dose(s)Matching placebo tablet sto BAY 63 -2521 / Riociguat 0.5mg, 1mg, 1.5 mg, 
2mgand 2.5 mgadministered TID ; dose titration starting with 0.5 mg 
matching placebo tablet .
Route of administrationOral
Duration of treatm ent52weeks
Background treatm entNot applicable
IndicationdcSSc
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  6of 167
Diagnosis and main criteria for 
inclusionMen orwomen aged 18 years andolder
Disease duration of ≤ 18 months (defined as time from the first 
non−Raynaud ’sphenomenon manifestation), SSc as defined by 2013 the 
American College of Rheumatology ( ACR ) / European League Against 
Rheumatism ( EULAR )classification ,and presence of dcSSc based on L eroy 
criteria
≥ 10 and ≤ 22 modified Rodnan skin score (mRSS) units at the screening 
visit
Forced vital capacity (FVC) ≥ 45% of predicted at screening
Diffusion capacity of the lung for carbon monoxide (DL CO) ≥40% 
(hemoglobin -corrected) of predicted at sc reening
Wom en of childbearing potential must have a negative serum pregnancy test 
at the s creening visit.
Study designRandomized (1:1), double -blind, placebo -controlled , parallel -group , 
multicenter, multi national study
MethodologyThis study is designed to investigate the efficacy and safety of riociguat 
(0.5mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg TID) in patients with dcSSc.  The 
study consists of 2parts: a main treatment phase for efficacy and safety 
(placebo -controlled) and a long -term extension phase for collection of 
exploratory long -term outcomes .
Type of controlPlacebo 
Number of patientsUp to a pproximately 130 randomized patients3
Prim ary variableChange in mRSS from baseline to Week 52
Plan for statistical analysisThe change in mRSS from baseline to all assessments post baseline up to 
Week 52 w ill be analyzed using mixed model repeated measures (MMRM) 
with baseline mRSS as a covariate, fixed effects treatment arm and region, 
the interaction effect between study visi t and treatment arm, and 
patient -specific random effects.  The main estimand of interest is the 
treatment difference between the riociguat and placebo treatment arms at 
Week 52.
                                                
3Per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  7of 167
Protocol amendment summary of changes table
Amendment no. 7 ( 17APR 2018)
This amendment is considered to be non-substantial based on the criteria set forth in Article 
10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European 
Union because it neither significantl y impacts the safet y or physical/mental integrit y of 
participants nor the scientific value of the stud y.
Overall rationale for the amendment
Overall rationale: Theprotocol amendment 7 was prepared based on the main treatment phase 
results of the study
 to better characterize the enrolled patient population and their 
autoantibody  profile.
Thischange do esnot affect the design or the overall concept of the study .
In addition, a change of responsible Global Clinical Lead was made. 
Section # and name Description of change Brief rationale
Signature of the sponsor’s 
medically responsible person The Global Clinical Lead was 
updated to Change of responsible Global 
Clinical Lead
7.6.4 Autoantibody screen The addition of the anti -
centr omere was included in the 
autoantibod y screen .Further autoantibodies will 
allow better characterization of 
the enrolled patient population 
and their autoantibody profil e.
PPD
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  8of 167
Table of contents
Title page - amended ................................ ................................ ................................ ................ 2
Signature of the sponsor’s medically responsible person ..................................................... 3
Signature of principal investigator
......................................................................................... 4
Synopsis -amended .................................................................................................................. 5
Protocol amendment summary of changes table
................................................................... 7
Table of contents ....................................................................................................................... 8
Table of in-text tables ............................................................................................................. 12
Table of in -text figures ........................................................................................................... 12
List of abbreviations ............................................................................................................... 13
1.
Introduction ..................................................................................................................... 16
1.1 Background .................................................................................................................... 16
1.1.1 Scleroderma (s ystemic sclerosis) ................................................................................ 16
1.1.2 Riociguat ..................................................................................................................... 17
1.1.2.1
Mechanism of Action.............................................................................................. 17
1.1.2.2 Preclinical Data -amended ..................................................................................... 18
1.1.2.3
Clinical Data............................................................................................................ 19
1.2 Rationale of the study .................................................................................................... 19
1.3 Benefit -risk assessment 
-amended ................................................................................ 20
2.Study objectives -amended ............................................................................................ 21
3.Investigators and other study personnel -amended .................................................... 22
4.Study design ..................................................................................................................... 24
4.1 Design overview -amended ............................................................................................ 24
4.1.1 Screening phase (up to 2 weeks) ................................................................................ 26
4.1.2 Main treatment phase (Week 0 to Week 52) -amended ............................................ 26
4.1.3 Long -term extension phase ......................................................................................... 27
4.1.4
Dose Interruptions - amended ..................................................................................... 28
4.1.5 Termination visit and safety  follow -up visit 
-amended ............................................. 29
4.2 Primary  variable ............................................................................................................. 29
4.3 Justification of the design .............................................................................................. 29
4.4 End of study ................................................................................................................... 30
5.Study pop ulation ............................................................................................................. 30
5.1 Eligibility ....................................................................................................................... 30
5.1.1 Inclusion criteria -amended ....................................................................................... 30
5.1.2 Exclusion Criteria -amended ..................................................................................... 30
5.1.3 Justification of selection criteria ................................................................................. 32
5.2 Withdrawal of patients from study  -amended ............................................................... 33
5.2.1
Withdrawal - amended ................................................................................................ 33
5.2.1.1 Withdrawal from the study ...................................................................................... 33
5.2.1.2 Discontinuation of study  medication ....................................................................... 33
5.2.1.3 Handling of withdrawals or discontinuations from study  medication ....................
34
5.2.2 Replacement -amended .............................................................................................. 35
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  9of 167
5.3 Patient identification ................................ ................................ ................................ ...... 36
6.Treatment ......................................................................................................................... 36
6.1 Treatments to be administered ....................................................................................... 36
6.2 Identity  of study  treatment ............................................................................................. 36
6.3 Treatment assignment .................................................................................................... 37
6.4
Dosage and administration............................................................................................. 38
6.4.1 Selection of doses in the study  -amended .................................................................. 38
6.5 Blinding 
-amended ........................................................................................................ 38
6.6 Drug logistics and accountability ................................................................................... 39
6.7 Treatment compliance .................................................................................................... 39
6.8 Post-study  therapy .......................................................................................................... 40
6.9 Prior and concomitant therap y -amended ..................................................................... 40
7.Procedures and variables ............................................................................................... 43
7.1 Schedule of procedures .................................................................................................. 43
7.1.1 Tabulated overview -amended ................................................................................... 44
7.1.2 Timing of assessments ................................................................................................ 49
7.1.2.1 Visit 0 
Screening phase –Screening visit ............................................................ 49
7.1.2.2 Visit 1 
Main treatment phase -Baseline (Day  0, Week 0) ................................... 50
7.1.2.3 Visits 2 through to 6 Main treatment phase –Dose -
titration period - amended .. 51
7.1.2.4 Visits 7 through to 11 Main treatment phase -Maintenance period -amended .. 52
7.1.2.5 Visit 12 (Week 52) -amended ................................................................................ 53
7.1.2.6 Visits 13 through to 17 Long-term extension phase 
-Dose -titration period -
amended .................................................................................................................. 55
7.1.2.7 Visits 18 through Visit n (every  12 weeks) Long- term extension phase Open -
label extension period - amended ............................................................................ 55
7.1.2.8 Termination Visit -amended ................................................................................... 56
7.1.2.9 Safety  follow -up visit 
-amended ............................................................................ 57
7.1.2.10 Premature discontinuation of study  drug treatment -amended ...............................
58
7.2 Population characteristics .............................................................................................. 58
7.2.1 Demographic .............................................................................................................. 58
7.2.2 Medical history ........................................................................................................... 58
7.3 Efficacy  -amended ........................................................................................................ 58
7.4 Pharmacokinetics / pharmacod ynamics -amended ....................................................... 60
7.5 Safety ............................................................................................................................. 62
7.5.1 Adverse events ............................................................................................................ 62
7.5.1.1
Definitions - amended ................................ ................................ ............................. 62
7.5.1.2 Classifications for adverse event assessment .......................................................... 63
7.5.1.2.1 Seriousness ........................................................................................................... 63
7.5.1.2.2 Intensit y................................................................................................................ 63
7.5.1.2.3 Causal relationship ................................ ................................ ............................... 63
7.5.1.2.4 Action taken with study  treatment ....................................................................... 65
7.5.1.2.5
Other specific treatment(s) of adverse events...................................................... 65
7.5.1.2.6 Outcome ............................................................................................................... 65
7.5.1.3 Assessments and documentation of adverse events ................................................ 65
7.5.1.4
Reporting of serious adverse events ........................................................................ 65
7.5.1.5 Expected adverse events .......................................................................................... 66
7.5.1.6 Adverse events of special safet y interest ................................................................. 67
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  10of 167
7.5.1.7 Overdose of Study  Medication ................................ ................................ ................ 67
7.5.2 Pregnancies ................................................................................................................. 67
7.6
Other procedures and variables...................................................................................... 67
7.6.1 Pregnancy  testing ........................................................................................................ 67
7.6.2 Laboratory  parameters -amended ................................ ................................ .............. 68
7.6.3 Exploratory  Biomarkers -amended ............................................................................ 69
7.6.4 Autoantibody  screen ................................................................................................... 70
7.6.5 Blood pressure and heart rate measurement -amended ............................................. 70
7.6.6 Modified Rodnan skin scoring (mRSS) ...................................................................... 70
7.6.7 Electrocardiogram ...................................................................................................... 71
7.6.8 Pulmonary  function testing ......................................................................................... 71
7.6.9 Skin biopsy ................................................................................................................. 71
7.6.10 Digital ulcer net burden .............................................................................................. 72
7.6.11 Digital gangrene ......................................................................................................... 72
7.6.12 Raynaud’s attacks assessment .................................................................................... 73
7.6.13
Patient-reported outcomes (PROs) / Health- related quality  of life (HRQoL) 
questionnaires ............................................................................................................. 73
7.6.14 Tender and swol len joint count
.................................................................................. 74
7.6.15 Patient’s and phy sician’s global assessment 
-amended ............................................. 74
7.6.16
Patient interference with skin assessment .................................................................. 75
7.6.17 Tendon friction rubs ................................................................................................... 75
7.6.18 Oxygen saturation measurement using forehead pulse oximetry
............................... 75
7.7 Appropriateness of procedures / measurements ............................................................ 75
8.Statistical methods and determination of sample size ................................................. 75
8.1 General considerations ................................................................................................... 75
8.2 Analy sis sets 
-amended ................................................................................................. 76
8.3 Variables ........................................................................................................................ 76
8.4 Statistical and analy tical plans ....................................................................................... 76
8.4.1 Demographic and other baseline characteristics ........................................................ 76
8.4.2 Efficacy  -amended ................................ ................................ ................................ ..... 76
8.4.2.1 Primary  endpoint ................................ ................................ ................................ ..... 76
8.4.2.2 Secondary and exploratory endpoints ..................................................................... 78
8.4.3 Safety  
-amended ........................................................................................................ 80
8.4.4 Pharmacokinetics ........................................................................................................ 81
8.5 Planned interim anal yses -amended .............................................................................. 81
8.6 Determination of sample size 
-amended ....................................................................... 81
9.
Data handling and quality assurance ............................................................................ 83
9.1
Data recording................................................................................................................ 83
9.2 Monitoring ..................................................................................................................... 83
9.3 Data processing .............................................................................................................. 84
9.4 Audi t and inspection ...................................................................................................... 84
9.5 Archiving ....................................................................................................................... 84
10.Premature termination of the study .............................................................................. 85
11.Ethical and legal aspects ................................................................................................. 85
11.1 Ethical and legal conduct of the study ........................................................................... 85
11.2
Patient information and consent .................................................................................... 86
11.3 Publication policy .......................................................................................................... 87
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  11of 167
11.4 Compensation for health damage of patients / insurance ................................ .............. 87
11.5 Confidentiality ............................................................................................................... 87
12.Reference list -amended, ................................................................................................ 89
13.Protocol amendments ...................................................................................................... 93
13.1 Amendment 1 ................................................................................................................. 93
13.1.1 Overview of changes to the study ............................................................................... 93
13.1.2
Changes to the protocol text ....................................................................................... 93
13.2 Amendment 4 ............................................................................................................... 117
13.2.1 Overview of changes to the study ............................................................................. 117
13.2.2
Changes to the protocol text ..................................................................................... 117
13.3 Amendment 5 ............................................................................................................... 132
13.3.1 Overview of changes to the study ............................................................................. 132
13.3.2
Changes to the protocol text ..................................................................................... 133
13.4 Amendment 6 ............................................................................................................... 146
13.4.1 Overview of changes to the study ............................................................................. 146
13.4.2
Changes to the protocol text ..................................................................................... 146
13.5 Amendment 7 ............................................................................................................... 164
14.Appendices ..................................................................................................................... 165
14.1 Child -
Pugh Classification of L iver Disease ................................................................. 165
14.2 Definition of Sy stemic Sclerosis Renal Crisis -amended ........................................... 166
14.3 Tender and Swollen Joint Count Assessment Form .................................................... 167
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  12of 167
Table of in -text tables
Table 6–1 Identity  of investigational product ........................................................................ 37
Table 6
–2Prohibited prior and concomitant therapy  -amended ........................................... 41
Table 7
–1Schedule of evaluations -amended ....................................................................... 44
Table 7
–2Profile Day  PK Sampling (Visit 1 and Visit 12) ................................................... 48
Table 7
–3 PK Sampling (Visits 2 – 6 and Visits 13 – 17) ..................................................... 48
Table 7
–4 PK Sampling (Visit 11) ......................................................................................... 49
Table 8–1 References for estimate of variability ................................................................... 82
Table 8
–2Power calculations: power vary ing from 70% to 80% in 2% stages ..................... 82
Table of in -text figures
Figure 4 –1Main treatment phase design ................................................................................. 25
Figure 4 –2Long -term extension phase design ................................ ................................ ........ 25
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  13of 167
List of abbreviations
ACR American College of Rheumatology
ADMA asymmetrical dimethy larginine
AE adverse event
ALT alanine aminotransferase (also known as SGPT, qv)
ANCOVA analysis of covariance
AP alkaline phosphatase
aPTT activated partial thromboplastin time
AST aspartate aminotransferase (also known as SGOT, qv) 
ATC Anatomical Therapeutic Chemical
AUC area under the plasma concentration versus time curve
BMI body  mass index
BP blood pressure
BPM beats per minute
cGMP cyclic guanosine monophosphate
CK creatine kinase
Cmax maximum plasma concentration
COL 1A1 collagen t ype 1 alpha 1
COL 1A2 collagen t ype 1 alpha 2
COL 3A1 collagen t ype 3 alpha 1
COMP cartilage oligomeric matrix protein
CREST calcinosis, Ray naud’s phenomenon, esophageal dy smotility , 
sclerodacty ly, and telangiectasias
CRISS (American College of Rheumatology ) Composite Response Index for 
Clinical Trials
CRO clinical research organization
CSRG Canadian Scleroderma Research Group
CTEPH chronic thromboembolic pulmonary  hypertension
CXCL -4 platelet factor -4
CYP cytochrome P450
DBP diastolic blood pressure
dcSSc diffuse cutaneous s ystemic sclerosis
dL Deciliter
DL CO diffusion capacity of the lung for carbon monoxide
DMC data monitoring committee
EC Ethics Committee  
ECG Electrocardiogram
eCRF electronic case report form
eg exempli gratia , for example
eGFR estimated glomerular filtration rate
EU European Union
EULAR European League Against Rheumatism
EUSTAR EULAR Scleroderma Trials and Research
FAS full analy sis set
FDA Food and Drug Administration
FVC forced vital capacity
g Gram
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  14of 167
GCP Good Clinical Practice
GGT gamma glutam yl transpeptidase
GLDH Glutamate deh ydrogenase
GMP Good Manufacturing Practice
h Hour
HAQ- DI Health Assessment Questionnaire disability  index
HDPE high densit y polyeth ylene
HPF High power field
HR heart rate
HRCT High resolution computed tomograph y
HRQoL health- related quality  of life
hsCRP high-sensitivity  C-reactive protein
IB investigator’s brochure
ICH International Conference on Harmonization
ie id est, that is
IEC independent ethics committee
IHC Immunohistochemistry
ILD Interstitial lung disease
IND Investigational New Drug
INR international normalized ratio (prothrombin time expressed in relation 
to normal value)
IRB institutional review board
ITT intent to treat
IxRS telephone -based or web- based response s ystem
L Liter
lcSSc limited cutaneous sy stemic sclerosis
LPLV Last Patient Last Visit
m2square meter
MCP Metacarpophalangeal joint
MDRD modification of diet in renal disease
MedDRA Medical Dictionary  for Regulatory  Activities
mg Milligram
min Minute
mL Milliliter
mol Molarity
mmHg millimeter sof mercury
MMRM mixed model repeated measures
mRNA messenger ribonucleic acid
mRSS modified Rodnan skin score
NO nitric oxide
NSAID nonsteroidal anti-inflammatory  drug
PAH pulmonary  arterial hy pertension
PD pharmacod ynamics
PDE Phosphodiesterase
PDE5 phosphodiesterase 5
p-ERK phosphory lated extracellular regulated kinase
P
-gp P-glycoprotein
PIP Proximal interphalangeal joint
PK pharmacokinetic(s)
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  15of 167
popPK population PK
PPS per protocol set
PRO patient -reported outcome (s)
PROMI S Patient- Reported Outcomes Measurement Information Sy stem
p-VASP phosphory lated vasodilator -stimulated phosphoprotein
RBC red blood cells
s Second
SAE serious adverse event
SAP statistical analy sis plan
SAS Statistical Analy sis Sy stem
SBP systolic blood pressure
SD standard deviation
SDMA symmetrical dimethy larginine
sE-Selectin soluble E -selectin
SF-
36 Short Form 36
SFU safet y follow-up
sGC soluble guan ylate cy clase
SHAQ Scleroderma Health Assessment Questionnaire
SNAP S-nitroso-N- acetyl-penicillamine
sPECAM-1 soluble platelet endothelial cell adhesion molecule
SpO2 peripheral ox ygen saturation
SSc systemic sclerosis
SUSAR suspected unexpected serious adverse reaction
TEAEs treatment -emergent AEs
TGF - transforming growth factor -beta
TID ter in die , 3 times a day
TSP1 thrombospondin 1
TV termination visit
UCL A SCTC GIT University  of California, Los Angeles, Scleroderma Clinical Trial 
Consortium Gastrointestinal Scale
UK United Kingdom
ULN Upper limit of normal
US/ USA United States/ United States of America
VAS visual analog scale
WBC white blood cell
WHO -DD World Health Organization Drug Dictionary
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  16of 167
1. Introduction
1.1 Background
1.1.1 Scleroderma (systemic sclerosis)
Systemic sclerosis (SSc) is a rare, orphan disease featuring chronic, fibrosing, autoimmune 
responses characterized by  small vessel vasculopathy , autoantibody  production, and fibroblast 
dysfunction leading to inc reased deposition of extracellular matrix.[ 1] 
Systemic sclerosis is further divided into 2 subty pes defined b y the extent of skin 
involvement: limited cutaneous s ystemic sclerosis (lcSSc) and diffuse cutaneous sy stemic 
sclerosis (dcSSc).[ 2]  According to LeRo y and colleagues, classification aslimited or diffuse 
disease is based on the extent of skin tightening.[ 3]  In limited disease (formerly  called 
CREST [calcinosis, Ray naud's phenomen
on, esophageal d ysmotility , sclerodact yly, and 
telangiectasias] sy ndrome), skin tightening is confined to the fingers, hands, and forearms 
distal to the elbows, with or without tightening of skin of the feet and of the legs distal to the 
knees. Proximal e xtremities and the trunk are not involved.  I n dcSSc, the skin of the 
proximal extremities and trunk is also involved.  Both dcSSc and lcSSc are associated with 
internal organ involvement; however, patients with dcSSc are at greater risk for clinicall y 
significant major organ dy sfunction. Diffuse cutaneous SSc is one of the most fatal rheumatic 
diseases, and is associated with substantial morbidity  and man y detrimental effects on 
health- related quality  of life (HRQoL) .
Systemic sclerosis is an orphan disease with an estimated prevalence of 50,000 in Europe and
276/106patients in the United States of America (USA).[4] With a 2010 US Acensus of 
309million people, there are < 100,000 patients in the 
USAwith SSc. Approximately  60% 
have limited SSc and 35 to 40% have diffuse SSc.
The tissue fibrosis in SS c is caused b y an increased production of extracellular matrix 
components by  activated fibroblasts [ 5] and affects the skin and various internal or gans such 
as the heart, lungs, kidneys and gastrointestinal tract.  Tissue fibrosis contributes significantl y 
to the high morbidity  and the increased mortality  of SSc.[ 6] The vascular alterations show a 
predilection for the small arteries and arterioles.  Vascular d ysfunction (ie, Ray naud’s 
phenomenon) is one of the earliest alterations of SSc and may  represent the initiating event in 
its pathogenesis.  Severe alterations in small blood vessels of skin and internal organs, 
including fibrosis and perivascular cellular infiltration with diverse inflammatory  cells, are 
almost alway s present in SSc.
Survival in SSc is dependent on the extent of internal organ involvement and the disease 
course.[ 2]  Because internal organ and skin involvement aremore extensive and progress 
faster in dcSSc compared to lcSSc, the average 6- year survival rate is 50% in lcSSc comp ared 
to30% in dcSSc. Twelve -year survival is 50% for lcSSc and 15% for dcSSc.[ 3] Death is 
generall y attributed to progressive pulmonary fibrosis, pulmonary h ypertension, extensive 
gastrointestinal deterioration, and scleroderma heart disease.  Except when pulmonary  
hypertension develops, limited disease is associated with a be tter prognosis.
No definitive diagnostic test for SSc is available; therefore, several diagnostic classifications 
have been developed.  Until recently , the standard classification used for diagnosis was the 
1980 preliminary  criteria for the classification 
of SSc, developed by  the American College of 
Rheumatology  (ACR).[ 7]  Due to concern regarding the sensitivity  of the 1980 criteria ,as 
well as advan ces in knowledge about SSc in the past 30+ y ears, the ACR and the European 
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  17of 167
League Against Rheumatism (EUL AR) established a committee to provide a joint proposal 
for new classification criteria for SSc.  The goals of the committee were to develop criteria 
that 1) encompass a broader spectrum of SSc, including patients whose disease is in the earl y 
stage as well as those in the late stage; 2) include vascular, immunologic, and fibrotic 
manifestations; 3) are feasible to use in daily  clinical practice; and 4) are in accordance with 
criteria used for diagnosis of SSc in clinical practice.  The updated classification criteria were 
published in 2013.[ 1]  Usi ng consensus methods, the committee determined that skin 
thickening of the fingers extending proximal to the metacarpophalangeal joints is sufficient 
for the patient to be classified as having SSc; if that feature is not present, the following 
7additive items can be used, with vary ing weights for each: skin thickening of the fingers, 
fingertip lesions, telangiectasia, abnormal nailfold capillaries, interstitial lung disease or 
pulmonary  arterial hy pertension ( PAH ), Ray naud’s phenomenon, and SSc -related 
autoantibodies.
Currently , no therapy  has been prove nto reverse the vascular and fibrotic damage in patients 
with scleroderma.[ 2]  However, due to the high medical need, a number of drugs, such as 
methotrexate, my cophenolate mofetil, cy clophosphamide, azathioprine, and cy closporine, are 
used off -label in an attempt to slow the progression of fibrosis. Current treatment options only  
target vari ous SSc -related sy mptoms. No disease -modify ing drug is available for SSc. In the 
European Union ( EU), only  bosentan is approved “to reduce the number of new digital ulcers 
in patients with SSc and ongoing digital ulcer disease
,” thus addressing also only one aspect 
of the disease. 
Based on the positive results of riociguat in patients with PAH and chronic thromboembolic 
pulmonary  hypertension (
CTEPH )together with the compound ’s known anti -proliferati veand 
antifibrotic effects as seen in vitro and in animal models, patients with SSc may  benefit from 
treatment with riociguat.
The current study  will be the first study  testing riociguat in this indication.  The efficacy  and 
safet y of riociguat in patients with dcSSc will be evaluated.
1.1.2 Riociguat
1.1.2.1 Mechanism of Action
Riociguat is the first- in-class of a new group of compounds, soluble guan ylate cy clase (sGC) 
stimulators. Riociguat directly stimulates sGC, thereb y increasing levels of the signaling 
molecule cyclic guanosine monophosphate ( cGMP ). The cGMP molecule plays a pivotal role 
in regulating cellular processes, such as vascular tone, proliferation, fibrosis, and 
inflammation. Two key  features of riociguat include: 1) it directl y stimulates sGC 
independentl y of nitric oxide (NO), and 2) it sensitizes sGC to low levels of NO. Because of
thebroad spectrum of cGMP actions and specific mode of action of riociguat , the efficacy  of 
sGC stimulators for the treatment of patients with SSc was investigated. Both, the vascular 
effects of riociguat and the direct antifibrotic effects could be beneficial for the treatment of 
patients with SSc . More specificall y, it was shown that sGC stimulators decrease collagen 
production in dermal fibroblasts from SSc patients.[ 8] In addition, sGC stimulators block 
fibroblast to my ofibroblasts differentiation of dermal fibroblasts .[9]Thus, sGC stimulators 
could block production of collagen and extracellular matrix components, which may explain , 
at least in part , the antifibrotic effects of sGC stimulators.
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  18of 167
1.1.2.2 Preclinical Data -amended
To support the use of riociguat for treatment of SSc, in vitro and in vivo investigations were 
undertaken, providing ample evidence of beneficial effects of cGMP elevation and the 
potential of sGC stimulators in the treatment of fibrotic diseases.
In vitro evidence for antifibrotic effects of cGMP elevation in the skin, which is a prerequisite 
to the effects of sGC stimulators for the treatment of SSc, includes the following findings:
Collagen production was evaluated in human dermal fibroblasts derived fro m 
hypertrophic scars as well as from normal cells from the patient’s donor site.  
Collagen production in fibroblasts, regardless of source, was substantially  stimulated 
by TGF -β1(transforming growth factor -beta)exposure. Increase of cGMP by  either 
the NO donor SN AP (S- nitroso-N- acetyl-penicillamine )or the cGMP analog 8-
Bromo -cGMP offset the stimulation of collagen production [10]
sGC stimulation dose -dependently  inhibited collagen mRNA expression and collagen 
release in dermal fibroblasts from SSc patients
.[8,9]
In vivo evidence for anti- fibrotic effects of cGMP elevation in fibrotic diseases includes t he 
following:
In a mouse model of pulmonary  fibrosis, daily  administration of riociguat ameliorated 
pulmonary  inflammation and fibrosis and improved survival 
[11]
In a rat model for h ypertension and organ damage, riociguat significantly ameliorated 
fibrotic tissue remodeling and degeneration in hearts and kidney s
.[12,13]
To further evaluate the treatment potential of riociguat for SSc, riociguat was tested in 2
widely  accepted mouse models for SSc, namely  the a) bleom ycin-induced skin fibrosis model, 
which r esembles an earl y, inflammatory -driven stage of SSc and b) in the TSK -
1 model 
which resembles a later, non -inflammatory , stage of the SSc. 
As also the vascular effects of riociguat could be beneficial for the treatment of patients with 
SSc, especially  with regard to prevention and healing of digital ulcers. To this end, wound 
healing was analy zed in the TSK -1 skin fibrosis mouse model. 
In summary , investigations of the anti- fibrotic efficacy  of sGC stimulators riociguat and 
BAY 41-2272, another sGC compou nd4,showed that these agents act dose-dependentl y:
reduced collagen production in human dermal fibroblasts  
reduced fibroblast -to-myofibroblast differentiation of human dermal fibroblasts
prevented TGF -ß-induced skin fibrosis in vivo
prevented skin fibro sis in bleomy cin model
reduced established skin fibrosis in genetic TSK- 1 model
promoted wound healing in TSK -1 mice.
                                                
4Per Amendment 1
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  19of 167
1.1.2.3 Clinical Data
Riociguat was recently  approved in a number of regions / countries including the USA,
Canada, Switzerland, Australia, Europe, Turkey , South Korea and Japan, for the treatment of 
2forms of pulmonary  hypertension: PAH and /orCTEPH .
Further details can be found in the investigator's brochure (IB), which contains 
comprehensive information on the study  drug.
1.2 Rationale of the study
Diffuse cutaneous SSc is one of the most severel y incapacitating and life- threatening 
rheumatic diseases. Fibrosis of the skin and internal organs is a hallmark of the disease and 
the progression of the fibrosis disrupts tissue architecture and causes organ failure, resulting 
in high morbidity  and mortality  among patients with SSc.
Based on preclinical in vitro and in vivo data demonstrating that riociguat was safe and 
efficacious in different models of fibrotic diseases including scleroderma, the hy pothesis is 
that riociguat may  bring significant clinical benefit to patients with scleroderma b y acting not 
only by improving vascular disease but, most importantly , by its inhibition of bio chemical 
fibrotic pathway s.[8]Based on the preclinical data, it is anticipated that riociguat may  slow 
down the progression of the fibrotic disease b y acting throu gh TGF -mediated pathways and, 
by its vasoactive properties, decrease the number and severit y of Raynaud’s attacks as well as 
decrease digital ulcer net burden.
This study  aims to recruit patients with dcSSc.  The rationale is: a) there is a better 
understanding of the natural history  of dcSSc than lcSSc, and b) 
dcSSc is a subset of SSc in 
which more rapid progression in disease occurs with worse prognosis , and wh ere there is a 
high unme t need for effective treatment.
To better design this study
with regard to theinclusion criteria ,a recent study  [14]was taken 
into consideration and predictive parameters were identified 
for the progression of skin 
fibrosis within 1 year in patients with dcSSc. An observational study  using the EUSTAR 
(EULAR Scleroderma Trials and Research) database was assessed. Worsening of skin 
fibrosis was defined as increase in modified Rodnan skin score (mRSS) > 5 points and ≥ 25% 
from baseline to the second visit. Inclusion criteria were dcSSc, ACR criteria fulfil led, mRSS
≥7 at the baseline visit, valid data for mRSS at the second visit, and available follow up of 
12 (±2)months. In the univariate analy sis, patients with progressive fibrosis were compared 
to non-progressors and predictive markers with p< 0.2 were included in the logistic regression 
analysis. The prediction models were then validated in a second cohort.
A total of 637 dcSSc patients were eligible. Univariate anal yses identified joint sy novitis, 
short disease duration (≤ 15 months), short disease duration in females/patients without 
creatine kinase ( CK) elevation, low baseline mRSS (≤22/51), and absence of esophageal 
symptoms as potential predictors for progressive skin fibrosis. In the multivariate anal ysis, by  
employ ing combinations of the predictors, 17 models with vary ing prediction success were 
generated, allowing cohort enrichment from 9.7% progressive patients in the whole cohort to 
44.4% in the optimized enrichment cohort. Using a second validation cohort of 188 dcSSc 
patients, short disease duration, low baseline mRSS ,and joint sy novitis were confirmed as 
independent predictors of progressive skin fibrosis within 1year showing a 4.5
-fold increased 
prediction success rate.
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  20of 167
From the 17 models generated b y the multivariate anal ysis,the combination of 2predictors, 
short disease duration, and low baseline mRSS, which allowed for a cohort enrichment of 
around 20%, was chosen.
1.3 Benefit-risk assessment -amended
Diffuse cutaneous s ystemic sclerosis is a progressive ,rare, orphan disease characterized b y 
vasculopath y (Ra ynaud’s phenomenon, digital ulcers) and progressive fibrosis of the skin and 
internal organs, ultimately  leading to death.  There are currentl y no disease -speci fic 
pharmacotherapies approved ,and there fore, there is a high unmet medical need in this 
indication . 
Considering the mechanism of action of riociguat and the results of the preclinical studies 
demonstrating beneficial effects of riociguat in a) decreasing collagen s ynthesis by  dermal 
fibroblast s, b) inhibiting fibroblast to my ofibroblast differentiation, c) decrease in skin 
thickness in in vivo models ,and d) improving wound healing in the skin of an animal model, 
the hy pothesis is that riociguat treatment may  bring the following benefits to pat ients with 
dcSSc:
Antifibrotic effect, as measured b y a treatment effect between verum and placebo, as 
measured b y the mRSS and by change from baseline in skin thickness;
Decrease number and sever
ity of Ray naud’s attacks;
Decrease digital ulcer net burden.
Additional benefits that may  occur include reduction in arthralgia and joint tenderness and 
slowing the progression of internal organ fibrosis.
Relevant risks for the dcSSc population may be unmasking of pulmonary  vascular occlusive 
disease, h ypotension, gastrointestinal motility  disorders, serious bleeds ,and embry o-fetal 
toxicity .
During the pivotal riociguat PATENT- 1 trial for PAH, patients with PAH -SSc were included 
and the overall benefit- risk profile was positive.
Taking into account the seriousness of the disease as well as the medical need for an effective 
and safetherapy , on balance the expected benefit to patients with this life -threatening 
condition outweighs potential risks.
Recently , a potential safety  issue has been reported for patients with pulmonary  hypertension 
associated with idiopathic interstitial pneumonias (PH- IIP) and ,therefore , the benefit-risk 
assessment for this indication has changed from positive to unfavorable . Following the data 
monitoring committee (DMC) recommendation ,the study  treatment has been terminated. 
Also per DMC recommendation patients are continuing in a safet y follow-up for 4 months 
after stud y drug discontinuation and the study is expected to close in September 2016. 
A careful review, assessment and anal ysis wi ll be done by  the sponsor with unblinded and 
clean data originating from clinical study  13605 (RISE-IIP; final clinical study report 
expected in 2017). Information of h ealth care professionals ( via Dear Healthcare Professional 
Letter), label updates and anupdate of the risk management plan have been initiated in 
July 2016 in collaboration with the European Medicines Agency as well as national 
competent authorities .
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  21of 167
The benefit -risk profile for conditions being studied in ongoing clinical studies also has been 
carefully  re-evaluated. In the case of the present study  in the dcSSc indication, 2ad-hoc 
meetings of the DMC for this study  took place, on 23 MAY 2016 and on 25 MAY 2016, 
followed b y a third meeting on 15 AUG 2016. The DMC concluded that this study  may 
continue without amendment or modification. Overall, the benefit -risk balance for this 
indication remains positive.5
2. Study objectives -amended
The overall objective sof this study  are toevaluate the efficacy  and safety  of 52 week sof 
treatment with riociguat versus placebo in patients with dcSSc.
The primary  objective of this study  is:
To assess the efficacy  of riociguat admi nistered 
3 times a day  (TID)as compared with
placebo in terms of change in the mRSS from baseline to Week 52
The secondary  objective sof this study  are to assess the efficacy  of treatment with riociguat 
administered TID as compared with placebo in terms of : 
Efficacy6:
oKey secondary  objective:
American College of Rheumatology  Combined Response Index for 
Systemic Sclerosis (CRISS) at Week 52.7
oFurther secondary  objectives:
Health Assessment Questionnaire disability  index (HAQ -DI) domain 
(separatel y from the Scleroderma Health Assessment Questionnaire 
[SHAQ ]
as part of the calculation of the CRI SS algorithm)
Patient ’s global assessment
Physician’s global assessment
Change in FVC (forced vital capacit y) % predicted 
Further clinical outcomes (to be adjudicated b y an Independent Central Adjudication 
Committee) :
oNew renal crisis
oWorsening of cardiac disease , defined as new or worsened clinically  
symptomatic and significant heart disease, considered secondary  to dcSSc, 
including congestive heart failure requiring hospitalization, new onset 
pulmonary  hypertension requiring treatment, pericardial disease requiring 
intervent ion or exhibiting clinical decompensation, and arrh ythmias and/or 
conduction defects requiring treatment
oWorsening of gastrointestinal disease requiring hospitalization or new 
requirement for parenteral nutrition
                                                
5Per Amendment 5
6Per Amendment 4
7Per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  22of 167
oCritical digital ischemia requiring hospita lization , or digital gangrene
Additional information regarding the events to be adjudicated may  be requested to be sent to 
the Adjudication Committee.  All events listed above, in addition to all cases of death, 
regardless of causality  or seriousness will be reviewed b y the Adjudication Committee.
3. Investigators and other study personnel -amended
Sponsor’s medical expert8:
Name:
Address: Bayer Healthcare Company  Ltd
Bayer Center, 
No.27, Dong San Huan North Road, Chao yang District, 
Beijing, 100020, China
Tel: 
Fax:
Coordinating investigator s:
Title/Name: 
Address: 
 USA 
Telephone No:  
Fax No:
Title/Name: 
Address : 
Switzerland
Telephone No:
All other study  personnel not included in this section are identified in a separate personnel list 
(not part of this clinical study  protocol) as appropriate.  This list will be updated as needed; an 
abbreviated version with personnel relevant for the centers will be available in each center’s 
investigator sit e file.
                                                
8Per Amendment 1
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  23of 167
Whenever the term “investigator” is noted in the protocol text, it may  refer to either the 
principal investigator at the site or an appropriately  qualified, trained ,and delegated 
individual of the investigative site.
The principal investigator of each center must sign the protocol signature sheet before patient 
recruitment may  start at the respective center.  Likewise, all protocol amendments/integrated 
protocols must be signed and dated b y the principal investigator b efore becoming effective at 
the respective center.
Acomplete list of all participating centers and their investigators, as well as all required 
signature documents, will be maintained in the sponsor study  file.
External data evaluation bodies
The independent DMC will be involved in the review of data for safet y.  Detailed information 
on the roles and responsibilities of the DMC will b e described in the DMC Charter.
Blinded adjudication of further clinical outcomes as described in Section 2will be performed 
by an independent C entral Adjudication C ommittee as described in the Adjudication 
Committee charter. 
Integrated Clinical Study Protocol
No. BAY 63 -2521 / 16277
17 APR 2018 Version 6.0 Page:  24of 167
4. Study design
4.1 Design overview -ame nded
In this multinational, multicenter, randomized (1:1), double -blind, placebo -controlled ,
parallel -group study , a total of approximately  200 patients are planned for enrollment in order 
to randomize 
up to9approximately  130 patients to study  drug treatment (approximately  65
patients to 
theriociguat group and 65to the placebo group).
The study  design consists of a main treatment phase followed by  a long -term extension phase 
as follows (seeFigure 4–1andFigure 4–2):
Screening phase: up to 2weeks
Main treatment phase:   52weeks of double -blind treatment , consisting of:
oDosetitration period of up to 10 weeks
oMaintenance period of up to 42 weeks 
Long -term extension phase
oDose -titration period of up to 10 weeks (double -blind)
oOpen -label extension period
Termination visit and safety f ollow -up visit
                                                
9Per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
16 APR 2018 Version 6.0 Page:  25of 167
Figure 4–1 Main treatment phase design
Abbreviations:  V = visit; R = randomization; TID = 3 times a day.
Figure 4
–2 Long -term extension phase design
Abbreviations:  TID = 3 times a day ; V = visit .

Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  26of 167
4.1.1 Screening phase (up to 2 weeks)
After providing written informed consent, patients will undergo a screening evaluation to 
determine their eligibility (see Section 7.1for adetailed schedule of assessments).  Patients 
will complete a diary  including detail s on the number and duration of Ray naud’s attacks per 
day for a period of 7 consecutive days leading up to Visit 1 / Day  0.
4.1.2 Main treatment phase (Week 0 to Week 52) -amended
At the baseline visit, patients who have met all of the inclusion and none of the exclusion 
criteria will be randomized viaatelephone -based or web- based response sy stem ( IxRS)to 
receive treatment with either active study  drug (riociguat) or placebo (Day  0, Visit 1).
Dose -titration p eriod (Visits 1 to 6)
During the first 10 weeks of the main treatment phase , patients will undergo dose titration.
The starting dos age is 0.5mg TID. The dose should be increased by  0.5 mg increments no 
sooner than 2 weeks apart to 1 mg, 1.5 mg, 2 mg, and 2.5 mg T ID, resulting in a maxim um
total daily  dose of 7.5 mg.  Patients will be maintained on a lower dose if higher doses are not 
tolerated (minimum dosag e of 0.5 mg TID, total daily dose 1.5 mg ;see Section 5.2.1).
To maintain blinding of the treatment arms, p atients randomized to the 
placebo group will 
undergo sham titration from Visit 1 onwards during the dose -titration period according to the 
rules of the dose titration scheme. At Visit 6, the last visit of the Titration Phase, no further 
increase in study  medication will be possible (seeFigure 4–1)10.
Dose titration algorithm
The study  medication dose forthe 
next titration step will be determined every  2weeks 
according to the patient’s well -being and the peripheral s ystolic blood pressure (SBP) 
measured at trough before intake of the morning dose as well as based on any ofthe 
2measurements (supine or sitting) performed 2 hours after dose intake to assess orthostatic 
changes11according to the following algorithm (dose titration scheme):
If SBP is ≥ 95 mmHg and the patient has no signs or sy mptoms of hy potension , the
dosage should be increased by  0.5mg TID .
If SBP is< 95 mmHg ,thedosage should be maintained provided the patient does not
show an y signs or s ymptoms of hy potension.
If SBP is< 95 mmHg, and the patient exhibits signs or sy mptoms of hy potension , the
current dos age should be decreased b y 0.5 mg TID .
During the dose -titration period a dose reduction can be performed according to patient well -
being / safet y concerns at investigator’s discretion irrespective of SBP. If the investigator 
requests an increase or decrease in stud y medication dose via I xRS, the subsequent dose 
modification will not exceed ± 0.5 mg TID. Dose increase s are allowed after a down -titration 
provided it is not done sooner than two weeks apart.
                                                
10Per Amendment 4
11Per Amendment 6
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  27of 167
Maintenance period (Visits 7 to 1 2)
The overall duration of the main treatment phase is 52weeks , including the dose titration 
period
.At the end of the dose titrat ion period ( Week 10) the patient’s maintenance dose will 
be determined using the treatment algorithm above. No further increase in dose will be 
allowed.  The established dose will then be taken as the “optimal dose” to be administered for 
the remaining du ration of the main treatment phase (up to Week 52).
Dose reductions for safety  reasons ( eg,in case of any  treatment -emergent adverse event
[TEAE] ) are allowed, but a subsequent dose increase during the maintenance period is not 
permitted .
From Week 26 (Visit 10), patients will have the opportunity  to add “ rescue12therap y”, 
consisting of immunosuppressant drugs, to their randomized study  medication if they  meet
certain criteria for worsening skin or pulmonary  disease.  Please refer to Section 6.9 for 
further details.
4.1.3 Long
-term extension phase
At Visit 12 (Week 52), patients randomized to the placebo arm in the main treatment phase 
will initiate active treatment with riociguat , as part of the long- term extension phase . During 
the first 10 weeks, a titration/sham- titration will be performed to maintain the study  blind, 
after which the extension phase become s open- label. During the extension phase, clinical 
outcomes will continue to be measured for exploratory  long -term treatment effects. Adverse 
event information will continue to be collected during the extension phase as we ll.
The long-term extension phase will continue up to 6 y ears after the L ast Patient L ast Visit 
(LPLV) in the main treatment phase. Subsequent treatment should be discussed between the 
patient and his/her doctor during the final visit at the end of the ex tension phase . At the end of 
this study , it is expected that the patient will receive standard treatment at the discretion of the 
physician.
Dose -Titration period (Visits 1 2to 17; Week 52 to 62)
At Visit 12 (Week 52), all patients will be assigned in I xRS to treatment with riociguat. To 
maintain the study  blinding, neither the patient’s prior treatment assignment nor dose will be 
unblinded. During the first 10 weeks of the long- term extension phase, patients previously  on 
placebo will be up- titrated on riociguat according to the dose titration algorithm described 
above in the main treatment phase (Section 4.1.2). Patients randomized to riociguat in the 
main treatment phase will undergo sham titration to maintain the blinding during this period
.
Open -label Extension period (Visit 18; Week 64 onward)
After completing the double- blind dose -titration p eriod , from Week 6 4onwar dsthe study  is 
open -label and the investigator will be able to see the current treatment dose. All patients will 
return to the clinic for visits every  3 months ± 2 weeks. Ongoing titration of riociguat within 
the range of 0.5 mg to 2.5mg TID will remain at the discretion of the investigator , and dose 
reductions for safet y reasons are allowed. 
                                                
12Per Amendment 1
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  28of 167
4.1.4 Dose Interruptions -amended
Although not intended, patients may interrupt their intake of study  medication forvarious 
reasons ( eg,hospitalization in a remote ho spital without study  medication access, safet y 
reasons or side effects). If treatment is interrupted, the following rules should be applied:
Main treatment phase:
≤3 consecutive day s without treatment (9 missing doses) in the dose -titration period:  
resta rt at the same dose
>3 consecutive day s in the dose -titration period: discontinue13the patient from study  
medication
>3 day s but ≤14 consecutive day s without treatment during the maintenance phase: 
treatment can be restarted at the discretion of the investigator at 0.5 mg TID lower 
than the last dose 
>14 consecutive day s without treatment in the maintenance phase: discontinue14the 
patient from study  medication.
Long -term extension phase:
≤3consecutive day s without treatment (9 missing doses) in the dose -titration period:  
restart at the same dose
>3days but ≤14 consecutive day s without treatment inthe dose -titration pe riod:
treatment can be restarted at the discretion of the investigator at 0.5 mg TID lower 
than the last dose 
>14 consecutive day s without treatment in the dose -titration period: discontinue15the 
patient from study  medication.
Interruptions in the open- label extension period16: 
o>13 and ≤
28 consecutive days: treatment can be restarted at the discretion of 
the investigator at 0.5 mg TID lower than the last dose .
o>28consecutive days: discontinue the patient from study  medication.
                                                
13Per Amendment 4
14Per Amendment 4
15Per Amendment 4
16Per Amendment 4 and Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  29of 167
4.1.5 Termination visit and safety follow -up visit -amended
A termination visit should be performed for patients who discontinue17from study  medication 
for an y reason except death or lost to follow
-up, and should occur as soon as possible after the 
patient receives his/her last dose of study  drug. In general, at the Termination Visit the same 
safet y and efficacy relevant measurements and procedures should be performed as at Visit 12. 
If the discontinuation occurs before Visit 8 (Week 14) , the skin biopsy  and the blood sample s
for biomarkers 
areto be collected. No blood samples for pharmacokinetics ( PK)have to be 
taken and vi talsigns post dose are not needed because no new medication will be dispensed to 
the patient. If the Termination V isit will be performed after Visit 12 (Week 52) the patient’s 
and phy sician’s global assessment, patient interference with skin assessment, and t ender and 
swollen joint count assessment must not be performed.
A safet y follow
-up visit (30 [+5] days after the last dose of study  medication) will be 
performed for all 
patients .
If the patient discontinues study  drug18prematurel y during the main treatment phase (Week 0 
–
Week 52) he/she will be invited to come for limited assessments (mRSS, pulmonary  
function test [FVC and DL CO(diffusion capacity  of the l ung for carbon monoxide ) including 
hemoglobin measurement at the local laboratory ]19, patient -reported outcomes [PROs] , and 
patient’s and ph ysician’s global assessment20) at Week 12, Week 26, Week 39, and Week 52, 
depending on the timing of discontinuation21.  The collection of these assessments is
important for endpoint analy sis which considers all assessments post baseline up to Week 52.
A detailed schedule of evaluations is presented in Section 7.1.1.
4.2 Primary variable
The primary  efficacy  outcome measure is the change in mRSS from baseline to Week 52.
4.3 Justification of the design
Riociguat has been safe and well tolerated in previous clinical studies at multiple dose s 
between 0.5 and 2.5 mg TIDin patients with PAH. Based on the positive results of riociguat 
in patients with PAH and CTEPH together with the compound ’s known 
antifibrotic effects as 
seen in in vitro and in animal models, patients with sy mptomatic dcSScmay benefit from 
treatment with riociguat. Currently , there is no approved therapy  for dcSSc and no suitable 
active comparator in this target population. Therefore, the purpose of this study  is to evaluate 
the efficacy  and safety  of riociguat versus placebo in patients with sy mpto matic dcSSc.The 
follow up time of 12 months has been chosen for the primary  endpoint since it is considered 
an appropriate observation period to detect significant changes in the modified Rodnan Skin 
Score (mRSS) and is therefo re used in many  clinical studies with skin fibrosis .[15,16,17 ]
Moreover, t he 12-month trial duration is supported and validated b y a 3 -round Delphi 
consensus of measures for clinical trials of SSc [18]. See also Section 8.6for further details.     
                                                
17Per Amendment 4
18Per Amendment 1
19Per Amendment 4
20Per Amendment 5
21Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  30of 167
4.4 End of study
For each participating EU country , the end of the study  according to the EU Clinical Trial 
Directive will be reached when the last visit of the last patient for all centers in the re spective 
country  has occurred.
The end of the stud y as a whole will be rea ched as soon as the end of the study  according to 
the above definition has been reached in all participat ing countries (EU and non -EU).
5. Study population
5.1 Eligibility
5.1.1 Inclusion criteria -amended
Patients must meet the following criteria to be eligible for enrollment in the study :
1.Written informed consent
2.Men or women aged 18 years and older
3.Systemic sclerosis, as defined by  ACR/EULAR 2013 criteria [1]
4.dcSSc according to the LeRoy  criteria [3]ie, skin fibrosis proximal to the elbows and 
knees in addition to acral fibrosis22.
5.Disease duration of ≤
18months (defined as time from the first non −Ray naud ’s
phenomenon manifestation)
6. ≥ 10 and ≤ 22 mRSS units at the s creening visit
7.FVC ≥45% of predicted at screening
8.DL CO≥40% of predicted (hemoglobin- corrected) at screening
9.Negative serum pregnancy  test in a woman of childbearing potential at the screening
visit
10. Women of childbearing potential must agree to use adequate contraception when 
sexually  active.  “Adequate contraception” is defined as an y combination of at least 2 
effective methods of birth cont rol, of which at least 1 is a phy sical barrier ( eg,condom 
with hormonal contraception like implants or combined oral contraceptives, condom 
with intrauterine devices ).  This applies since signing of the informed consent form 
until 30 (+5) days after the last study  drug administration.
11.Ability to comply  with the clinical visits schedule and the study -related procedures
5.1.2 Exclusion Criteria -amended
Patients who meet an y of the following criteria will be excluded from enrollment in the study :
1.Medical and sur gical history
Limited cutaneous SSc at screening
Major surgery  (including joint surgery ) within 8 weeks prior to screening
                                                
22Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  31of 167
Patients with a history  of malignancy  in the last 5 y ears other than non -melanoma 
skin cell cancers cured by  local resection or carcinoma in situ
Known hy persensitivity  to the study  drug (active substance or excipients)
2.Hepatic -related criteria
Hepatic insufficiency  classified as Child -Pugh C (see Appendix 14.1 for 
classification table)
oPatients with isolated aspartate aminotransferase (AST )or ALT >3xULN 
(upper limit normal) or bilirubin >2xUL N can be included in the trial under 
the condition of ad ditional monitoring during the trial (see section 7.6.2)23
3.Renal -related criteria
Estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73m2(Modification of 
Diet in Renal Disease [MDRD] formula) 
or on dialy sis at the screening visit. 
Patients entering the trial with eGFR 15- 29 mL/min/1.73m2will be undergo 
additional monitoring of renal function (see section 7.6.2)24
oBecause the MDRD formula is thought to cause significant bias for 
Japanese patients, the equation for Japanese patients is: 
194 x serum creatinine (mg/dL) -1.094 x Age 
-0.287 x 0.739 (if f emale).
Any prior history  of renal crisis (see Appendix 14.2 for definition)
4.Cardiovascular -related criteria
Sitting SBP <95 mmHg at the screening visit
Sitting heart rate <50 beats per minute (BPM) at the screening visit
Left ventricular ejection fraction <40% prior to screening
5.Pulmonary -related criteria
Any form of pulmonary  hypertension25as determined by right heart catheterization 
Pulmonary  disease with FVC <45% of predicted or DL CO(hemoglobin- corrected) 
<40% of predicted at screening
Active state of hemopty sis or pulmonary  hemorrhage, including those events 
managed b y bronchial artery  embolization
Any history  of bronchial artery  embolization or massive hemoptysis within 
3months before screening. (Massive hemopt ysis isdefined as acute bleeding 
>240 mL  in a 24-hour period or recurrent bleeding >100 mL/d ayover consecutive 
days)
6.Laboratory  examinations
Patients with: hemoglobin < 9.0 g/dL, white blood cell (WBC) count <3000/mm3
(<3 × 109/L), platelet count <100,000/mm3(<100 × 109/L)26
                                                
23Per Amendment 1
24Per Amendment 1
25Per Amendment 4 and Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  32of 167
7.Prior and c oncomitant therapy
Concomitant use of nitrates or NO donors (such as amy l nitrate) in any  form , 
including topical ; phosphodiesterase (PDE) 5 (PDE5) inhibitors (such as sildenafil, 
tadalafil, vardenafil); and nonspecific PDE 5inhibitors (theophy lline, 
dipyridamole)
Concomitant therap y with prostacyclin analog s. Oral beraprost for the treatment of 
digital ulcers / Ray naud’s disease , and short-term / intermittent therapy  of up to 21 
days with intravenous prostacy clin analogs 
for digital / vascular lesions is allowed
Treatment with methotrexate, cy clophosphamide, hy droxychloroquine, 
cyclosporine A, azathioprine, my cophenolate mofetil, rapam ycin, colchicine, 
D-penicillamine ,tacrolimus27, mizoribine28or intravenous immunoglobulin within 
4weeks before the screening visit
Treatment with etanercept within 2 weeks; infliximab, leflunomide, certo lizumab, 
golimumab, adalimumab ,abatacept or tocilizumab within 8 weeks ; oranakinra 
within 1 week prior to the screening visit
Previous treatment with chlorambucil, bone marrow transplantation, or total 
lymphoid irradiation
Treatment with rituximab orother anti -CD20 antibodies within the last 6 months 
before screening
8.Other
Pregnant women or breast feeding women
Women of childbearing potential not willing to use adequate contraception (as 
defined in the afore mentioned inclusion criteria, Section 5.1.1) and not willing to 
agree to 4 -weekly  pregnancy  testing from Visit 1 (first administration of study  
drug) onwards until 
30 (+5) daysafter last study  drug intake.
Any other condition or therapy thatwould make the patient unsuitable for this 
study  and will not allow participation for the full planned study  period
Previous assignment to treatment during this study
Participation in another clinical study  with an investigation aldrug or medical 
device w ithin 30 day s prior to randomization (phase s
IIII clinical studies)
5.1.3 Justification of selection criteria
The selection criteria were carefull y selected to exclude patients from the study  who may  
potentially  be exposed to specific risks after administering the study  drug as well as patients 
with conditions that may  have an impact on the aims of this study .
                                                                                                                                                        
26Per Amendment 6
27Per Amendment 1
28Per Amendment 1
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  33of 167
5.2 Withdrawal of patients from study -amended
5.2.1 Withdrawal29-amended
5.2.1.1 Withdraw al from the study30
Patients must be withdrawn from the stud y for the following reasons:
At their own request or at the request of their legally  acceptable representative at an y 
time during the study and without giving reasons, a patient may decline to participate 
further (withdrawal from study ).  The patient will not suffer an y disadvantage as a 
result.
Participation in another clinical trial after Visit 12.  Participation in observational 
registries is allowed.
5.2.1.2 Discontinuation of study medication31
Patients must be discontinued from the stud y medication32for the following reasons:
If, in the investigator's opinion, continuation of the study  would be harmful to the 
patient's well
-being
Occurrence of AEs or intercurrent diseases which the investigator judges unacceptable 
for continuation of participation in the study
Occurrence of adverse drug reactions, which inthe investigator’s opinion have a 
negative impact on the patient’s individual risk -benefit ratio. (Investigators are 
obliged to reassess the patient’s individual risk -benefit ratio on a continuous basis.  
Factors such as anticipated treatment effect, progression of underl ying disease, 
occurrence of side effects ,and alternative treatment options must be considered.)
If a subject, during the course of the study , develops 
a)renal disease that leads to eGFR <15/mL/min/1.73m2, 
b)hepatic insufficie ncy classified as Child- Pugh C 33.
Non-compliance with the conditions for the trial or instructions by  the investigator
If treatment is interrupted for > 3 consecutive day s(9 doses)34during the dose titration 
period of the main treatment phase
If treatment is interrupted for 
>14consecutive days during the maintenance period of 
the main treatment phase or the dose -titration period of the long- term extension phase
If trea tment is interrupted for >28 consecutive days during the open- label extension 
period (of the long- term extension phase)35
In case of pregnancy  or breast feeding .
                                                
29Per Amendment 4
30Per Amendment 4
31Per Amendment 4
32Per Amendment 4
33Per Amendment 5
34Per Amendment 1
35Per Amendment 4 and Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  34of 167
In case a female patient of childbearing potential is not compliant with 4 -weekl y 
pregnancy  testingor with contraceptive measures.
In case no further dose reduction is possible and the patient does not tolerate the 
lowest possible dos age (0.5 mg TI D)of study  drug
Patients may be discontinued from the stud ymedication36for the following reasons:
Atthe specific request of the sponsor and in liaison with the investigator ( eg,safet y 
concerns)
Arelative decline in FVC % predicted by  ≥ 10% (eg, a change of FVC from 60% to 
54%) or a relative decline in FVC % predicted between 5 to < 10% with associated 
relative decline in DL CO%predicted by ≥ 15%, provided that the decline in FVC 
results in FVC <75% of predicted (confirmed b y repeat pulmonary  function testing 
within 1 month) . Please refer to Section 6.9for the option of adding rescue37therap y .
An absolute increase in mRSS by  > 5 units and ≥ 25% ( Please refer to S ection 6.9for 
the option of adding rescue38therap y
), life-threatening or organ -threatening event 
attributable to SSc (such as renal crisis, digital gangrene, development of new PAH on 
right heart catheterization ) or not attributable to SSc .
5.2.1.3 Handling of withdrawals or discontinuations from study medication39
A patient 
who, for an y reas on (eg,failure to satisfy  the selection criteria), terminates the study  
before the time point used for the definition of “dropout” (see below ) is regarded a “screening 
failure”.  Restarting the defined set of screening procedures to enable the “screening failure” 
patient’s participation at a later time point is not allowed.
One re -assessment of laboratory  parameters is allowed during the screening phase to re- assess 
the eligibility  of patients.
A patient who discontinues study  participation prematurely  forany reason is defined as a 
“dropout” if the patient has alread y been randomized.
Any randomized patient removed from the trial should undergo the assessments at the 
termination visit.  The patient will remain under medical supervision until discharge or 
transfer is medically  acceptable and will complete the 30- day safet y follow- up period.
If the patient discontinues study  drug40prematurel y during the main treatment phase (Week 0 
–
Week 52) he/she will be invited to come for limited assessments (mRSS, pulmonary  
function test [FVC and DL COincluding hemoglobin measurement at the local laboratory ]41, 
PROs, and patient’s and physician’s global assessment )42at Week 12, Week 26, Week 39,
and Week 52, depending on the timing of discontinuation43. This will be in addition to the 
termination visit assessments (see Section 7.1.2.8), provided that the patient does not object to 
                                                
36Per Amendment 4
37Per Amendment 1
38Per Amendment 1
39Per Amendment 4
40Per Amendment 1
41Per Amendment 4
42Per Amendment 5
43Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  35of 167
collection of study  data after withdraw alof consent.  I f the discontinuat ion occurs before Visit 
8 (Week 14), the skin biopsy and blood sample sfor biomarkers are to be collected.
All reasons for discontinuation44(including lost to follow up), will be rec orded in the
electronic case report from ( eCRF ) and site medical record. Study  medication assigned to the 
discontinued45patient may not be assigned to another patient. 
In the event that a patient is lost to follow -up, every possible effort must be made b y study 
site personnel to contact the patient to obtain complete data and determine the reason for 
discontinuation46.
A patient may  withdraw from further participation in the study  and, unless he/she objects to 
further data collection , the following informa tion should be obtained and documented in the 
eCRF47:
Vital status (at Week 52)
Outcome of serious adverse events (S AEs)
Efficacy  endpoints at Weeks 12, 26, 39, and52(depending on timing of 
discontinuation of study  medication )
The information should be collected in the eCRF until the safety  follow -up visit 30 (
+5)days 
after the last intake of study  drug. Serious a dverse events 
thatoccur within 30 (+5) days after 
the last dose of study  drug will be followed up until resolution, if possible.
If patients refuse to be contacted via telephone (eg, patient objects to further release of 
information or are lost to follow -
up), every  effort should be made to obtain vital status (dead 
or alive) information at Week 52 through consultation of public databases, wher ever allowed 
by local regulations48. 
The measures taken for follow up must be documented in the site medical record. Follow -
up 
data will be collected for all randomized patients except those who specifically  withdraw 
consent for release of such information, except as noted above. Thus, it is imperative to 
obtain complete data for all randomized patients, including infor mation on efficacy  and safet y 
endpoint events, whether or not they  receive study drug, or discontinue study  drug 
prematurel y.
Details for the premature termination of the study  as a whole (or components thereof 
[eg,centers, treatment arms, dose steps]) ar e provided in Section 10.
5.2.2 Replacement -amended
There will be no replacement of 
randomized patients who withdraw from the study or 
prematurel y discontinue study  medication49.
                                                
44Per Amendment 4
45Per Amendment 4
46Per Amendment 4
47Per Amendment 4
48Per Amendment 4
49Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  36of 167
5.3 Patient identification
After a patient signs the informed consent form, the patient identification number for each 
patient will be provided to the investigators via IxRS. Patients will be identified by a unique 
9-digit number consisting of the following : 
First 2 digits = Unique country  code
Next 3 digits = Unique study  center number within the country
Last 4 digits = Unique current 
patient number within the study  center of a given 
country ; sequential number reflecting the order in which the 
patients signed the 
informed consent form at the center (4 digits)
Patient identification numbers must be used in sequence and no number should be skipped, 
substituted, or reused.
6. Treatment
6.1 Treatments to be administered
Test drug: Riociguat
Dosage: 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg ( dose 
titration)
Route of administration: Oral
Time and frequency  of administration: TID
The optimal dose should be determined during the initial 10- week dose titration period based 
on monitoring of the patient’s SBP and well -being.
The recommended starting dose is 0.5 mg TID . The intervals between drug intake should be 
68 hours. The dosage should be increased b y 0.5 mg increments no sooner than 2 weeks 
apart to 1mg, 1.5mg, 2 mg, and 2.5 mg TI D, resulting in a maxim umtotal daily  dose of 
7.5mg. Patients should be maintained on lower doses if higher doses are not tolerated 
(minim umdose of 0.5 mg TID, see Section 5.2.1). After the dose titration period ,riociguat 
should be continued at the optimal dose for the duration of the maintenance period.
6.2 Identity of study treatment
Riociguat
Riociguat is supplied in various strengths as film -coated , immediate -release tablets (see 
Table 6–1). Riociguat and placebo tablets will ha ve similar appearance at all dose strengths.
All study  drugs will be label led according to the requirements of local law and legislation. 
Label text will be approved according to the sponsor’s agreed procedures, and a cop y of the 
labels will be made avail able to the study  site upon request.
For all stud y drugs, a s ystem of numbering in accordance with all requirements of Good 
Manufacturing Practice (GMP) will be used, ensuring that each dose of study  drug can be 
traced back to the respective bulk ware of t he ingredients. Lists linking all numbering levels 
will be maintained by
 the sponsor’s clinical supplies Quality  Assurance group.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  37of 167
Acomplete record of batch numbers and expiry  dates of all study  treatment, as well as the 
labels ,will be maintained in the sponsor study  file.
Table 6–1 Identity of investigational product
International non -proprietary name (INN) Riociguat 
Sponsor’s internal reference number BAY 63 -2521
Form ulation Film-coated tablets
Galenical form Round immediate -release tablets, diameter 6 mm
Composition Active ingredient: Methyl 4,6 -diamino -2-[1-(2-
fluorobenzyl) -1H-pyrazolo [3,4 b]pyridine -3-yl]-5-
pyrimidinyl (methyl)carbamate
Empirical formula: C 20H19FN8O2
Molar mass: 422.42 g/mol (molarity )
Excipients: lactose, microcrystalline cellulose, 
magnesium stearate, crospovidone *, hypromellose *, 
and sodium laur yl sulphate *
Coating: hydroxypropyl cellulose, hypromellose, 
propylene gly col, iron oxide (red and yellow), and 
titanium dioxide.
Strength 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg
Material numbers 83296470 BAY 63 -2521 TABL 0.5 mg 511 COAT
83296535 BAY 63 -2521 TABL 1 mg 512 COAT
83296543 BAY 63 -2521 TABL 1.5 mg 513 COAT
83296578 BAY 63 -2521 TABL 2 mg 504 COAT
83296608 BAY 63 -2521 TABL 2.5 mg 515 COAT
Packaging High-density polyethylene (HDPE) bottles
Abbreviation: TABL = tablet
*Not in p lacebo tablets 
Matching placebo
Matching placebo tablets will appear identical to active riociguat tablets but will not contain 
active study  drug product (riociguat) 
or any  of the excipients marked with an asterisk as 
outlined in Table 6–1.
Storage r equirements
All investigational drugs used during the trial will be stored at the investigational sites at 
room temperature in a place inaccessible to unauthorized personnel, ie,in a locked cabinet.
No special storage conditions are required.
6.3 Treatment assignment
This is a randomized, double -blind, placebo -controlled, parallel -group , multinational, 
multicenter study . Patients who complete 
all screening procedures and meet all eligibility  
criteria are to be randomized via IxRS in a 1:1 ratio to receive either riociguat or placebo .
The patient randomization scheme will use permutated blocks sized as a multiple of 2.  Each 
block will be allocated to a country  or group of nearby  countries within a region.  No other 
stratification is planned.
An IxRS site manual will be provided to the investigative centers.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  38of 167
6.4 Dosage and administration
6.4.1 Selection of doses in the study -amended
Riociguat has been safe and well tolerated in previous clinical studies at multiple doses 
betw een 0.5 and 2.5 mg TID in patients with various forms of pulmonary  hypertension, 
including PAH, CTEPH, and, in a small patient population, SSc -related pulmonary  
hypertension. The intervals between drug intake should be 6 to 8 hours50.
Data from the phase I II clinical program for riociguat in patients with pulmonary  hypertension 
(PATENT and CHEST studies) show edthat a starting dose of 1 mg TID was safe and 
effective. Because a few patients in both studies had their dosage reduced to 0.5 mg TID, the 
sponsor recognized that the 0.5 mg TID dosage may  offer additional tolerability  for some 
patients and adopted this additional dose recommendation. Inthe present study , the titration 
will start at 0.5 mg TI D.
For further details refer to the IB.
6.5 Blinding -amended
Apart from the open -label extension period in the long -term extension phase, the study  will be 
conducted in a double- blind fashion. Active riociguat and placebo tablet formulations will be 
identical in appearance (size, shape, color) and smell. The packaging and labeling will be 
designed to maintain blinded conditions for the investigator’s team and the patients. The 
study  data will remain blinded until database lock and authorization of data release according 
to standard operating procedures.
Appropriate measures will be taken to maintain blinding of the stud y team while PK and 
biomarker anal ysis is ongoing. Data with a potential to unblind (eg, plasma concentrations) 
are not to be handled b y or shown to the study team members and will only be uploaded into 
the clinical database after official unblinding. The process of data flow will be documented 
separately  (see also Section 7.4and Section 7.6.3.).51
Statistical analy sis as described in the SAP 
(Statistical Anal ysis Plan) will be done after 
database lock and authorization o f data release according to standard operating procedures. 52
Unblinding by drug safety personnel of the sponsor
For regulatory  reporting purposes, drug safet y personnel of the sponsor are permitted to 
unblind individual cases.
In compliance with applicable regulations, in the event of a suspected unexpected serious 
adverse reaction (SUSAR) (see Section 7.5.1.5), the patient’s treatment code will usually  be 
unblinded before reporting to the health authorities, Independent E thics Committees (IECs) / 
Institutional Review Boards (IRBs) , and investigators (see Section 7.5.1.4) if the SUSAR was 
related to the blinded treatment.
                                                
50Per Amendment 4
51Per Amendment 5
52Per Amendment 5 
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  39of 167
Emergency unblinding by the investigator
In case of emergency , investigators are permitted to unblind individual cases via the IxRS.  
However, investigat ors are obligated to restrict such unblinding to cases of emergency  where 
the unblinding result is of importance for the acute treatment strategy . 
Investigators should note that the occurrence of a serious adverse event (SAE )should not 
routinely  precipit ate the immediate unblinding of the label.  
Date, time, and reason for unblinding must be captured in the relevant eCRF .  Please refer to 
the IxRSand eCRF completion guideline for instructions.
Any patient who discontinues study  medication will remain under medical supervision until 
discharge or transfer is medicall y acceptable.  
Patients who withdraw from the study  or 
discontinue study  medication should take part at the termination visit (refer to Section 7.1.2.8) 
and the safety  follow -up visit (refer to Section 7.1.2.9 )53.  Further therap y is at the discretion 
of the investigational site.
Unblinding for ongoing safety monitoring
In order to allow ongoing safet y monitoring during the conduct of the stud y by an external 
DMC, members of the committee will receive unblinded safet y data.  The involvement of an 
external statistical analy sis center 
in this process will ensure that unblinded information is not 
available for third parties.  Details of the process are described in the DMC charter.
6.6 Drug logistics and accountability
All study  drugs will be stored at the investigational site in accordance with Good Clinical 
Practice ( GCP )and GMP requirements and the instructions given b y the clinical supplies 
department of the sponsor, and will be inaccessible to unauthorized personne l.  Special 
storage conditions and a complete record of batch numbers and expiry  dates can be found in 
the sponsor study  file; the site -relevant elements of this information will be available in the 
investigator site file.  The responsible site personnel w ill confirm receipt of study  drug via 
IxRSand will use the study  drug onl y within the framework of this clinical study  and in 
accordance with this protocol.  Receipt, distribution, return and destruction (if any ) of the 
study  drug must be properly  documen ted according to the sponsor’s agreed and specified 
procedures.
Written instructions on medication destruction will be made available to affected parties as 
applicable.
6.7 Treatment compliance
A drug dispensing log will be completed for each patient .  The overall compliance with study  
drug intake should be between 80% and 120% of the calculated dose. The date of dispensing 
the study  drug to the patient will be documented. 
Patients will receive study  medication dispensed per visit schedule (see Section 7.1.1).
To record treatment compliance, patients will be instructed to bring all study  drug packaging, 
including unused stud y drug and empt y packaging, to the investigative site at each stud y visit .  
Tablets will be counted for a compliance check.
                                                
53Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  40of 167
If a dose of study  drug is missed, the patient should take a dose immediately  and continue 
with the TID intake as recommended on the following day . The dose should not be doubled to 
make up for a missed do se within the same day . 
6.8 Post-study therapy
In case patients discontinue study  drug treatment during this study , further therapy  is at the 
discretion of the investigat or.
6.9 Prior and concomitant therapy -amended
A summary  of the prohibited prior and concomi tant therap y, outlined in the exclusion criteria 
(Section 5.1.2), is provided in Table 6–2.  During the trial, concomitant treatment is allowed 
with oral corticosteroids ( ≤10 mg/day  of prednisone or equivalent), non -steroidal anti -
inflammatory  drugs (NSAIDs), angiotensin converting enzy me (ACE) 
inhibitors, or calcium 
channel blockers if stable for ≥2 weeks before and including at baseline. These treatments 
will also be allowed as new -onset during the study  at the discretion of the investigator to treat 
SSc-specific adverse events (eg, Ray naud’s phenomena, joint inflammation, new onset renal 
crisis) .
During the long -term extension phase (ie, after completion of all efficacy -and safet y-related 
procedures at Visit 12), except for the contraindicated nitrates or NO donors and PDE5 
inhibitors, the addition of any other concomitant medication is at the discretion of the 
investigator. 54
                                                
54Per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  41of 167
Table 6–2 Prohibited prior and concomitant therapy -amended
Therapy Timeframe 
Chlorambucil, bone marrow transplantation ,or total lymphoid irradiation Any previous t herapya, b
Rituximab or other anti-CD20 antibodies Within 6 m onths prior to 
the screening visita, b
Infliximab, certolizumab, golimumab, adalimumab, abatacept ,
leflunomide or tocilizumabWithin 8 weeks prior to the 
screening visita, b
Methotrexate, cyclophosphamide, hydroxychloroquine, cy closporine A, 
azathioprine, m ycophenolate mofetil, rapam ycin, colchicine, D 
penicillamine ,tacrolimus55,mizoribine56or intravenous immunoglobulinWithin 4 weeks prior to the 
screening visita, b
Etanercept Within 2 weeks prior to the 
screening visita,b 
Anakinra Within 1 week prior to the 
screening visita,b 
Nitrates or NO donors (such as am yl nitrate) in any form, including 
topical; phosphodiesterase (PDE) 5 (PDE5) inhibitors (such as 
sildenafil, tadalafil, vardenafil); and nonspecific PDE 5inhibitors 
(theophylline, dipyridamole)Concomitant therapy with 
study drug
Prostacyclin analog s (oral beraprost for digital ulcers / Raynaud’s 
disease and short -term / intermittent therapy of up to 21 days 
with intravenous prostacyclin analogs for digital / vascular lesions is 
allowed)Concomitant therapy with 
study drug
aConcomitant use of these treatments with study medication is also prohibited, except for certain 
agents from Week 26 onwards; please see “ Rescue57Therapy” below. 
bConcomitant use of these medications will be allowed during the long -term extension phase58
In addition, as described in Section 8.4.1 of the IB, “Interaction with other medicinal products 
and other forms of interaction”, caution is advised during the intake of an y of the foll owing 
concomitant medications :
The concomitant use of riociguat with strong multi-pa thway  cytochrome P450 ( CYP) 
and P -glycoprotein 1 (P -
gp)/breast cancer resistance protein inhibitors such as azole 
antimy cotics ( eg,ketoconazole, itraconazole) or human immunodeficiency  virus 
protease inhibitors ( eg,ritonavir) is not recommended, due to t he pronounced increase 
in riociguat exposure.
The concomitant use of riociguat with strong CYP1A1 (CYP family  1, subfamily  A, 
polypeptide 1) inhibitors, such as the t yrosine kinase inhibitor erlotinib, and strong 
P-gp inhibitors, such as the immunosuppressive agent cy closporine A, may  increase 
                                                
55Per Amendment 1
56Per Amendment 1
57Per Amendment 1
58Per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  42of 167
riociguat exposure. These drugs should be used with caution. Blood pressure should 
be monitored and dose reduction of riociguat considered.
Other medications andconsiderations (detailed information can be found in the current IB)
Pre-and co ncomitant treatment with the proton pump inhibitor omeprazole (40 mg 
once dail y) reduced riociguat mean area under the plasma concentration versus time 
curve (AUC) b y 26% and mean maximum plasma concentration (C max)by 35%. This 
is not considered clinically  relevant.
Co-administration of the antacid aluminum hy droxide / magnesium hy droxide reduced 
riociguat mean AUC b y 34% and mean C maxby 56%. Antacids should be taken at 
least 1 h ourafter riociguat.
Plasma concentrations in smokers are reduced b y 5060% compared with 
nonsmokers. For this reason, it is highly  recommended to strongl y advise patients to 
stop smoking while taking this medication59. A dose reduction should be co nsidered 
in patients who stop smoking whilst participating in the study .
Rescue60therapy
From Week 26 (Visit 10), patients with the following will have the opportunity  to add rescue 
therap y to their randomized study  medication . “Rescue 
therapy ” is defined as treatment with 
an immunosuppressant drug, under the following situations:
Worsening of skin disease (defined as >5 units and ≥25% increase in mRSS), or
Relative decline in FVC % predicted b y ≥10%, or relative decline in FVC % predicted 
between ≥5% and <10% with associated relative decline in DL CO% predicted by  
≥15% ,provided that the decline in FVC results in FVC <75% of predicted  (confirmed 
by repeat pulmonary  function testing within 1 month).
The decision to initiate rescue therapy  is based on investigator discretion in eligible patients.  
Rescue therapy  may  include any  of the following 4 agents: methotrexate, my cophenolate 
mofetil, cy clophosphamide, or azathioprine .
Worsening of inflammatory  joint disease or my ositis.61
Rescue therap y can be initiated at investigator’s discretion in eligible patients. In addition to 
the 4 agents methotrexate, mycophenolate mofetil, cyclophosphamide, or azathioprine , 
hydroxychloroquine will be allowed for the treatment of inflammatory  joint disease and 
myositis . 62
These treatments are not provided b y the Sponsor.
A survey conducted by  the Scleroderma Clinical Trials Consortium (SCTC) and Canadian 
Scleroderma Research Group (CSRG) to gain a consensus from SSc experts worldwide 
recommended th ese agents in the management of SSc after failure of first -line therapy .[19]
                                                
59Per Amendment 1
60Per Amendment 1 –this footnote covers all changes in the section from escape to rescue
61Per Amendment 5
62Per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  43of 167
These agents also are feature din EULAR recommendations for the treatment of SSc[20]and 
in a recently  published review of old and new therapies for SSc used in clinical practice.[ 21]
7. Procedures and variables
7.1 Schedule of procedures
The study  will be divided into the following 
phases:  screening phase ,main treatment p hase
and long-term extension phase .  Please refer to Table 7–1for a schedule of evaluations.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  44of 167
7.1.1 Tabulated overview - amended
Table 7–1 Schedule of evaluations -amended63
Scr Main Treatment Phase  (Double -blind)vLong- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension PeriodSafety  Follow -
up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364
-14
to+2378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
V18 ± 2
Vn ± 1430 +5
Written informed consent X
Inclusion / exclusion criteria
X X
Demographic dataX
Medical and surgical history
X X
Other history (alcohol)X
Smoking historyX X X X X X
Height and weightc
X X X X X X X X
Physical examinationX X X X X X X X
mRSS X X X X X X X
Assessment of Raynaud’s 
attacks XdXeXfXe
Digital ulcer net burden
assessment X X X X X X X X X X X X X X X X X X X X
                                                
63Visit window  forV12 changed per Amendment 4 ; visit window  for V18 changed per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  45of 167
Table 7–1 Schedule of evaluations -amended63
Scr Main Treatment Phase  (Double -blind)vLong- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension PeriodSafety  Follow -
up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364
-14
to+2378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
V18 ± 2
Vn ± 1430 +5
Tender & swollen joint countX X Xg
Oximetryw, 64
X X X X X X X X X X X X
Vital signs (BP, HR)hX X X X X X X X X X X X X X X X X X X X X
Vital signs post -dose 
(BP, HR)i,j XiXjXi
BP and HR for assessment 
of orthostatic changesx, 65 X X X X X X X
Blood sample for safetyk, u
X X XuXuXuXuX X66X X X X X X
Blood sample for PK XlXmXmXmXmXmXnXlXmXmXmXmXm
Blood sample for biomarkers X X Xr
Blood sample for 
Autoantibody screenX
Pregnancy test (if 
applicable)o X X X X X X X X X X X X
12-lead ECGp
X X X X X X X X X
                                                
64Per Amendment 6
65Per Amendment 6
66Per Amendment 1
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  46of 167
Table 7–1 Schedule of evaluations -amended63
Scr Main Treatment Phase  (Double -blind)vLong- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension PeriodSafety  Follow -
up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364
-14
to+2378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
V18 ± 2
Vn ± 1430 +5
Pulmonary function testsq
X X X X X X X
Skin biopsyX X Xr
Questionnairess
X X X X X X X
Patient’s and physician’s 
global assessmentX X X Xg
Patient interference with skin X X X Xg
Tendon Friction Rubst
X X
Randomization (IxRS)X
Dispensation of study drugX X X X X X X X X X X X X X X X X X
Drug accountability X X X X X X X X X X X X X X X X X X
Adverse events recordingX X X X X X X X X X X X X X X X X X X X X
Prior and concomitant 
therapy X X X X X X X X X X X X X X X X X X X X X
Survival statusX
Abbreviations:  BP = blood pressure; ECG = electrocardiogram; TV = Termination Visit; SFU =30-Day Safety Follow -up (30 [+5] days after the last dose of study drug); HR = heart rate; IxRS = 
telephone -based or web -based response system; mRSS = modified Rodnan skin score; PK =pharmacokinetics; q 12 wk = every 12 weeks; Scr = Screening.
Note:  Day 0 (Visit 1) is the baseline visit.
a Visit 12 ( Week 52) is the last visit in the Maintenance Period of the Main Treatment phase and the first (baseline) visit in the Long -term Extension phase.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  47of 167
b To be performed as soon as possible after discontinuation67of study medication.  
c Height to be measured only at the screening visit
d Patient to be provided with 7 -day diary, to complete daily for 7 consecutive days leading up to Visit 1 
e Patient and physici an assessment of Raynaud’s disease (see Section 7.6.12 )
f Patient to be provided with 7 -day diary, to complete daily for 7 consecutive days leading up to Visit 8.
g Must not be performed if TV is after V12.
h Blood pressure and heart rate will be measured at all visits with the patient in a sitting position, after the patient has be en at rest for at least 5 minutes.  The same arm is always used for th ese 
measurements (see Section 7.6.5 ).
i Vital signs to be measured within 20 minutes prior to each post -dose PK sampling (see Table 7–2)
j Vital signs to be measured within 20 minutes prior to PK sampling (see Table 7–2)
k Coagulation tests to be performed at a local laboratory
l Samples for PK to be taken 1 –2 hours and 3 –4 hours after the morning dose of study medication (see Table 7–2)
m Sample for PK to be taken up to 1 hour before the morning dose of study medication (trough) (see Table 7–3)
n Samples for PK to be taken up to 1 hour before the morning dose of study medication (trough) and 2 –3 hours after the morning dose of study medication (peak) 
(see Table 7–4)
o For women of childbearing potential only. Serum pregnancy test is required only at screening; pregnancy testing (urine) will be done every 4 weeks and should co ntinue until 30 days after the 
last dose of study drug. When pregnancy testing coincides with a visit, the test should be performed at the site, but otherwi se should be performed at home. 
p Standard ECG (12 -lead ECG) will be recorded with the patient in the supine position, after the patient has been at rest for at least 5 minutes (see Section 7.6.7 ).
q Pulmonary function tests include forced vital c apacity (FV C)and diffusion capacity of the lung for carbon monoxide ( DLCO).
r Must be done at a TV if this visit occurs before Visit 8.
s Questionnaires include Scleroderma Health Assessment Questionnaire (SHAQ), Short Form 36 (SF -36), Patient -Reported Outcomes Measurement Information System (PROMIS) -29, and 
University of California, Los Angeles, Scleroderma Clinical Trial Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0.
t Assessment of the presence or absence of tendon friction rubs
u     Addition al monitoring may apply for patients with impaired renal and liver function at Visit 2, 3, 4, 5 as needed (see Section 7.6.2 )68
v All patients who di scontinue study drug prematurely during the main treatment phase (Week 0 –Week 52) will be invited to come for limited assessments (see Sections 7.1.2.10 and 7.6.2 ).69
w Oxygen saturation will be measured using forehead pulse oximetry. At visits with blood samples for PK and blood pressure measurements for the assessment of orthostatic changes , post -dose 
measurements will be performed in addition to pre -dose measurements (see Section 7.6.18 , Table 7–2, Table 7–3, Table 7–4)70
x Measure supine and sitting blood pressure and heart rate to check for orthostatic changes approximately 2 hours after intake of study medication. (see Section 7.6.5 , Table 7–2, Table 7–3, 
Table 7–4).71
                                                
67Per Amendment 4
68Per Amendment 1
69Per Amendment 4
70Per Amendment 6
71Per Amendment 6
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  48of 167
Pharmacokinetics sampling flow charts -amended
Profile day (Visit 1 and Visit 12)
2 hours after administration of the morning dose of study  medication72
3 –4 hours after administration of the morning dose of study  medication
Table 7–2 Profile Day PK Sampling (Visit 1 and Visit 12)73
Visit 1 and Visit 1 2(profile days) Cycle of procedures
Order of 
proceduresStarting point of procedures Time interval (h) 00 001:45 – 2 h2h 3 –4 h
At Visit 12 only: oxygen saturation using 
forehead pulse oximetryX
Blood pressure, heart rate X
Administration of morning dose of study 
medication X
At Visit 12 only: oxygen saturation using 
forehead pulse oximetryXa
Blood pressure, heart rate; at Visit 12 only: 
supine and sitting positionXa
Blood sample for PK X
Blood pressure, heart rate (within 20 minutes 
prior to PK sample)X
Blood sample for PK X
a At Visit 12 only: measure oxygen saturation, blood pressure and heart rate in supine and sitting 
position (see Section 7.6.5 and Section 7.6.18 ).
Abbreviations:  h = hours; PK = pharmacokinetic.
Visits 2 to 6 and Visits 1 3to 17
Up to 1 hour before administration of the morning dose of study  medication (trough)
Table 7–3 PK Sampling (Visits 2 –6 and Visits 13 –17)74
Visit 2 to Visit 6 and Visit 1 3to Visit 1 7 Cycle of procedures
Order of 
proceduresStarting point of procedures Time interval (h) 1 h 00 00 00 2h
Blood sample for PK X
Visit 13 -17 only: ox ygen saturation using forehead 
pulse oximetryX
Blood pressure, heart rate X
Administration of morning dose of study medication X
Visit 13 -17 only: ox ygen saturation using forehead 
pulse oximetryX
Visits 13 -17 only: Blood pressure, heart rate in 
supine and sitting positionX
                                                
72Per Amendment 6
73Per Amendment 6
74Per Amendment 6
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  49of 167
Abbreviations:  h = hours; PK = pharmacokinetic.
Visit 11
Up to 1 hour before administration of morning dose of study  medication (trough)
2 hours after administration of morning dose of study  medication (peak)75
Table 7–4 PK Sampling (Visit 11)76
Visit 1 1 Cycle of procedures
Order of 
proceduresStarting point of procedures Time interval (h) 1 h 00 00 00 1:45-2 h 2 h
Blood sample for PK X
Oxygen saturation using forehead pulse 
oximetryX
Blood pressure, heart rate X
Administration of morning dose of study 
medication X
Oxygen saturation using forehead pulse 
oximetryXa
Blood pressure, heart rate in supine and sitting 
position Xa
Blood sample for PK X
aMeasure oxygen saturation, blood pressure and heart rate in supine and sitting position (see 
Section 7.6.5 and Section 7.6.18).
Abbreviations:  h = hour; PK = pharmacokinetics.
7.1.2 Timing of assessments
If not stated otherwise, allassessments and procedures will be performed by  or under the 
supervision of an investigator.
For timing of assessments and procedures, please refer to Section 7.1.1 .
7.1.2.1 Visit 0  Screening phase –Screening visit
Screening evaluations will be performed onl y after the patient has provided written informed 
consent.  The following evaluations will be performed and information obtained up to 14days 
(but not less than 8 day s) before randomization and the start of study drug treatment:
Patient information and obtaining of written informed consent
Eligibility : Assessment of inclusion and exclusion criteria (see Section 5.1)
Demographic data, including sex, ethnic ity, date of birth, smoking history  and alcohol 
consumption (See Section 7.2.1 )
Medical and surgical history (see Section 7.2.2 )
Prior and concomitant therapy (see Section 6.9for prohibited medication)
                                                
75Per Amendment 6
76Per Amendment 6
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  50of 167
Physical examination ,including h eight andweight (Note: body  mass index [BMI]
will be calculated automatically  in the eCRF)
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position ,after the patient has been at 
rest for at least 5 minutes. The same arm is always used for these measurements (See 
Section 7.6.5 )
mRSS (see Section 7.6.6 )
Provision of 7-daydiary  to patients which they  will complete daily  for 7 consecutive 
days leading up to Visit 1 (see Section 7.6.12 )
Digital ulcer net burden assessment (see Section 7.6.10)
Tender and swollen joint count assessment (see Section 7.6.14 )
Blood samples for safet y(see Section 7.6.2 )
Blood sample for autoantibody  screen (see Section 7.6.4 )
Pregnancy  test (seru m) for all women of childbearing potential (s ee Section 7.6.1 )
12-lead electrocardiogram ( ECG )for central ized reading .  A standard 12- lead ECG 
will be obtained with the patient in the supine position after resting for at least 
5 minutes (s ee Section 7.6.7 )
Pulmonary  function tests (FVC and DL CO) (see Section 7.6.8 )
Continuous assessment of AEs will start immediately  after signing the informed 
consent form (see Section 7.5.1 )
7.1.2.2 Visit 1  Main treatment phase -Baseline (Day 0, Week 0 )
The following assessments will be performed at Visit 1 (Day  0 of study  drug treatment) :
Before intake of study  medication
Reconfirm ation of eligibility  (assessment of inclusion/exclusion criteria ; Section 5.1)
Questionnaires (see Section 7.6.13 )
Update of medical and surgical history , if needed (see Section 7.2.2 )
Smoking history
Physical examination , including weight
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position ,after the patient has been at 
rest for at least 5minutes. The same arm is always used for these measurements ( see 
Section 7.6.5 ).
Patient and phy sician assessments of Ray naud’s attacks , and patient to return 
completed 7-daydiary  (see Se ction 7.6.12 )
Digital ulcer net burden assessment (see Section 7.6.10)
Patient’s and phy sician’s global assessment (see Section 7.6.15 )
Patient interference with skin assessment (see Section 7.6.16 )
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  51of 167
Assessment for the presence or absence of tendon friction rubs (see Section 7.6.17 )
Blood samples for safet y(see Section 7.6.2 )
Blood sample for biomarkers to be obtained before the start of stud y drug treatment
(see Section 7.6.3 )
Pregnancy  test (urine) for all women of childbearing potential (see Section 7.6.1 )
12-lead ECG for centralized reading.  A st andard 12 -lead ECG will be obtained with 
the patient in the supine position after resting for at least 5 minutes (See Section 7.6.7 )
Skin biopsy to be obtained before the start of study  drug treatment (see Section 7.6.9 )
Recording and assessment of AEs (see Section 7.5.1 )
Concomitant therap y
Randomization (IxRS) to study  drug treatment with either riociguat or placebo (see 
Section 6)
Dispens ation of study  drug and first intake by  patient
After intake of study  medication
Blood sample for PK (see Section 7.4)
oPK blood sample between 1 – 2 hours after administration of themorning dose 
of study  medication
oPK blood sample between 3 –4 hours after administration of the morning dose 
of study  medicat ion
Vital signs (blood pressure and heart rate) should be measured within 20 minutes prior 
to each post -dose PK sampling with the patient in a sitting position andafter the 
patient has been at rest for at least 5 minutes.  The same arm is always used for these 
measurements (see Section 7.6.5 ).
7.1.2.3 Visits 2 through to 6Main treatment phase – Dose -titration period -
amended
At these study  visits ,the patient should attend the clinic without having taken the mornin g 
dose of study  medication .
During the dose titration period of the main treatment phase , the following assessments will 
be performed according to the Schedule of evaluations ( Section 7.1.1 ):
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position ,after the patient has been at 
rest for at least 5minutes. The same arm is always used for these measurements ( see 
Section 7.6.5 ).
Digital ulcer net burden assessment (see Section 7.6.10)
Recording and assessment of AEs (see Section 7.5)
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  52of 167
Blood samples for additional saf ety for patients with impaired renal and liver function 
at Visit 2, 3, 4, 5 as needed77(see Section 7.6.2 )
Blood samples for safet y Visit 6 (see Se ction 7.6.2 )
Blood sample for PK up to 1 hour before the morning dose of stud y medication (see 
Section 7.4)
Pregnancy  test (urine) for all women of childbearing potential (Visit 3 and Visit 5)
(see Sect ion 7.6.1 )
Concomitant therap y
Dose titration according to the titration algorithm (see Section 4.1.2 )
Dispens ation of study  drug and drug accountability
7.1.2.4 Visits 7 through to 11Main treatment p hase - Maintenance period -
amended
At these visits , the patient should attend the clinic without having taken the morning dose of 
riociguat or placebo.
During the maintenance period of the main treatment phase , the following assessments will be 
performed according to the Schedule of evaluations (Section 7.1.1 ):
Questionnaires (Visit 8, 10, and 11) (see Section 7.6.13 )
Smoking history  (Vis it 10)
Physical examination , including weight (at Visit 7 and Visit 1 0) (Note: BMI will be 
calculated automaticall y in the eCRF)
Oxygen saturation measurement using forehead pulse oximetry  at Visit 9 only . At 
Visits 10 and 11 only , oxygen saturation will be measured before and after intake of 
study  drug ( see Section 7.6.18, Table 7–2, Table 7–3, and Table 7–4)78
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position ,after the patient has been at 
rest for at least 5 minutes. The same arm is alway s used for these measurements (s ee 
Section 7.6.5 ) 
Assessment of orthostatic changes: measure blood pressure and heart rate in supine 
position and sitting position approximately  2 h after intake of stud y drug (Visit 11 
only, see Section 7.6.5 ).79
mRSS (Visit s 7, 10 and11) (see Section 7.6.6 )
Digital ulcer net burden assessment (see Section 7.6.10)
Provision of 7 -day diary to patients at Visit 7, which they  will complete daily  for 
7consecutive day s leading up to Visit 8 (see Section 7.6.12 )
                                                
77Per Amendment 1
78Per Amendment 6
79Per Amendment 6
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  53of 167
Patient and phy sician assessment of Ray naud’s attacks , and patient to return 
completed 7-daydiary  (Visit 8) (see Section 7.6.12)
Patient’s and phy sician’s global assessment (Visit 1 0) (see Section 7.6.15 )
Patient interference wi th skin assessment (Visit 1 0) (see Section 7.6.16 )
Assessment for the presence or absence of tendon friction rubs (Visit 8) (see Section 
7.6.17 )
Blood samples for safet y (Visit 10 and 11) ( see Section 7.6.2 )
Blood sample for PK at Visit 1 1up to 1 hour before the morning dose of study  
medication (see Section 7.4)
Blood sample for biomarkers (Visit 8) (see Section 7.6.3 )
Pregnancy  test (urine) for all women of childbearing potential ( Visits 7 and 9 )(see 
Section 7.6.1 )and every  4 weeks in between as required
12-lead ECG for centralized reading ( Visit s 7, 10 and11).  A standard 1 2-lead ECG 
will be obtained with the patient in the supine position after resting for at least 
5minutes ( see Section 7.6.7 )
Pulmonary  function tests (FVC and DL CO) (Visit s 7, 10 and11)(see Section 7.6.8 )
Skin biopsy  (Visit 8) (see Section 7.6.9 )
Recording and assessment of AEs (see Section 7.5)
Concomitant therap y
Dispens ation of study  drug and drug accountability
After intake of study  medication (at Visit 1 1only):
Blood sample for PK :between 2 3 hours after administration of the morning dose 
of study  medication (see Section 7.4)
Vital signs (blood pressure and heart rate) within 20 minutes prior to the PK sampling 
with the patient in a sitting position andafter the patient has been at rest for at least 
5minutes.  The same arm is alway s used for these measurements (see Section 7.6.5 ).
7.1.2.5 Visit 12 (Week 52) -amended
This is the last visit of the main treatment phase, and the first visit of the long -term extension 
phase. At this visit, the patient should attend the clinic without having taken the morning dose 
of riociguat or placebo.
Before intake of study  medication:
Questionnaires (see Section 7.6.13 )
Smoking history  
Physical examination, including weight (Note: BMI  will be calculated automatically  
in the eCRF)
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  54of 167
Oxygen saturation will be measured before and after intake of stud y drug ( see Section 
7.6.18 , Table 7–2, Table 7–3, and Table 7–4).80
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position ,after the patient has been at 
rest for at least 5 minutes.  The same arm is always used for these measurements (see 
Section 7.6.5 ) 
Assessment of orthostatic changes: measure blood pressure and heart rate in supine 
position and sitting position approximately  2 h after intake of stud y drug (see 
Section 7.6.5 ).81
mRSS (see Section 7.6.6 )
Digital ulcer net burd en assessment (see Section 7.6.9 )
Patient’s and phy sician’s global assessment (see Section 7.6.15 )
Patient interference with skin assessment (see Section 7.6.16 )
Tender and swollen joint count assessment (see Section 7.6.14 )
Blood samples for safet y (see Section 7.6.2 )
Pregnancy  test (urine) for all women of childbearing potential (see Section 7.6.1 )
12-lead ECG for centralized reading.  A standard 12- lead ECG will be obtained with 
the patient in the supine position after resting for at least 5 minutes (see Section 7.6.7 )
Pulmonary  function tests (FVC and DL CO) (see Section 7.6.8 )
Recording and assessment of AEs (see Section 7.5)
Concomitant therap y
Drug accountability
Start of long- term extension phase
Assignment of patients to treatment with riociguat via IxRS, dispensation of study  
drug and intake b y patient
After intake of study  medication:
Blood sample for PK (see Section 7.4)
oPK blood sample between 1 – 2 hours after administration of the morning 
(first) dose of stud y medication 
oPK blood sample between 3 –4 hours after administration of the morning
(first) dose of stud y medication
Vital signs (blood pressure and heart rate) should be measured within 20 minutes prior 
toeach PK sampling with the patient in a sitting position and after the patient has been 
at rest for at least 5 minutes.  The same arm is alway s used for these measurements 
(see Section 7.6.5 ).
                                                
80Per Amendment 6
81Per Amendment 6
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  55of 167
7.1.2.6 Visits 13 through to17Long -term extension phase -Dose -titration 
period -amended
At these study  visits, the patient should attend the clinic without having taken the morning 
dose of riociguat.
During the double -blind dose -titration period of the long-term extension phase , the following 
assessments will be performed according to the Schedule of evaluations (Section 7.1.1 ):
Oxygen saturation will be measured before and after intake of stud y drug ( see Section 
7.6.18 , Table 7–2, Table 7–3, and Table 7–4)82
Vital signs (blood pressure and heart rate).  Blood pressure and hear t rate will be 
measured at all visits with the patient in a sitting position ,after the patient has been at 
rest for at least 5 minutes. The same arm is alway s used for these measurements (s ee 
Section 7.6.5 )
Assessment of orthostatic changes: measure blood pressure and heart rate in supine 
position and sitting position approximately  2 h after intake of stud y drug (see 
Section 7.6.5 ).83
Digital ulcer net burden assessment (see Section 7.6.10)
Blood samples for safety  (Visit 17; see Section 7.6.2 )
Blood sample for PK up to 1 hour before the morning dose of stud y drug (see 
Section 7.4)
Pregnancy  test (urine) for all women of childbearing potential (on- site at Visits 14 and 
16) (see Section 7.6.1 )
Recording and assessment of AEs (see Section 7.5)
Concomitant therap y
Dose titrati on according to the titration algorithm (see Section 4.1.2 )
Dispens ation of study  drug and drug accountability
7.1.2.7 Visits 18 through Visit n (every 12weeks) Long -term extension 
phase Open- label extension period -amended
At these study  visits, the patient should attend the clinic without having taken the morning 
dose of riociguat. 
During the open -label extension period , the following assessments and procedures will be 
performed according to the Schedule of evaluations (Section 7.1.1 ):
Questionnaires (see Section 7.6.13 )
Smoking history
Physical examination , incl udingweight
                                                
82Per Amendment 6
83Per Amendment 6
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  56of 167
Oxygen saturation measurement using forehead pulse oximetry  (see Section 7.6.18 ).84
Vital signs (blood pressure and heart rate).  Blood pr essure and heart rate will be 
measured at all visits with the patient in a sitting position ,after the patient has been at 
rest for at least 5 minutes. The same arm is always used for these measurements ( see 
Section 7.6.5 )
mRSS (see Section 7.6.6 )
Digital ulcer net burden assessm ent (see Section 7.6.10)
Blood samples for safet y(see Section 7.6.2 )
Pregnancy  test (urine) for all women of childbearing potential (every  4weeks) (see 
Section 7.6.1 ). When pregnancy  testing coincides with a visit, the test should be 
performed at the site, but otherwise should be performed at home.
12-lead ECG for centralized reading.  A standard 12- lead ECG will be obtained with 
the patient in the supine position after resting for at least 5 minutes (s ee Section 7.6.7 )
Pulmonary  function tests (FVC and DL CO) (see Section 7.6.8 )
Recording and assessment of AEs (see Section 7.5)
Concomitant therap y
Dispens ation of study  drug and drug accountability
7.1.2.8 Termination Visit -amended
Thetermination visit will be performed if the patient is discontinued85from study  medication 
for an y reason except death or lost to follow-up, and should occur as soon as possible after the 
patient receives his/her last dose of study  drug.  Assessments and procedures at this visit 
include the following:
Questionnaires (see Se ction 7.6.13 )
Smoking history
Physical examination , including weight
Oxygen saturation measurement using forehead pulse oximetry  (see Section 7.6.18 ).86
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position, after the patient has been at 
rest for at least 5 minutes. The same arm is alway s used for these measurements (s ee 
Section 7.6.5 )
mRSS ( see Section 7.6.6 )
Digital ulcer net burden assessment (see Section 7.6.10)
Tender and swollen joint count assessment (not needed after V12, see Section 
7.6.14 )87
                                                
84Per Amendment 6
85Per Amendment 4
86Per Amendment 6
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  57of 167
Patient’s and phy sician’s global assessment ( not needed after V1288, see Section 
7.6.15 )
Patient interference with skin assessment ( not needed after V1289, see Section 7.6.16 )
Blood samples for safet y (see Section 7.6.2 )
Pulmonary  function tests (FVC and DL CO) (see Section 7.6.8 )
Blood sample for biomarkers (if TV occurs before Visit 8) (see Section 7.6.3 )
Skin biopsy  (if TV occurs before Visit 8) (see Section 7.6.9 )
Pregnancy  test (urin e) for all women of childbearing potential (if 4 weeks since the 
previous visit) (see Section 7.6.1 )
12-lead ECG for centralized reading.  A standa rd 12- lead ECG will be obtained with 
the patient in the supine position after resting for at least 5 minutes (s ee Section 7.6.7 )
Recording and assessment of AEs (see Section 7.5)
Drug accountability
Concomitant therap y
See also Section 7.1.2.10 for further planned assessments.
7.1.2.9 Safety follow -upvisit -amended
Patients must be evaluated for safety  30 (+5)days after the last dose intake of study  
medication .  Assessments will include the following:
Physical examination , including weight
Oxygen saturation measurement using forehead pulse oximetry  (see Section 7.6.18 ).90
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position, after the patient has been at
rest for at least 5 minutes.  The same arm is always used for t hese measurements (see 
Section 7.6.5 )
Recording and assessment of AEs (see Section 7.5)
Blood samples for safet y (see Section 7.6.2 )
Pregnancy  test (urine) for all women of childbearing potential
12-lead ECG for centralized reading.  A standard 12- lead ECG will be obtained with 
the patient in the supine position after resting for at least 5 minutes (see Section 7.6.7 )
Concomitant therap y
Survival status (see Section 5.2.1 )
                                                                                                                                                        
87Per Amendment 1
88Per Amendment 1
89Per Amendment 1
90Per Amendment 6
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  58of 167
7.1.2.10 Premature discontinuation of study drug treatment -amended
In the event of premature discontinuation of study  drug treatment, patients must undergo the 
same procedures as outlined for the termination visit (Section 7.1.2.8 ) and then undergo 
evaluation at the safet y follow -up visit, 30 (+5) days later (Section 7.1.2.9 ).
The reason for premature discontinuation of study  drug treatment or earl y withdrawal from 
the study  must be recorded in the eCRF (please refer to Section 5.2).
If the patient discontinues study drug91prematurel y during the main treatment phase (Week 0 
–Week 52) he/she will be invited to come for limite d assessments (mRSS, pulmonary  
function test [ FVC andDL COincluding hemoglobin measurement at the local laboratory ]92,
PRO s, and patient’s and physician’s global assessment )93at Week 12, Week 26, Week 39 and 
Week 52, depending on the timing of discontinuation94. This will be in addition to the 
termination visit assessments (see Section 7.1.2.8 ), provided that the patient does not object t o 
collection of study  data after withdraw alof consent.  I f the discontinuation occurs before Visit 
8 (Week 14), a skin biopsy  will also be performed.
7.2 Population characteristics
7.2.1 Demographic
The following demographic data will be recorded: 
Date of birth (m onth and y ear) (age)
Sex
Ethnicity
Smoking status, including number of cigarettes per day
Alcohol consumption
7.2.2 Medical history
Medical history  findings ( ie,previous diagnoses, diseases or surgeries) meeting all criteria 
listed below will be collected:
Pertaining to the stud y indication
Start ed before signing of the informed consent 
Considered relevant to the study
Medical history  related to concomitant therap y
Detailed instructions on the differentiation between (i) medical history  and (ii) AEs can be 
found in Section 7.5.1.1 .
7.3 Efficacy -amended
Primary eff icacy outcome measure
                                                
91PerAmendment 1
92Per Amendment 4
93Per Amendment 5
94Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  59of 167
Change in mRSS from baseline to Week 52
Secondary efficacy outcome95measures96
Key secondary  endpoint:
CRISSat Week 5297, consisting of five variables: mRSS, FVC % predicted, phy sician 
and patient global assessments, and HAQ -DI score (from SHAQ patient reported 
outcome)
Further secondary  endpoints:
HAQ -DI domain (separately from the SHAQ as part of the calculation of the CRI SS 
algorithm).
Patient’s global assessment
Physician’s global assessment
Change in FVC (forced vital capacit y) % predicted 
Further clinical outcomes (to be adjudicated by an Independent Central Adjudicat ion 
Committee)
New renal crisis
Worsening of cardiac disease, defined as new or worsened clinically symptomatic and 
significant heart disease, considered secondary  to dcSSc, including congestive heart 
failure requiring hospitalization, new onset pulmonary  hypertension requiring 
treatment, pericardial disease requiring intervention or exhibiting clinical 
decompensation, and arrhy thmias and/or conduction defects requiring treatment.
Worsening of gastrointestinal disease requiring hospitalization or new requir ement for 
parenteral nutrition
Critical digital ischemia requiring hospitalization, or digital gangrene
Additional information regarding the events to be adjudicated may  be requested to be sent to 
the Adjudication Committee.  All events listed above, in addition to all cases of death, 
regardless of causality  or seriousness will be reviewed b y the Adjudication Committee.
Other exploratory measures:98
mRSS progression rate (defined as increase in mRSS by  > 5 units and > 25% from 
baseline) and mRSS regressio n rate (defined as decrease in mRSS by  > 5 units and 
>25% from baseline)
HRQoL  using SF -36 and the SHAQ.
Digital ulcer net burden (defined as total number of ulcers at time point minus number 
of ulcers at baseline) and proportion of patients who do not de velop new ulcers
                                                
95Per Amendment 1
96Per Amendment 4
97Per Amendment 5
98Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  60of 167
Change in DL CO(carbon monoxide diffusing capacity ) % predicted
Need for Rescue99Therapy  (see definition in Section 6.9)
All-cause Mortality
Gastrointestinal involvement as assessed b y University  of California, Los Angeles, 
Scleroderma Clinical Trial Consortium Gastrointestinal Scale ( UCLA SCTC GI T) 2.0 
instrument
Patient- Reported Outcomes Measurement Information Sy stem ( PROMIS )-29 (subset 
of patients)
Patient interference with skin 
Presence or absence of tendon friction rubs
Pain visual analog scale ( VAS )
Change in BMI
Joint involvement using tender and swollen joint counts
New items for Ray naud’s response index excluding items inc luded in s econdary  
outcome measures
oPatient and phy sician assessment of Raynaud's phenomenon ; pain, numbness, 
and tingling during a Raynaud's phenomenon attack; Raynaud’s condition 
score, average number of attacks/day ; and duration of attacks
Endpoints long- term extension phase (Week 52 to study completion)
mRSS
Pulmonary  function testing
PROs / HRQoL
Worsening end -organ disease (cardiac, renal, pulmonary , gastrointestinal & digital 
ischemia)
7.4 Pharmacokinetics / pharmacodynamics -amended
At these study  visits the patients should present themselves to the hospital without taking the 
morning dose of study  medication. The trough PK sample should alway s be obtained at up to 
1 hour before administration of the morning dose of study  medication and approximate ly 5 to 
15hours after the evening dose100.
It is essential that the exact time of blood sampling and time of dose administration of the 
3preceding doses of study  medication are documented accuratel y in the eCRF. For samples 
taken before riociguat administr ation, also the time of the first dose taken at the visit needs to 
be documented101.
                                                
99Per Amendment 1
100Per Amendment 5
101PerAmendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  61of 167
For investigation of exposure behavior, plasma concentrations of BAY63 -2521 and its 
metabolite (M1) will be determined at the times given below using a sparse sampling 
appro ach in all participating patients. If the investigator decides to take additional PK 
samples, those may  be used for PK analy sis as well.102
Blood samples for PK will be taken at the following times:
Profile day (Visit 1 and Visit 12)
2 hours after administra tion of the morning dose of study  medication103
3 –4 hours after administration of the morning dose of study  medication
Visits 2 through to 6 and Visits 1 3 through to 17
Up to 1 hour before administration of morning dose of study  medication (trough)
Visit 11
Up to 1 hour before administration of morning dose of study  medication (trough)
2 hours after administration of morning dose of study  medication (peak)104
For details regarding the timing of PK sampling and flow charts detailing the order of 
procedures at these visits, please refer to Section 7.1.1 .
Plasma concentration time points will be compared to the available plasma concentration 
profiles in health y volunteers and selected patient populations. Pharmacokinetic and 
exposure -response anal ysis might be performed using population approaches (popPK
(population PK )and popPK/ pharmacod ynamic ( PD), eg, b y non -linear mixed effect 
modeling). Analy sis and report will be done under separate cover. This evaluation might be 
started prior to database lock. If this is applicable, appropriate measures will be taken to 
maintain blinding of the study  team , eg, data will be stored separatel y, and members of the 
study  team will nei ther have access to the randomization list nor to individual data .105
Sample collection, processing and storage
Further details on collection, labeling, storage and shipping of samples are provided in a 
separate laboratory  manual.
Pharmacokinetic (PK) samples will be analy zed under the responsibility  of the Bay er 
HealthCare Bioanaly tics Laboratory , Bay er Pharma AG, GDD -GED -DMPK Bioanal ytics, 
42096 Wuppertal, Germany . The bioanal yst will be unblinded and have access to the 
randomizat ion list.106
Any residual PK samples will be destroy ed at end of study .
                                                
102Per Amendment 5
103Per Amendment 6
104Per Amendment 6
105Per Amendment 5
106Per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  62of 167
7.5 Safety
7.5.1 Adverse events
7.5.1.1 Definitions -amended
Definition of adverse event (AE)
In a clinical stud y, an AE is any untoward medical occurrence ( ie,any unfavorable and 
unintended sign [inclu ding abnormal laboratory  findings], sy mptom or disease) in a 
patient or clinical investigation subject after providing written informed consent for 
participation in the study .  Therefore, an AE may  or may  not be temporall y or causall y 
associated with the u se of a medicinal (investigational) product.
A surgical procedure that was planned prior to the start of the study  by any physician treating 
the patient should not be recorded as AE (however, the condition for which the surgery  is 
required may be an AE).
In the following differentiation between medical history  and AEs, the term “condition” may  
include abnormal eg,physical examination findings, sy mptoms, diseases, laboratory , ECG.
Conditions that started before signing of informed consent and for which no s ymptoms 
or treatment are present until signing of informed consent are recorded as medical 
history  (eg,seasonal allergy  without acute complaints).
Conditions that started before signing of informed consent and for which symptoms or 
treatment are present after signing of informed consent, at unchanged intensity, are 
recorded as medical history (eg,allergic pollinosis) .
Conditions that started or deteriorated after signing of informed consent will be 
documented as AEs.This includes any  conditions related to the underl ying disease107.
Definition of serious adverse event (SAE)
An SAE is classified as any untoward medical occurrence that, at any  dose, meets any  of the 
following criteria (a –f):
a.Results in death
b.Is life -threatening
The term ‘life -threatening’ in the definition refers to an event in which the subject 
was at risk of death at the time of the event, it does not refer to an event which 
hypothetically  might have caused death if it were more severe.
                                                
107Per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  63of 167
c.Requires inpatient hospi talization or prolongation of existing hospitalization
A hospitalization or prolongation of hospitalization will not be regarded as an SAE if 
at least one of the following exceptions is met:
-The admission results in a hospital stay  of less than 12 hours
- The admission is pre- planned 
(ie,elective or scheduled surgery  arranged prior to the start of the study )
-The admission is not associated with an AE 
(eg,social hospitalization for purposes of respite care).
However, it should be noted that invasive trea tment during an y hospitalization may 
fulfill the criterion of ‘medicall y important’ and as such may be reportable as an SAE 
dependent on clinical judgment.  In addition, where local regulatory  authorities 
specificall y require a more stringent definition, t he local regulation takes precedence.
d.Results in persistent or significant disability  / incapacity
Disability means a substantial disruption of a person’s ability  to conduct normal life’s 
functions.
e.Is a congenital anomal y / birth defect
f.Is another medical ly important serious event as judged b y the investigator
7.5.1.2 Classifications for adverse event assessment
All AEs will be assessed and documented b y the investigator according to the categories 
detailed below. 
7.5.1.2.1 Seriousness
For each AE, the seriousness must be determined according to the criteria given in 
Section 7.5.1.1 .
7.5.1.2.2 Intensity
The intensity  of an AE is classified according to the following categories :
-Mild
-Moderate
-Severe
7.5.1.2.3 Causal relationship 
The assessment of the causal relationship between an AE and the administration of treatment 
is a clinical decision based on all available information at the time of the completion of the 
eCRF .
The assessment is b ased on the question whether there was a “reasonable causal relationship” 
to the study  treatment in question.
Possible answers are “y es” or “no”
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  64of 167
An assessment of “no” would include:
1. The existence of a clear alternative explanation, eg,mechanical bleeding at surgical 
site.
or
2.Non-plausibility , eg,the subject is struck by  an automobile when there is no indication 
that the drug caused disorientation that may  have caused the event; cancer developing a 
few day s after the first drug admi nistration.
An assessment of “y es” indicates that there is a reasonable suspicion that the AE is associated 
with the use of the study  treatment.
Important factors to be considered in assessing the relationship of the AE to study  treatment 
include:
-The temporal sequence from drug administration:  The event should occur after the drug 
is given.  The length of time from drug exposure to event should be evaluated in the 
clinical context of the event.
-Recovery  on drug discontinuation (de -challenge), recurren ce on drug re -introduction (re -
challenge):
-Subject’s response after de -challenge or subjects response after re- challenge should be 
considered in the view of the usual clinical course of the event in question.
-Underl ying, concomitant, intercurrent diseases:   
Each event should be evaluated in the context of the natural history  and course of the 
disease being treated and any  other disease the subject may  have.
-Concomitant medication or treatment: 
The other drugs the subject is taking or the treatment the subject receives should be 
examined to determine whether an y of them may  be suspected to cause the event in 
question.
-The pharmacology  and PKof the study  treatment: 
The PKproperties (absorption, distribution, metabolism and excretion) of the study  
treatmen t, coupled with the individual subject’s pharmacod ynamics should be considered.
Causal relationship to protocol -required procedure(s)
The assessment of a possible causal relationship between the AE and protocol -required 
procedure(s) is based on the question whether there was a “reasonable causal relationship” to 
protocol -required procedure(s).
Possible answers are “y es” or “no”
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  65of 167
7.5.1.2.4 Action taken with study treatment 
Any action on study  treatment to resolve the AE is to be documented using the categories 
listed below.
-Drug withdrawn
-Drug interrupted
-Dose reduced
-Dose not changed
-Dose increased
-Not applicable
-Unknown
7.5.1.2.5 Other specific treatment(s) of adverse events
-None
-Remedial drug therap y
-Other
7.5.1.2.6 Outcome
The outcome of the AE is to be documented as follows: 
-Recovered/resolved
- Recovering/resolving
-Recovered/resolved with sequelae
-Not recovered/not resolved
-Fatal
-Unknown
7.5.1.3 Assessments and documentation of adverse events
The investigator has the obligation to report AEs. All non- serious events will be assessed and 
recorded during the specified observational phase (from signing the informed consent form up 
to the follow -up visit 30 (+5) days after last study  medication inta ke), whether believed to be 
related or unrelated to the treatment. AE forms will be included in the eCRF s. The record will 
include clinical s ymptoms or final diagnosis when available, date of appearance, duration, 
severit y and relationship to treatment. A record will also be kept of the action taken and the 
follow -up until resolution of the AE.
7.5.1.4 Reporting of serious adverse events
The definition of SAEs is given in Section 7.5.1.1 .
Investigator’s notification of the sponsor
All investigators will be thoroughly instructed and trained on all relevant aspects of the 
investigator’s reporting obligations for SAEs.  This information, including all relevant c ontact 
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  66of 167
details, is summarized in the investigator site file.  This information will be updated as 
needed.
All SAEs occurring during the observation period defined in Section 7.5.1.3 must 
immediately  (within 24 hours of the investigator’s awareness) be reported to the recipient 
detailed in the manual.  An SAE form must also be completed within 24 hours of the 
investigator awareness and forwarded to th e designated recipient.  Each SAE must be 
followed up until resolution or stabilization by  submission of updated reports to the 
designated recipient.
SAEs occurring after the protocol -defined observation period will be processed by  the 
sponsor according to all applicable regulations.
Notification of the IECs / IRBs
Notification of the IECs / I RBs about all relevant events ( eg,SAEs, suspected, unexpected, 
serious adverse reactions [SUSARs ]) will be performed by the sponsor and/or by the 
investigator according to all applicable regulations.
Notification of the authorities
The processing and reporting of all relevant events ( eg,SAEs, SUSARs) to the authorities 
will be done by  the sponsor according to all applicable regulations.
Sponsor’s notification o f the investigational site
The sponsor will inform all investigational sites about reported relevant events ( eg,SUSARs) 
according to all applicable regulations.
7.5.1.5 Expected adverse events
For this study , the applicable reference document is the most current version of the 
IB/summary  of product characteristics.
Overview listings of frequent events that have occurred so far in the clinical development are 
shown in the current IB.  If relevant new safet y information is identified, the information will 
be integra ted into an update of the IB and distributed to all participating sites.
The expectedness of AEs will be determined b y the sponsor according to the applicable 
reference document and according to all local regulations.
In this stud y, the following events ar e outcome events and/or consistent with the underl ying 
condition and will be considered as disease related in the defined study  population:  
New renal crisis
Worsening of cardiac disease considered secondary to dcSSc
Worsening of gastrointestinal disease requiring hospitalization or new requirement for 
parenteral nutrition
Critical digital ischemia requiring hospitalization, or digital gangrene
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  67of 167
For the purposes of this trial, these events will not be subject to sy stematic unblinding and 
expedited reporting process, if reported as serious adverse drug reactions. They  will be 
captured in the Global Pharmacovigilance database, in the eCRF and undergo regular central 
adjudication and unblinded DMC review.
7.5.1.6 Adverse events of special safety interest
Symptomatic hypotension and serious hemopt ysis have been defined as AEs of special 
interest and must be documented accordingly  in the corresponding AEs of special safet y 
interest pages in the eCRF. Events of asymptomatic hy potension and non -serious hemopty sis 
should not automatically  be upgraded b y the reporting investigator to serious. Declaration of 
an event as serious should only occur when 1or more of the serious criteri a(as defined in 
Section 7.5.1.1 ) areapplicable.
7.5.1.7 Overdose of Study Medication
In case of overdose, standard supportive measures should be adopted as required.  In case of 
pronounced h ypotension, active cardiovascu lar support may  be required.  If sy mptoms 
develop after the investigational drug has been administered, any  therap y that becomes 
necessary  has to be guided by  the predominant s ymptoms.  Patients must remain under 
medical supervision until all relevant adve rse effects have resolved in the event of overdose; 
patient continuation remains at the discretion of the investigator.
7.5.2 Pregnancies
The investigator must report to the sponsor an y pregnancy occurring in a study  subject or his 
female partner during the subj ect’s participation in this study .  The report should be submitted 
within the same timelines as an SAE, although a pregnancy  per se is not considered an SAE.  
For a stud y subject, the outcome of the pregnancy should be followed up carefull y, and an y 
outco me of the mother or the child should be reported.
Bayer usuall y does not gather information of drug exposure via the father, however, if those 
cases are reported, all efforts should be made to obtain similar information on course and 
outcome, subject to the partner’s consent.
For all reports, the forms provided are to be used.
7.6 Other procedures and variables
7.6.1 Pregnancy testing
Pregnancy  testing is to be performed at the screening visit (serum onl y), Visit 1 (Day  0; urine ) 
and at4-weekl y intervals thereafter (urine) , at a termination visit, and until 30 (+ 5) daysafter 
the patient stops intake of study  drug. If the interval falls on a visit date ,pregnancy  testing is 
to be performed locall yat the site ,while at all other dates the patient is to perform a ur ine 
dipstick test at home. The results are to be documented in the eCRF and in the patient file.
The result of every  home urine pregnancy  test should be activel y requested by the site as soon 
as the test is due. The patient must report a positive result to the site without delay . The 
results are to be documented in the eCRF and in the patient file in a timel y manner. It is not 
acceptable to obtain the result only  at the next scheduled visit at the site. In the event of 
pregnancy ,a referral to a gyneco logist for confirmation of pregnancy  must be organized as 
soon as possible. In addition ,the pregnancy  must be reported to the sponsor as described in 
Section 7.5.2 and further consequences with regard to ongoing participation in the study  must 
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  68of 167
be discussed with the patient. In the event uncertainties about a pregnancy  test outcome exist , 
the patient should contact the site immediately  to discuss further steps (eg,exclusion of 
pregnancy  by serum pregnancy  test).
Based on country -specific regulations, further measurements may be performed.
Women of childbearing potential must agree to use adequate contraception when sexually  
active.
“Adequate contraception” is defined as an y combination of at least 2 effective methods of 
birth control, of which at least 1 is a phy sical barrier ( eg,condom with hormonal 
contraception like implants or combin ed oral contraceptives, condom with intrauterine 
devices ).  Patients must agree to utilize 2 methods of contraception simultaneously , of which 
at least 1should be a physical barrier ( eg,condom, diaphragm or cervical cap).
7.6.2 Laboratory parameters -amended
The following safet y laboratory  parameters will be anal yzed in a central laboratory  (apart 
from coagulation tests, which will be anal yzed at a local laboratory ) at the screening visit
(Visit 0) , Visit 1 (Day 0), Visit 6(Week 10),Visit 10 (Week 26)108, Visit 1 1(Week 3 9), Visit 
12(Week 52), Visit 1 7(Week 62), every  12 weeks during the Open -label extension period, 
termination visit, and safety  follow -up visit :
Hematology :WBC differential count, ery throcy tes, hemoglobin, hematocrit and
platelets
The hem oglobin value required for the pulmonary function tests performed at visits 
with limited assessments (see Section 7.1.2.10 ) will be measured at the local 
laboratory .The hemoglobin value will be entered in the eCRF and used for the 
calculation of predicted DL COonly.109
Coagulation tests :activated partial thromboplastin time ( aPTT) andinternational 
normalized ratio ( INR)(to be performed at a local laboratory )
Clinical chemistry : aspartate aminotransferase ( AST ), alanine aminotransferase 
(ALT ), alkaline phosphatase (AP), gamma glutamy l transferase (GGT), CK, sodium, 
potassium, magnesium, calcium, phosphate, creatinine, ur ea, uric acid, total bilirubin , 
total protein, serum albumin .
Patients with isolated AST or ALT >3xULN or bilirubin >2xUL N at screening and /or
baseline will have additional anal ysis of coagulation tests, AST, ALT, AP, GGT, total 
bilirubin and serum albumin until normalization and/ or stabilization at Visit 2 (Day 14), Visit 
3 (Day  28), Visit 4 (Day 42), Visit 5 (Day  56), as needed . Worsening of the parameters in the 
order of 2 -fold from baseline values will be considered clinically  significant [22]and 
additional diagnostic procedures may be requested110.See Section 5.2.1.2 for discontinuation 
criteria related to liver function .111
Patients entering the trial with eGFR 15- 29 mL/min/1.73m2will be undergo additional serum 
creatinine and eGFR calculation until normalization and/ or stabilization at Visit 2 (Day  14), 
Visit 3 (Day  28), Visit 4 (Day  42), and Visit 5 (Day  56), as needed . A decrease in eGFR 
                                                
108Per Amendment 1
109Per Amendment 4
110Per Amendment 1
111Per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  69of 167
equal or greater than 5ml/min/1.73m2in these patients (eGFR 15 -29 ml/min/1.73m2) during 
the study  or a reduction of 25% or more in 12 months will be considered clinically  
significant112[23,24].See Section 5.2.1.2 for discontinuation criteria rela ted to eGFR 
values.113
At latest ,at the end of the study  when all planned anal yses are co mpleted, all blood samples 
will be destroy ed. The name and address for the central lab oratory service provider can be 
found in the document ation supplied by  the vendor.
Note:   One re -assessment of laboratory  parameters is allowed during the screening phase to 
re-assess the eligibility  of patients .
7.6.3 Exploratory Biomarkers -amended
Exploratory  biomarkers will be evaluated at Visit 1 (Day  0) and Visit 8(Week 1 4)and at a 
termina tion visit if this visit occurs before Visit 8 .  Skin biopsy  and blood samples (serum and 
plasma) will be collected and processed to measure the following biomarkers (see 
Section 7.6.9 for details of skin biopsy ):
Skin biomarkers:
o  
 
 
 
Serum /plasma biomarkers: 
o  
 
 
Blood samples for inflammatory , vascular ,and fibrosis as well as skin samples will be 
analyzed by an external central laboratory ;details will be provided in the Laboratory  Manual. 
The evaluation of biomarkers might be started prior to database lock; if this is applicable, 
appropriate measures will be taken to maintain blinding of the stud y team (see also 
Section 6.5and Section 7.4). 114
The results of the biomarker anal ysis will be reported separatel y to the clinical study report.115
                                                
112Per Amendment 1
113Per Amendment 5
114Per Amendment 5
115Per Amendment 5
CCI
CCI
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  70of 167
7.6.4 Autoantibody s creen
Blood samples will be sent to the central laboratory at the Screening Visit (Visit 0) for 
anti-nuclear antibod y immunofluorescence and to detect the presence of SSc-associated anti -
nuclear autoantibodies , such as anti-Scl- 70 (anti -topoisomerase 1), anti-RNA poly merase III, 
and anti-centromere .
7.6.5 Blood pressure and heart rate measurement -amended
Blood pressure and heart rate will be measured at all visits with the patient in a sitting 
position ,after the patient has been at rest for 5 minutes. The same arm is alway s used for 
these measurements.
At certain visits where a blood sample fo r PK is scheduled after the morning dose of study  
medication , an additional vital signs measurement (blood pressure and heart rate) will be 
taken within 20 minutes prior to PK sampling. Please refer to Section 7.1.1 .
Methodology : Noninvasive measurement preferably  with a validated electronic device in 
accordance with published guidelines ( eg,American Heart Association Recommendations for 
Blood Pres sure Measurement in Humans and Experimental Animals [25]).
Assessment of orthostatic changes116
To assess orthostatic changes, blood pressure and heart rate will be measured with the patient 
in a supine position, after the patient has rested for 5 m inutes. Immediatel y thereafter , the 
patient should sit up and blood pressure and heart rate will be measured after the patient has 
rested for 2 minutes. 
These measurements should be performed approximately  2 hours after study  medication 
intake.
Frequency : Visit 11 (Week 39), Visit 12 (Week 52), during the Dose -Titration Period of the 
Long -Term Extension Phase (Visits 13 to 17).
7.6.6 Modified Rodnan skin s coring (mRSS) 
The mRSS is a validated phy sical examination method for estimating skin induration. It
corre lates with biopsy  measures of skin thickness and reflects prognosis and visceral 
involvement, especiall y in earl y disease. It is scored on 0 (normal) to 3+ (severe induration) 
ordinal scales over 17 body  areas, with a maximum score of 51 and is used to ca tegorize 
severit y of SSc. [26] It has been extensivel y used as a primary andsecondary  outcome 
measure in randomized clinical trials .[27,28]
This assessment should be perfor med b y a physician who is experienced and trained in skin 
scoring. To prevent inter- observer variabilit y, the same physician must perform skin scoring 
for the same patient throughout the entire study .
Frequency : Screening Visit (Visit 0) , Visit 7(Week 1 2), Visit 10 (Week 26), Visit 11 (Week 
39), Visit 12 (Week 52), and every  3 months thereafter in the long -term extension phase and 
termination visit . 
                                                
116Per Amendment 6
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  71of 167
7.6.7 Electrocardiogram
Standard ECGs (12-lead ECG) will be recorded with the patient in the supine position af ter 
the patient has rested for at least 5 minutes .
All ECG printouts will be identified with the patient identification as well as date and time of 
recording and will be attached to the patient’s file. All ECG printouts will be examined 
locally  by the investigator on the day  of recording for safety and qualit y. Any clinically  
relevant abnormality  will be documented as an AE. 
Electrocardiogram s will then be transferred electro nically  and assessed centrally by anexpert 
in cardiology  who will provide ex pert assessment and interpretation of all ECGs obtained . 
The name and address for the ECG service provider can be found in the documentation
supplied by  the vendor. Electrocardiogram procedures will be described in a separate manual. 
Frequency : screeni ng visit (Visit 0) , Visit 1 (Day 0), Visit 7 (Week 1 2), Visit 1 0(Week 26), 
Visit 1 1(Week 3 9),Visit 1 2(Week 52) , every  3 months (12 weeks) in the long -term 
extension phase, termination visit and safety  follow -up visit.
7.6.8 Pulmonary function testing
The following lung function measurements will be performed locall y: 
FVC and % of predicted
DL CO(mmol/min/kPa) and % of predicted ( hemoglobin -corrected)
Printouts from the analy zer must be stored in the patient file and the measured values 
trans ferred to the eCRF.
The hemoglobin value required for the pulmonary function tests performed at visits with 
limited assessments (see Section 7.1.2.10 ) will be me asured at the local laboratory . The 
hemoglobin value will be entered in the eCRF and used for the calculation of predicted DL CO
only.117.
Frequency : screening visit (Visit 0) , Visit 7 (Week 12), Visit 1 0(Week 26), Visit 1 1(Week 
39), Visit 1 2(Week 52) ,and every  3months (12weeks) in the long-term e xtension phase and 
termination visit .
7.6.9 Skin biopsy
As stated in Section 7.6.3 above ,biomarker analy sis will b e performed using skin and blood
samples.
Skin biopsies will be obtained from the mid dorsal surface of the forearm (15 0± 20 m m 
proximal to the ulnar sty loid) at Visit 1 (Day 0) and at Visit 8 (Week 14 ) and at a termination 
visit if this visit occurs before Visit 8 .
If affected skin is located in that area ,then the affected skin should be used. A biopsy  should 
be performed regardless of whether or not affected skin is present. The skin biopsy  obtained 
after treatment should be taken from the same arm,approximately  25 mm distance away  from 
the initial biopsy , so as to avoid healing of the initial biopsy  interfering with mRNA 
measurement . The location of the biopsy  (right or left forearm) and distance from the ulnar 
                                                
117Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  72of 167
styloid will be documented. If in the opinion of the investigator the mid dorsal forearm is not 
appropriate ,another location can be chosen. The alternative site and the reason for changing 
the site will be documented.
At each time point ( Visit 1 and Visit 8 ), two 4-mm skin punch biopsies next to each other will 
be obtained (one for RNA extraction and the other for histology /immunohistochemistry ).The 
skin to be biopsied will be cleaned before biops y and the remainder of the procedure will be 
performed using clean t echnique, per standard dermatological practice. The skin at the biopsy  
site will be marked by drawing a circle of about 10 m m diameter using a dermatological ink 
skin marker. 
Skin will be biopsied with a 4 -mm Baker st yle skin punch , provided b y the Spons or.  The 
punch will be centered at the 1 0-mm diameter circle.  The biopsy  site will be closed by  Steri -
strips or sutures (at the discretion of the investigator ) to provide hemostasis and ensure proper 
healing.
At the discretion of the investigator, patient s may be instructed to appl y a small amount of 
antibiotic ointment and a sterile bandage to the site daily ; these supplies will be provided by  
the investigator. At the discretion of the investigator the biopsy  site can be dressed with a n 
appropriate dress ing. If sutures are used the sutures will be removed after 5 to 14 days.
7.6.10 Digital ulcer net burden
Digital ulcers are defined as a full thickness skin lesion with loss of epithelium including 
lesions covered b y eschar. Ulcers should be > 3mm in maximal di ameter. Healing is defined 
by re-epithelialization with loss of pain and exudate. Pitting scars and h yperkeratot ic lesions 
are alway s excluded.
Digital ulcer net burden will be assessed b y the following methods:
Ulcer count –this ideall y will be performed b y the same healthcare professional at 
every  visit: 
oTotal ulcer counts
oDistal counts: distal (fingertip) –any ulcer including skin area distal to proximal 
interphalangeal (PI P) joint
Ulcer burden:
oNumber of ulcers at time point minus b aseline number of ulcers
Visual analog score (VAS) for patient -reported severity  of digital ulcers as part of the 
SHAQ (see section 7.6.13)
Frequenc y: Digital ulcer net burden assessment at every  visit. VAS as part of SHAQ: Visit 1 
(Day  0), Visit 8 (Week 14), Visit 10 (Week 26), Visit 11 (Week 39), Visit 12 (Week 52), 
Visit 18 (week 64), and every  3 months thereafter in the long -term extension phase and 
termination visit.
7.6.11 Digital gangrene
Digital gangrene will be recorded as a separate event and may  co-exist with digital ulcers that 
affect the same digit and fulfil the criteria in section 7.6.10 above. 
Gangrene is defined as diffuse necrosis (pathologic death of deeper, eg,subcutaneous 
structures) due to obstruction, loss, or diminution of blood supply ; it is of black color and 
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  73of 167
painful, and may  be localized to parts of the finger or involve an entire fi nger. It may  be wet 
or dry , reflecting a degree of adjacent tissue perfusion, time course of necrosis and presence 
or type of associated secondary  infection. 
7.6.12 Raynaud’s attacks assessment
Raynaud’s attacks will be assessed using the composite of the following 6 individual outcome 
measures in order to minimize the measurement variability  and placebo response: Raynaud’s 
condition score, patient assessment of Ray naud’s phenomenon, phy sician a ssessment of 
Raynaud’s phenomenon, attack s ymptoms, duration of attacks ,and average number of attacks 
per day .[29]
The Ray naud’s condition s core is a dail y patient self-assessment of Ray naud’s phenomenon 
activity  using a 0 -10 ordinal scale from ‘no difficulty ’ to ‘extreme difficulty’ . It incorporates 
the cumulative frequency, duration, severit y and impact of Raynaud’s phenomenon attacks, 
reflecting the overall degree that Ray naud’s has affected use of the patient’s hands .[30] 
The Ray naud’s condition score, details of the frequency and duration of Ray naud’s attacks, 
and attack s ymptoms of pain, numbness and tingling, each represented by  a 0 – 100 VAS, will 
be incorporated into the daily  diary  that patients will be asked to compl ete for 7 day s at the 
time points detailed below. 
The patien t and ph ysician assessment measur es the severit y of Raynaud’s phenomenon in the 
past week using a 0 100 VAS and will be assessed at the clinic visits outlined below .
Frequency : Daily  diary  to be completed b y patient for 7 consecutive day s leading up to Visit 
1(Day  0), and 7 consecutive day s leading up to Visit 8 ( Week 14 ). The patient and phy sician 
assessments of Ray naud’s phenomenon will be performed at Visit 1 and Visit 8. 
7.6.13 Patient -reported outcomes (PROs) / H ealth -related quality of l ife 
(HRQoL) questionnaires
Three PROs —the SF -36 v2.0 , SHAQ ,and UC LA SCTC GI T 2.0 —will be completed by  all 
patients in the study . The PROMI S-29 PRO will be completed b y patients in a subset of sites 
belonging to English -speaking countries as this instrument has not yet undergone translation 
into multiple languages. To minimize bias, patients will be assured that all data will be 
treated confidentially , will not be reported to their patient files, and that the answers will not 
have an y influence on study  drug treatment.  In addition, patients will complete the 
questionnaires on their own , or with the help of relatives , friends or study  staff if restricted b y 
digital lesions, before being seen b y the clinician at the respective visit. Subsequently , a 
member of the site investigator’s team will enter the responses into the eCRF.
Short Form 36 (SF -36) Questionnaire v2.0
The SF -36 is a multi -purpose, generic, HRQoL instrument that is composed of 1multi -item 
scale that assesses 8 health concepts: physical function, phy sical role limitations, bodily  pain, 
general health perceptions, vitality , social functioning, role limitations due to emotional 
problems ,and emotional well -being .[31]The instrument has 36 items and requires
approximately  5 minutes to complete.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  74of 167
Scleroderma Health Assessment Questionnaire (SHAQ)
The SHAQ consists of 8 domains from the HAQ -DI, a HRQoL instrument thatmeasures self -
reported function in 8domains of activity  in 20 weighted responses and a VAS of pain 
experienced in the past week. It additionall y measures 5 domains specific to scleroderma 
using a continuous VAS: Raynaud’s phenomenon, digital tip ulcers, lung sy mptoms, 
gastrointestinal s ymptoms , and a global patient assessment.[ 32]The VAS subscales of the 
SHAQ were shown to be significantl y correlated with objective parameters, [32]and was 
responsive to change in a cohort and in a Ray naud’s phenomenon trial in SSc. [30, 32]The 
SHAQ requir esappro ximately  5 minutes to complete.
University of California, Los Angeles, Scleroderma Clinical Trial Consortium 
Gastrointestinal Scale (UCLA SCTC GIT) 2.0
The UCLA SCTC GI T 2.0 instrument is a self -reported PRO consisting of 34 items, which 
are revised from the 52 -item instrument SSC -GIT version 1.0, and 7 multi -item scales that 
include reflux, distension/bloating, diarrhea, fecal soilage, constipation, emotional well -being ,
and social functioning. The validity  and reliability  of this tool has b een supported in a study  
performed in individuals with SSc, which also demonstrated good s ymptom correlation with 
gastrointestinal diagnoses. [33]The UCLA SCTC GIT 2.0 requires appro ximately  2 minutes 
to complete.
Patient -Reported Outcomes Measurement Information System (PROMIS) -29
The PROMI S-29 is a validated instrument to measure the health status of SSc patients, 
demonstrating moderate to high corr elation with other instruments validated in SSc ,including 
the SF -36 phy sical component score and HAQ -DI.[34]It incorporates 7 core domains from 
the PROMI S questionnaire, which specificall y relate to phy sical, mental , and social health 
aspects of chronic illness: pain, fatigue, depression, anxiety , sleep ,and ph ysical function, as 
well as one 11 -point rating scale for pain intensity .[34] It contains 8 items with 29 weighted 
responses in total, and requires approximately  5 minutes to complete. 
Frequency of all PROs: Visit 1 (Day  0), Visit 8 (Week 14), Visit 10 (Week 26), Visit 11 
(Week 39), Visit 12 (Week 52), Visit 18 (week 64), and every  3 months thereafter in the main 
treatment phase and long -term extension phase and at a termination visit.
7.6.14 Tender and swollen joint cou nt
This phy sician -reported tool evaluates 28 joints for swelling and tenderness. This outcome 
measure should be performed by  the same phy sician to assess the burden of joint disease from 
SSc-associated pol yarthritis and myopath y. 
A sample form is shown in A ppendix 14.3
Frequency : Screening Visit (Visit 0) and Visit 1 2(Week 52) and termination visit (not 
needed after V12).
7.6.15 Patient’s an d physician’s global assessmen t -amended
This tool incorporates a self- assessment and phy sician assessment on the patient’s overall 
health in the prior 1 week using a 0 10 ordinal scale and arating of overall SSc-related health 
transition compared with 1 month prior and 1 year prior .
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  75of 167
Frequency : Visit 1 (Day 0),Visit 1 0(Week 26) and Visit 1 2(Week 52) ,termination visit (not 
needed after V12) , and visits with limited assessments .118
7.6.16 Patient interference with skin assessment
This self- assessment evaluates the degree in which skin involvement has interfered with the 
patient’s daily  activities over the last month on an ordinal scale of 0 (does not limit activity ) 
to 10 (very severe limitation ). 
Frequency : Visit 1 ( Day 0), Visit 10(Week 26) and Visit 1 2(Week 52) and termination visit 
(not needed after V12) . 
7.6.17 Tendon friction rubs
Anatomical sites including the hands, wrists, elbows, shoulders, knees and ankles will be 
examined for the presence or absence of tendon friction rubs at the two time points detailed 
below. 
Frequency : Visit 1 (Day 0) and Visit 8 (Week 14). 
7.6.18 Oxygen saturation measurement using forehead pulse oximetry119
Oxygen saturation measurements will be performed in all subjects using non -invasive 
forehead pulse oximetry  expressing the SpO 2(peripheral ox ygen saturation) percentage. At 
visits with blood pressure measurements to assess orthostatic changes, ox ygen saturation will 
be measured pre -dose and post -dose (see Table 7–2, Table 7–3, and Table 7–4). At all other 
visits, ox ygen saturation will be measured pre -dose only . 
If the patient receives supplemental ox ygen, the amount [L /min] will be recorded in the 
eCRF.
Frequency : Visit 9 (Week 20), Visit 10 (Week 26), Visit 11 (Week 39), Visit 12 (Week 52), 
Visits 13 to 17 (Week 54 to 62), Visit 18 to Visit n (Open -label Extension Period), 
Termination Visit, and 30- day Safet y Follow -up.
7.7 Appropriateness of procedures / measurements
All safet y and efficacy variables, as well as the methods to measure them, are standard 
variables/ methods in clinical studies and/ or clinical practice.  They are widely  used and 
generall y recognized as reliable, accurate and relevant.
8. Statistical methods and determination of sa mple size
8.1 General considerations
All variables will be analyzed descriptively  with appropriate statistical methods: categorical 
variables b y frequency  tables and continuous variables by  sample statistics ,ie,mean, standard 
deviation, minimum, median, quartiles (if data are clearly  non- normal ) and maximum.
If not mentioned otherwise, all statistical tests will be performed with a t ype I two -sided error 
rate of =5%.
                                                
118Per Amendment 5
119Per Amendment 6
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  76of 167
Statistical analy ses will be performed using SAS (Statistical Analy sis Sy stem ); the version 
used will be specified in the statistical analy sis plan ( SAP).
8.2 Analysis sets -amended
Efficacy  and safet y analyses will be performed in patients valid for the full anal ysis set (FAS).  
This is defined as all patients randomized and treated w ith study  medication.  I nvestigators 
will be instructed not to make the call to the I xRS sy stem until they  are certain the patient is 
valid to be treated with study  medication, on the day  that study  medication is to start.  I n that 
way, we expect all patie nts who are randomized also to be treated, so the FAS population 
would then be consistent with the full intent -to-treat (ITT) definition.
For the primary  and secondary  exploratory  efficacy  and safet y endpoints, as a supportive 
analysis,a per protocol set (PPS) will also be defined, including patients who meet the major 
inclusion and exclusion criteria at randomization that may  affect efficacy , who are not taking 
excluded concomitant medications during the study  that could have an effect on efficacy (not 
including rescue120medication after Week 26), have the mRSS assessed at baseline and at 
least once during the main treatment phase and who are at least 80% compliant with study  
medication.  A full definition of valid for PPS will be given in the SAP.
8.3 Variables
Efficacy  variables are provided in Section 7.3and safet y variables are described in 
Section 7.5.
8.4 Statistical and analytical plans
8.4.1 Demographic and other baseline characteristics
Demographic variables and baseline characteristics will be summarized by  treatment group 
for both anal ysis populations, that is ,the FAS and PPS.
Medical history  findings and AEs will be coded by  Medical Dictionary  for Regulatory  
Activities (MedDRA )codes and medications b y Anatomical Therapeutic Chemical ( ATC )
codes ( World Health Organization Dru g Dictionary  [WHO -DD]).
8.4.2 Efficacy -amended
In the efficacy  anal yses, countries and centers will be clustered b y geographic region. The 
decision on country  pooling will be made before unblinding. Statistical analy ses will be 
adjusted for these countr ies/geographic regions.
8.4.2.1 Primary endpoint121
The primary  anal ysis will be the change in mRSS from baseline to all assessments post 
baseline up to Week 52 using mixed model repeated measures (MMRM) with baseline mRSS 
as a covariate, fixed effects treatment arm and region, the interaction effect between stud y 
visit and treatment arm, and patient specific random effects to account for both heterogeneit y 
among patients and correlation among measurements taken on the same patient with an 
unstructured covariance assumption .  The main estimand of interest is the treatment difference 
                                                
120Per Amendment 1
121Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  77of 167
between the riocig uat and placebo treatment arms at Week 52. The null hypothesis to be 
tested is no difference between riociguat and placebo at this visit.
The model statement is:
Yij= μ + βXi+ tk+ rl+ v j+ (tv) jk+ si+ εij
where Yij  is the change from baseline in mRSS to visit j for subject i that is in 
treatment group k and region l; μ is the intercept, β is the baseline covariate effect, X i
is the baseline mRSS for subject i, t kis the fixed effect of treatment k, r lis the fixed 
effect of region l, v jis the fixed effect of visit j, (tv) jkis the interaction effect of 
treatment k b y visit j, s iis the random effect of subject i and εij  ~ Normal(0, σ2) 
represents the residual variance component with corr( εi j, εi j’) = ρ jj’,  j≠ j’
As a sensitivity  anal ysis, the MMRM using the above model will also be applied to 
assessments post -baseline up to termination of study  medication or initiation of rescue 
medication.  In addition, the MMRM on all assessments will be repeated including addit ional 
effects time on rescue medication and time on study  medication.  MMRM assumes missing at 
random; mRSS by  time of patient discontinuation from study  medication122will be 
summarized and further methods using multiple imputation that allow for missing data not at 
random will be investigated.  Details of such methods will be described in the SAP.
An additional univariate sensitivity anal ysis will look at change in mRSS from baseline to 
Week 52 / last visit using anal ysis of covariance (ANCOVA) with basel ine mRSS as a 
covariate, treatment arm and region as main effects.  Last visit is defined as the last visit on 
treatment which in the case of premature termination of study  medication is the termination 
visit.  I n the case of rescue123medication, the last v isit is the visit where the decision is made 
to start rescue124medication with efficacy  being assessed prior to escape medication starting.
As a robustness analy sis, a stratified (by region) non -parametric Wilcoxon test comparing 
riociguat and placebo will also be performed.  In addition, and consistent with the primary 
analysis, a further ITT sensitivity  endpoint analy sis of change in mRSS to Week 52 / last visit 
will include all measurements recorded up to Week 52 or the termination visit, including 
those while rescue125medication was taken or if the patient returned after termination for a 
later visit up to Week 52.
Rules for the imputation of missing values where the patient discontinues the study  
(withdrawal of consent or death) or the study  medication126for the univariate anal ysis, null / 
alternative h ypothesis statements, and model statements in mathematical notation will be 
specified in the SAP.  Two -sided 95% confidence intervals of treatment (riociguat compared 
to placebo) differences will be calculat ed in addition to the statistical significance testing.
                                                
122Per Amendment 4
123Per Amendment 1
124Per Amendment 1
125Per Amendment 1
126Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  78of 167
8.4.2.2 Secondary and exploratory endpoints127
General aspects
The other secondary  and exploratory  efficacy  variables measured on a continuous or semi-
continuous scale will analy zed using the M MRM, ANCOVA ,and stratified Wilcoxon test, as 
for the mRSS above.
The time to first mRSS progression and regression and clinical outcome parameters will be 
analyzed using the log -rank test comparing between treatment groups.
Any binary  outcomes, such as the predicted CRI SSoutcome, will be anal yzed using Mantel -
Haenzel weights, stratified by  region.  Also as a sensitivity  analy sis in addition to the time to 
event anal ysis, the occurrence of the events mRSS progression and regression and clinical 
outcome parameters will be anal yzed using this method.
Details on an y descriptive subgroup anal yses will be specified in the SAP.  These will include 
gender and region.
Hierarchical testing of secondary en dpoints128
The following secondary endpoints will be tested in a hierarchical fashion at a 2-sided 5% 
level, only  if the primary  endpoint of mRSS is shown to be statistically  significant at a 2 -sided 
5% level.
The following order of testing will be applied:
CRISS
HAQ -DI (health assessment questionnaire -disability  index)
Patient's global assessm ent
Physician's global assessment
FVC % predicted
For example, if CRI SS is statistically  significant at a 2-sided 5% level, then theHAQ -DIwill 
be tested , if not the testing procedure will be stopped . This step is repeated further down the 
list of the 5secondary  endpoints until a non-statistically  significant endpoint is reached. 
These particular secondary  endpoints were chosen to be tested in this hierarchical fashion, 
because the mRSS and the above additional, secondary  variables were considered to have the 
greatest face validity  when designing the CRISS [ 41].
                                                
127Per Amendment 4
128Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  79of 167
American College of Rheumatology Combined Response Index for Systemic Sclerosis129
The key secondary  endpoint will be the CRI SSat Week 52 .130
Application of CRI SS algorithm in a randomized clinical trial is a 2-step process. Firstl y, 
evaluate if patients have met the criterion for not-improved. If yes, the sepatient sareassigned 
a probabil ity score of 0.0. For the remaining patients, calculate the probability  based on 
change in 5measures: mRSS, FVC %, HAQ -DI, patient ’sglobal assessment, and phy sician's 
global assessment, where each measure has a probability  score between 0 and 1 [41]. 
In Step 1, a patient is clinically  evaluated to determine whether the patient has improved or 
not.  Expert consensus on the definition of a patient who is not improved during a trial is the 
following:
A patient is considered not improved and is assigned a probabilit y score of improving equal to 
0.0, irrespective of improvement on other core items, if he/she develops: 
1. N ew scleroderma renal crisis, 
2. Decline in FVC % predicted ≥15% (relative), confirmed by  another FVC % within a 
month, high resolution computed tomograph y (HRCT )to confirm interstitial lung 
disease (if previous HRCT did not show interstitial lung disease ) and FVC % 
predicted below 80% pre dicted (attributable toSSc), 
3. New onset of left ventricular failure (defined as ejection fraction ≤45%) or new onset 
of pulmonary  arterial hypertension requiring treatment (attributable to SS c).
If the patient is determined to exhibit improvement in Step 1 (ie, not assigned a 0.0), Step 2 
involves computing the predicted probability  of improving (a score between 0.0 and 1.0, 
inclusive) for each patient using the equation:
      .    .  ∗∆      .  ∗∆   %  .  ∗∆         .  ∗∆         .  ∗∆       
        .    .  ∗∆      .  ∗∆   %  .  ∗∆         .  ∗∆         .  ∗∆       
where ∆MRSS indicates the change in mRSS from baseline to Week 52, ∆ FVCdenotes the 
change in FVC % predicted from baseline to Week 52, ∆ Pt-globindicates the change in patient 
global assessment, ∆MD-globdenotes the change in phy sician global assessment, and ∆ HAQ -DIis 
the change in HAQ -DI131. Note that all changes are absolute changes (Time 2–Time baseline ) 
and that the ph ysician’s and pat ient’s global assessment was measured on the L ikert scale 
ranging from 0 to 10, where 0 = excellent, and 10 = extremely  poor.
Hence, the CRI SS is comprised of 5 variables: mRSS, FVC % predicted, patient’s global 
assessment, phy sician’s global assessment , and HAQ- DI from the SHAQ patient reported 
outcome. Combined, the 5 variables explained 89.3% of the variability  in the data. 
Individuall y, when used in a single -variable logistic regression model, mRSS explaine d 
66.3% of the variation, FVC % predicted exp lained 36.1% of the variation, phy sician global 
assessment explained 24.5% of the variation, patient global assessment explained 23.7% of 
the variation, and HAQ -DI explained 28.5% of the variation. A change in mRSS, FVC % 
predicted and HAQ -DI are strong i ndicators of whether a patient is likely  to be improved or 
not. I n each scenario, a decrease of mRSS or HAQ -DI from baseline to Week 52132and an 
                                                
129Per Amendment 4
130Per Amendment 5
131Per Amendment 5
132Per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  80of 167
increase in FVC % predicted corresponds to very  high probabilities of improving. For 
patient ’sglobal and ph ysician’sglobal assessment, the association between probability  of 
improving and change in these 2core components is less evident. Subjects for which the 
predicted probability  is greater or equal to 0.60 are considered improved, while subjects for 
which the predicted probability  is below 0.60 are considered not improved. The 2groups 
(riociguat vs. placebo) can then be compared in a 2x2 table using appropriate significance 
tests. The predicted probabilities obtained using the CRI SS can also be assessed as a 
continuous variable and the distributions of the probability  of improving for patients on drug 
vs. placebo can be compared using non -parametric tests [41].In this study , the CRI SS 
outcome will be anal yzed using Mantel -Haenzel weights, stratified by  region, and 
additionally , the stratified Wilcoxon test will be used as non- parametric test.
However, Step 2 assumes that there is complete data; ie, all 5components of the CRI SS are 
fully recorded at Week 52. If the subject discontinues from study  drug before Week 52, or 
has one or more missing components of the CRI SS at this visit, then a mixed model repeated 
measures (MMRM) analy sis will be impleme nted to estimate the value or values for those 
components at Week 52. These estimates will then we used to calculate the CRI SS score at 
Week 52 as given in Step 2. Subjects for which the predicted probability  is greater or equal to 
0.60 are considered imp roved, while subjects for which the predicted probability  is below 
0.60 are considered not improved. [41]Further details will be provided in the st atistical 
analysis plan.
8.4.3 Safety - amended
The incidence of treatment -emergent AEs (TEAEs) will be tabulated by treatment group .  
Adverse event s are considered to be treatment- emergent if they  have started or worsened after 
first application of study  drug u p to 2 day s after end of treatment with study drug.  Further 
tables will be produced for serious and/or drug- related treatment -emergent AEs , also 
treatment -emergent AEs leading to discontinuation of study  drug and of special safet y 
interest .  The incidence of AEs during pre-treatment and during follow-up ( ie,AEs occurring 
more than 2 days after end of treatment with study drug) will be tabulated separately .In 
addition to the summary  tables of AEs, listings of SAEs , AEs leading to discontinuation of 
study  drug and AEs of special safet y interest will be provided.
Mortality  in the study  will be summarized descriptively . Any deaths in the study  period will 
be listed, with day  of death relative to start and stop of study  drug and cause of death.
Mortality  is also defined as an exploratory  efficacy  parameter, and so being a binary  outcome 
the difference in occurrence between treatment groups will be analy zed as de scribed in 
Section 8.4.2 .
The safet y evaluation of laboratory  data will include:
Incidence rates of treatment -emergent laboratory values outside of normal range
Incidence rates of pre -specifie d laboratory  data abnormalities
Descriptive anal ysis of continuous laboratory  parameters and their changes from 
baseline b y treatment group and visit.
Descriptive anal ysis of vital signs and their changes from baseline will be performed b y 
treatment group and visit. Descrip tive statistics of pulse oximetry  and blood pressure/heart 
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  81of 167
rate measurements for the assessment of orthostatic changes will be performed by  treatment 
group and visit.133
For ECGs, the status pre- treatment and post treatment -initiation will be tabulated.  The 
incidence rates of treatment-emergent ECG abnormalities will be tabulated by treatment 
group .  A descriptive analy sis of continuous ECG parameters and their changes fr om baseline 
by treatment group and visit will also be presented.
8.4.4 Pharmacokinetics
For the investigation of PK, the plasma concentrations of riociguat and its main metabolite 
M-1 (BAY 60 -4552) will be determined at the times given in Section 7.4using a sparse 
sampling approach.
The data processing and the statistical anal ysis will be performed in accordance with the 
sponsor’s current g uidelines.
Riociguat and its main metabolite M -1 (BAY 60 -4552) peak and trough concentrations will 
be summarized by  visit, separated according to actual dose.
8.5 Planned interim analyses - amended
A formal interim anal ysis of the main treatment phase is not p lanned.  The main treatment 
phase will be unblinded for data analy sis when the last patient completes the main treatment 
phase (Visit 12)134and the database for the main treatment phase is declared clean, whichever 
occurs last.
The first safety  update will be performed on the long-term extension phase when the last 
patient completes 24weeks of treatment (Visit 19)135.  Safety updates then will be performed 
at least y early  until the last patient completes the entire study , when a f inal anal ysis will be 
conducted.
8.6 Determination of sample size -amended
There is lack of positive trials in dc SSc.  Most trials have used change in mRSS to Month 6 or 
Month 12 as the primary  endpoint, and 4published articles are referenced f or the estimat e of 
variability  in this study  (Table 8–1).
                                                
133Per Amendment 6
134Per Amendment 5
135Per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  82of 167
Table 8–1 References for estimate of variability
Reference Trial treatment Active arm SD Placebo arm SD
Postlethwaite (2008) [35]Collagen 0 –12 months 7.6 7.7
Khanna (2009) [26] Relaxin 0 –24 weeks 7.0 7.0
Merkel (2012) [36] 0 –6 month meta -analy sis 7.2
0 –12 month meta -analysis 8.4
Amjadi (2009) [37] D- Pen 8.6
Relaxin 7.0
Collagen 7.1
Abbreviations:  D -Pen = D -penicillamine; SD = standard deviation.
Taking these sources into account, a reasonable upper bound for the estimate of the standard 
deviation to be used in the sample size calculation of this study  has been taken as 8.0.
One of the components of exploratory efficacy  measure136mRSS progression is a 5 point or 
more deterioration from baseline to an y assessment in the 12 month st udy period, this being 
considered a clinicall y meaningful change [14].  For the primary sample size calculation 
based on change in mRSS from baseline to Week 52, a slightly  more conservative 4 -point 
difference between riociguat and placebo has been taken, given that the trials referenced 
above never achieved a 5 -point, or even a 4 -point, superiority  of active over placebo.
The primary  efficacy  estimand in this study  will be change in mRSS from baseline to 
Week 52. Assuming a standard deviation of 8 points, a power of between 70% and 80% and a 
two-sided significance level of 5%, with a 1:1 randomization, then to detect a 
placebo -adjusted differen ce of 4 points, between 51 and 64 patients in each treatment group, a 
total of 102 to 128patients , would be required to be valid for the ITT anal ysis(see Table 8–
2). Allowing for up to two patients randomized and not treated, approximately 130 
randomized patients are planned.137
Table 8–2 Power calculations: power varying from 70% to 80% in 2% stages138
N per group 51 53 56 58 61 64
Total N 102 106 112 116 122 128
Power (%) 70 72 74 76 78 80
N =number of patients
Sources of these sample size and power calculations are nQuery version 7.0, module 
MTT0 -1.139
                                                
136Per Amendment 4
137Per Amendment 5
138Per Amendment 5
139Per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  83of 167
9. Data handling and quality assurance
9.1 Data recording
It is the expectation of the sponsor that all data entered into the eCRF has source 
documentation available at the site.  The site must implement processes to ensure this 
happens.  A source document checklist will be used at the site to identify the source data for 
all data points collected and the monitor will work with the s ite to complete this.
Specif icdata may  be entered directl y into the eCRF according to instructions provided in the 
eCRF completion manual. 
Data recorded from “only screened patients (screening failures)”
Data of 'onl y screened patients' will be recorded at least as source data, as far as the reason for 
the premature discontinuation is identifiable.  At minimum, data to be recorded in the eCRF
are demographic information ( patient number, date of birth/age, sex and ethnicity ), inclusion 
and exclusion criteria, the reason for premature discontinuation and date of last visit.  These 
data will be transferred to the respective database.
For screening failures with an SAE, the following additional data should be collected in the 
eCRF , in addition to demographic information, primary  reason for discontinuation and date of 
last visit :
All information about the SAE
All information related to the SAE such as: 
Concomitant medication
Medical history
Other information needed for SAE complementary  page
9.2 Monitoring
In accordance with applicable regulations, GCP, and sponsor’s/ clinical research 
organization’s (CRO’s ) procedures, monitors will contact the site prior to the start of the 
study  to review with the site staff the protocol, study  requirements, and their respons ibilities 
to satisfy  regulatory , ethical, and sponsor’s requirements. When reviewing data collection 
procedures, the discussion will also include identification and documentation of source data 
items.
Thesponsor /designee will monitor the site activity  toverify  that the:
Data are authentic, accurate and complete
Safety  and rights of patients are being protected
Study  is conducted in accordance with the currently  approved protocol 
(including stud y treatment being used in accordance with the protocol)
Any other study  agreements, GCP, and all applicable regulatory requirements are met.
The investigator and the head of the medical institution (where applicable) agrees to allow the 
monitor direct access to all relevant documents.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  84of 167
9.3 Data processing
The data collection tool for this study  will be a validated electronic s ystem called Medidata 
Rave. Patient data necessary  for anal ysis and reporting will be entered/ transmitted into a 
validated database or data sy stem ( eg,TOSCA V4 3_1_1; SAS 9.2).  Cli nical data 
management will be performed in accordance with applicable sponsor’s standards and data 
cleaning procedures. This is applicable for data recorded on eCRF as well as for data from 
other sources ( eg,IxRS, laboratory , ECG).
For data coding (eg, AEs, medication), internationally  recognized and accepted dictionaries 
will be used. After its initial release for biometrical analy sis, the clinical database is planned 
to be re -opened for the inclusion of the following additional data: eg,PKdata, biomar ker140
data.
9.4 Audit and inspection
To ensure compliance with GCP and regulatory  requirements, a member of the sponsor’s (or a 
designated CRO’s) quality  assurance unit may  arrange to conduct an audit to assess the 
performance of the study at the study  site and of the study  documents originating there.  The 
investigator/institution will be informed of the audit outcome.
In addition, inspections by regulatory  health authority  representatives and IEC(s)/I RB(s) are 
possible.  The investigator should notify  the spon sor immediately  of any  such inspection.
The investigator/institution agrees to allow the auditor or inspector direct access to all relevant 
documents and allocate his/her time and the time of his/her staff to the auditor/inspector to 
discuss findings and a ny issues.  Audits and inspections may  occur at any  time during or after 
completion of the study .
9.5 Archiving
Essential documents shall be archived safel y and securel y in such a way that ensures that they  
are readil y available upon authorities’ request.
Patient (hospital) files will be archived according to local regulations and in accordance with 
the maximum period of time permitted by  the hospital, institution or private practice.  Where 
the archiving procedures do not meet the minimum timelines require d by the sponsor, 
alternative arrangements must be made to ensure the availability  of the source documents for 
the required period.
The investigator/institution notifies the sponsor if the archival arrangements change 
(eg,relocation or transfer of ownersh ip).
The investigator site file is not to be destroy ed without the sponsor’s approval.
The contract with the investigator/institution will contain all regulations relevant for the stud y 
center.
                                                
140Per Amendment 5
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  85of 167
10. Premature termination of the study
The sponsor has the right to close this study  (or, if applicable, individual segments thereof 
[eg,treatment arms; dose steps; centers]) at an y time, which may be due but not limited to the 
following reasons: 
If risk -benefit ratio becomes unacceptable owing to, for example,
-Safety findings from this study  (eg,SAEs)
-Results of any  interim analy sis
-Evaluation of risk -benefit at any  time in the study  where a lack of substantial 
treatment benefit is shown
- Results of parallel clinical studies
-Results of parallel animal studies 
(on eg,toxicity , teratogenicity , carcinogenicity  or reproduction toxicity ).
If the stud y conduct ( eg,recruitment rate; drop -out rate; data qualit y; protocol 
compliance) does not suggest a proper completion of the trial within a reasonable time 
frame.
The invest igator has the right to close his/her center at an y time.
For an y of the above closures, the following applies:
Closures should occur only  after consulta tion between involved parties.   Final decision 
on the closure must be in writing.
All affected institut ions ( eg,IEC(s)/IRB(s); competent authority (ies); study  center ; 
head of stud y center ) must be informed as applicable according to local law.
All study  materials (except documentation that has to remain stored at site) must be 
returned to the sponsor.  The investigator will retain all other documents until 
notification given b y the sponsor for destruction.
In case of a partial study closure, ongoing patients , including those in post study  
follow -up, must be taken care of in an ethical manner.
Details for individual patient's discontinuation141can be found in Section 5.2.1 .
11. Ethical and legal aspects
11.1 Ethical and legal conduct of the study
The procedures set out in this protocol, pertaining to the conduct, evaluation, and 
documentation of this study , are designed to ensure that the sponsor and investigator abide by  
GCP g uidelines and under the guiding principles detailed in the Declaration of Helsinki.  The 
study  will also be carried out in keeping with applicable local law(s) and regulation(s).
Documented approval from appropriate IEC(s)/IRBs will be obtained for all participating 
centers/countries before start of the study , according to GCP, local laws, regulations and 
organizations.  When necessary , an extension, amendment or renewal of the Ethics 
                                                
141Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  86of 167
Committee ( EC)/IRB approval must be obtained and also forwarded to the sponsor .  The 
responsible unit ( eg,EC/IRB, head of the stud y center/medica l institution) must supply  to the 
sponsor , upon request, a list of the EC/I RB members involved in the vote and a statement to 
confirm that the EC/I RB is organized and operates according to GCP and applicable laws and 
regulations.
Strict adherence to all sp ecifications laid down in this protocol is required for all aspects of 
study  conduct; the investigator may  not modify  or alter the procedures described in this 
protocol.  
Modifications to the study  protocol will not be implemented by  either the sponsor or the 
investigator without agreement by  both parties.  However, the investigator or the sponsor may  
implement a deviation from, or a change of, the protocol to eliminate an immediate hazard(s) 
to the trial subjects without prior IEC/I RB/sponsor approval/fav orable opinion.  As soon as 
possible, the implemented deviation or change, the reasons for it and if appropriate the 
proposed protocol amendment should be submitted to the I EC/IRB/ head of medical 
institution/ sponsor.  Any  deviations from the protocol must be explained and documented b y 
the investigator.
Details on discontinuation of the entire stud y or parts thereof can be found in Section 10.
11.2 Patient information and consent
All relevant information on the study  will be summarized in an integrated patient information 
sheet and informed consent form provided b y the sponsor or the study center.  A sample 
patient information and informed consent form is provided as a docum ent separate to this 
protocol .
In addition there will be a Declaration of Objection to the Collection of Study  Data after 
Withdrawal of Consent and the Information Sheet & Informed Consent Form for Collection 
of Data on Pregnancy  and Birth .
Based on this patient information sheet, the investigator or designee will explain all relevant 
aspects of the stud y to each patient / legal representative or prox y consenter (if the patient is 
under legal protection), prior to his/her entry  into the stu dy (ie,before an y examinations and 
procedures associated with the selection for the study  are performed or an y study -specific data 
is recorded on study -specific forms).
The investigator or designee will also mention that written approval of the IRB/IEC ha s been 
obtained.
Each patient / legal representative or proxy  consenter will have ample time and opportunity  to 
ask questions and will be informed about the right to withdraw from the study  at any  time 
without any  disadvantage and without having to provide reasons for this decision.
Only  if the patient / legal representative or prox y consenter voluntaril y agrees to sign the 
informed consent form and has done so, may  he/she enter the stud y.  Additionally , the 
investigator and other information provider (if a ny) will personally  sign and date the form.  
The patient / legal representative or prox y consenter will receive a cop y of the signed and 
dated form.
The signed informed consent statement is to remain in the investigator site file or, if locall y 
required, i n the patient’s note/file of the medical institution.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  87of 167
In the event that informed consent is obtained on the date that baseline study procedures are 
performed, the study  record or patient ’s clinical record must clearl y show that informed 
consent was obtaine d prior to these procedures.
1.If the patient is not capable of providing a signature, a verbal statement of consent can 
also be given in the presence of an impartial witness (independent of the sponsor and the 
investigator).  This is to be documented b y a signature from the informing phy sician as 
well as b y a signature from the witness.
2.For adults under legal protection, consent shall be given b y the legal guardian(s).  The 
consent of anadult under legal protection shall also be requested where such a perso n is 
able to express his/her own will.  His/her refusal or the withdrawal of his/her consent may 
not be disregarded.
The informed consent form and an y other written information provided to patients / legal 
representatives or prox y consenters will be revise d whenever important new information 
becomes available that may  be relevant to the patient’s consent, or there is an amendment to 
the protocol that necessitates a change to the content of the patient information and / or the 
written informed consent form.  The investigator will inform the patient / legal representative 
or prox y consenter of changes in a timel y manner and will ask the patient to confirm his/her 
participation in the study  by signing the revised informed consent form.  Any  revised written 
informed consent form and written information must receive the IEC/I RB`s approval / 
favorable opinion in advance of use.
11.3 Publication policy
The sponsor is interested in the publication of the results of e very study  it performs.  
All relevant aspects regarding publication will be part of the contract between the sponsor and 
the investigator/institution.
The sponsor has made the information regarding the study  protocol publicly  available on the 
internet at www.clinicaltrials.gov .  
11.4 Compensation for health damage of patients / insurance
The sponsor maintains clinical trial insurance coverage for this study  in accordance with the 
laws and regulations of the country  in which the study  is performed.
11.5 Confidential ity
All records identify ing the patient will be kept confidential and, to the extent permitted by  the 
applicable laws and/or regulations, will not be made publicly available.
Patient names will not be supplied to the sponsor.  Only  the patient number will be recorded 
in the eCRF , and if the patient name appears on any  other document ( eg,pathologist report), it 
must be obliterated before a cop y of the document is supplied to the sponsor.  Study findings 
stored on a computer will be stored in accordance with local data protection laws.  As part of 
the informed consent process, the patients will be informed in writing that representatives of 
the sponsor, IEC/I RB, or regulatory  authorities may  inspect their medical records to verify  the 
information collected, and that all personal information made available for inspection will be 
handled in strictest confidence and in accordance with local data protection laws.
If the results of the stud y are published, the patient’s identity  will remain confidentia l.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  88of 167
The invest igator will maintain a list to enable patients to be identified.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  89of 167
12. Reference list -amended142,143
1.Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Ty ndall A, et al. 
2013 Classification criteria for s ystemic sclerosis. Arthritis Rheum. 2013; 65:2737 -
2747.
2.Chatterjee S. Sy stemic scleroderma. Cleveland Clinic Center for Continuing 
Education. 
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/rheumatolog
y/systemic -sclerosis/. Accessed on 29 Dec 2013.
3.LeRo y EC, Black C, Fleischmajer R, et al: Scleroderma (s ystemic sclerosis): 
Classification, subsets and pathogenesis. J Rheumatol. 1988; 15: 202 -205.
4.Mayes MD, Lacey  JV, Beebe -Dimmer K, Gillespie BW, Cooper B, Laing TK, 
Schottenfeld D. Prevalence, incidence, survival, and disease characteristi cs of 
systemic sclerosis in a large US population. Arthritis Rheum. 2003; 48(8):2246 -2255.
5.Varga J, Bashey  RI. Regulation of connective tissue sy nthesis in s ystemic sclerosis. 
Int Rev Immunol. 1995;12:187 -199.
6.Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish 
series of s ystemic sclerosis patients. Ann Rheum Dis. 1998; 57:682 -686.
7. Subcommittee for Scleroderma Criteria of the American Rheumatism Association 
Diagnostic and Therapeutic Criteria Committee. Preliminary  criteria for t he 
classification of s ystemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581 –590.
8.Beyer C, Reich N, Schindler SC, Akhmetshina A, Dees C, Tomcik M, et al. 
Stimulation of soluble guany late cy clase reduces experimental dermal fibrosis. Ann 
Rheum Dis. 2 012; 71:1019 -1026.
9.Beyer C, Zenzmaier C, Palumbo -Zerr K, Mancuso R, Distler A, Dees C, Zerr P, et al. 
Stimulation of the soluble guan ylate cy clase (sGC) inhibits fibrosis by blocking non -
canonical TGFβ signalling. Ann Rheum Dis. 2014 Feb 23 [Epub ahead of print].
10.Chu AJ, Prasad JK. Up -regulation by  human recombinant transforming growth factor 
β-1 of collagen production in cultured dermal fibroblasts is mediated by  the inhibition 
of nitric oxide signaling. J Am Coll Surg. 1999; 188:271-280.
11. Evgenov OV, Zou L, Zhang M, Mino- Kenudson M, Mark EJ, Buy s ES, et al. Nitric 
oxide -independent stimulation of soluble guan ylate cy clase attenuates pulmonary  
fibrosis. BMC Pharmacol. 2011;11(Suppl 1):O9 (abstract).
12. Geschka S, Kretschmer A, Sharkovska Y, Evgenov O, Lawrenz B , Hucke A et al. 
Soluble guan ylate cy clase stimulation prevents fibrotic tissue remodeling and 
improves survival in salt -sensitive Dahl rats. PLoD One. 2011;6(7):e21853.
13. Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffman L S, Wellkisch K et al. Nitric 
oxide -independent stimulation of soluble guan ylate cy clase reduces organ damage in 
experimental low -renin and high -renin models. J Hy pertens. 2010 Aug;28(8):1666 -
1675.
                                                
142References 22, 23, 24, 39, and 40 w ere added per Amendment 1
143References 41 and 40 w ere added per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  90of 167
14.Maurer B, Graf N, Michel BA, Müller -Ladner U, Czirják L , Denton CP, Ty ndall A, 
Metzig C, L anius V, Khanna D, Distler O. Prediction of worsening of skin fibrosis in 
patients with diffuse cutaneous sy stemic sclerosis using the EUSTAR database. Ann 
Rheum Dis, 2014 -http://ard.bmj.com/content/early /2014/06/30/annrheumdis -2014-
205226.full.
15.Khanna. Reco mbinant human relaxin in the treatment of sy stemic sclerosis with 
diffuse cutaneous involvement: a randomized, double -blind, placebo -controlled trial. 
Arthritis Rheum. 2009, 60(4):1102-11.
16.Pope JE, Bellamy  N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers 
IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley  J, Catoggio L, Furst DE. A 
randomized, controlled trial of methotrexate versus placebo in earl y diffuse 
scleroderma. Arthritis Rheum. 2001, 44:1351-8.
17.Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, Khanna 
PP, Khanna D. Course of the modified Rodnan skin thickness score in s ystemic 
sclerosis clinical trials: analy sis of three large multicenter, double- blind, randomized 
controlled trials. Arthritis Rheum. 2009, 6 0(8):2490 -8.
18.Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, Matucci -
Cerinic M, Denton CP, Mayes MD, Steen VD, Varga J, Furst DE. Development of a 
provisional core set of response measures for clinical trials of s ystemic sclerosis. Ann
Rheum Dis 2008;67:703 –709.
19. Walker KM, Pope J, participating members of the Scleroderma Clinical Trials 
Consortium (SCTC) and Canadian Scleroderma Research Group (CSRG). Treatment 
of sy stemic sclerosis complications: what to use when first- line treatment f ails—a 
consensus of s ystemic sclerosis experts. Semin Arthritis Rheum. 2012;42:42 -55.
20.Kowal -Bielecka, Landewe R, Avouac J, et al. EULAR recommendations for the 
treatment of s ystemic sclerosis: a report from the EULAR Scleroderma Trials and 
Research group ( EUSTAR). Ann Rheum Dis 2009;68:620 -628.
21. Nagaraja V, Denton CP, Khanna D. Old medications and new targeted therapies in 
systemic sclerosis. Rheumatology .2014 July  26 [Epub ahead of print].
22. Regev A, Seeff LB, Merz M, Ormarsdottir S, Aithal GP, Gallivan J, Watkins PB. 
Causality  Assessment for Suspected DILI During Clinical Phases of Drug 
Development. Drug Saf (2014) 37 (Suppl 1):S47 –S56.
23.NICE clinical guideline 182 “Chronic kidney  disease: ear ly identification and 
management of chronic kidney  disease in adults in primary  and secondary  care”, 
issued in July  2014 (guidance.nice.org.uk/cg182). 
24. MacGregor MS and Taal MW. Clinical Practice Guidelines - Detection, Monitoring 
and Care of Patients with CKD. UK renal association, 5th edition, 2011 
(www.renal.org/guidelines).
25.Thomas G. Pickering, J.E.H., Lawrence J. Appel, Bonita E. Falkner, John Graves, 
Martha N. Hill, Daniel W. Jones, Theodore Kurtz, Sheldon G. Sheps, Edward J. 
Roccella, AHA Scientific Statement: Recommendations for Blood Pressure 
Measurement in Humans and Experimental Animals. Hy pertension. 2005;(45):142 -
161.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  91of 167
26.Khanna D, Merkel PA. Outcome measures in sy stemic sclerosis: an update on 
instruments and current research. Curr Rheumatol Rep. 2 007;9:151 -157.
27.Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, et al. A 
randomized, double -blind, placebo -controlled trial of recombinant human relaxin in 
the treatment of s ystemic sclerosis with diffuse scleroderma. Arthritis Rheum 
2009;6 0(4):1102 -1111.
28.Denton C, Merkel PA, Furst DE, Khanna K, Emery  P, et al. Recombinant human anti -
transforming growth factor β1 antibody  therapy  in sy stemic sclerosis: a multicenter, 
randomized, placebo -controlled phase I/II trial of CAT -192. Arthritis Rheum
2007;56:323 -333.
29.Gladue H, Maranian P, Paulus H, Khanna D. Evaluation of test characteristics for 
outcome measures used in Ray naud’s phenomenon clinical trials. Arthritis Care & 
Res. 2013;65(4):630 -636.
30.Merkel PA, Herly n K, Martin RW, Anderson JJ, May es M D, Bell P, et al. 
Scleroderma Clinical Trials Consortium. Measuring Disease Activity  and Functional 
Status in Patients with Scleroderma and Ray naud’s Phenomenon. Arthritis Rheum 
2002;46:2410 -2420.
31.Ware JE, Sherbourne CD. The MOS 36 -item short- form health s urvey  (SF-36). I. 
Conceptual Framework and I tem Selection. Med Care. 1992;30(6):473 -483.
32. Steen VD, Medsger TA. The value of the Health Assessment Questionnaire and 
Special Patient -Generated Scales to Demonstrate Change in S ystemic Sclerosis 
Patients Over T ime. Arthritis Rheum 1997;40:1984 -1991.
33.Khanna D, Hay s RD, Maranian P, Seibold JR, I mpens A, May es MD, et al. Reliability  
and validity  of the University  of California, Los Angeles Scleroderma Clinical Trial 
Consortium Gastrointestinal Tract Instrument. Art hritis Rheum 2009;61(9):1257 -
1263.
34.Hinchcliff M, Beaumont JL , Thavarajah K, Varga J, Chung A, Podulsky  S, et al. 
Validity  of two new patient -reported outcome measures in sy stemic sclerosis:  Patient -
Reported Outcomes Measurement Information System 29 -Item Health Profile and 
Functional Assessment of Chronic Illness Therapy– Dyspnea Short Form. Arthritis 
Care & Res 2011;63(11):1620 -1628.
35. Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, et al. A 
multicenter, randomized, double- blind, pl acebo -controlled trial of oral t ype I collagen 
treatment in patients with diffuse cutaneous s ystemic sclerosis:  I . Oral t ype I collagen 
does not improve skin in all patients, but may  improve skin in late -phase disease. 
Arthritis Rheum 2008;58 (6):1810-1822.
36. Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, May es MD, et al. 
Patterns and predictors of change in outcome measures in clinical trials in scleroderma 
an individual patient meta- analysis of 629 subjects with diffuse scleroderma. Arthritis 
Rheum 2012;64(10): 3420 -3429.
37.Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al .for 
the investigators of the D -Penicillamine, human recombinant relaxin, and oral bovine 
type I collagen clinical trials. Course of modified Rodnan s kin score in s ystemic 
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  92of 167
sclerosis clinical trials:  analysis of 3 large multicenter, randomized clinical trials. 
Arthritis Rheum 2009;60(8):2490-2498.
38.Pugh RN, Murray -Lyon IM, Dawson J L, Pietroni MC, Williams R. Transection of the 
oesophagus for bleeding oesophageal varices. Br J Surg.1973;60:646 -649.
39.Steen VD and Medsger TA. L ong-Term Outcomes of Scleroderma Renal Crisis. Ann 
Intern Med. 2000;133:600 -603.
40. Shanmugam VK and Steen VD. Renal disease in scleroderma: an update on 
evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol. 
2012 November ; 24(6): 669 –676.
41.Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, May es MD, et al. The 
American College of Rheumatology  Provisional Composite Response I ndex for 
Clinical Trials in Early  Diffuse Cutaneous S ystemic Sclerosis. Arthritis Rheumatol. 
2016; 68(2):299 -311.
42.Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. 
Development of a provisional core set of response measures for clinical trials of 
systemic sc lerosis. Ann.Rheum Dis. 2008;67(5):703 -709.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  93of 167
13. Protocol amendments
13.1 Amendment 1
Amendment 1 was approved on 4 FEB 2015.
13.1.1 Overview of changes to the study
Due to regulatory  feedback, additional safet y laboratory monitoring is being included for 
patients entering the study  with elevated liver transaminases or bilirubin, or with eGFR 
between 15 -29 mL /min/1.73 m2.  These patients were not included in the riocig uat pivotal 
trials in pulmonary  hypertension.  While there is no evidence of liver or renal toxicity  with 
riociguat, there is an increased risk for adverse events related to the mechanism of action of 
the drug, such as h ypotension, due to a higher plasma c oncentration caused by  impaired 
riociguat metabolism/elimination by  liver and kidney s.
The list of immunosuppressant therapies requiring washout before inclusion in the study  was 
also expanded to account for standard of care treatment among the participati ng countries.
Safety  laboratory  tests were added at Visit 10, along with other safet y assessments such as 
ECG and lung function tests to be performed.  Measurement of glutamate dehy drogenase 
(GLDH) will be deleted from the list of standard safet y parameter s because the review of data 
from previous studies and the ongoing long- term studies did not show any  clinically  
significant changes of this parameter in patients treated with riociguat.
Typos and inconsistencies were also corrected, as well as re -wording to make the protocol 
clearer.
13.1.2 Changes to the protocol text
Section – Title page
Old text:
Sponsor’s medical expert:  
Bayer Healthcare UK
Strawberry  Hill
Newbury , RG14 1JA
United Kingdom
Phone: 
New text:
Sponsor’s medical expert:
Bayer Healthcare Company  Ltd
Bayer Center,
No.27, Dong San Huan North Road, Chao yang District, 
Beijing, 100020 , China
Tel: 
Fax:  
PPD
PPD
PPD
PPD
PPD
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  94of 167
1.1.2.2 Preclinical Data
Old text:
In summary , investigations of the anti -fibrotic efficacy  of sGC stimulators riociguat and 
BAY 41-2272 showed that these agents act dose-dependentl y:
reduced collagen production in human dermal fibroblasts  
reduced fibroblast -to-myofibroblast differentiation of human dermal fibrobl asts
prevented TGF -ß-induced skin fibrosis in vivo
prevented skin fibrosis in bleomy cin model
reduced established skin fibrosis in genetic TSK- 1 model
promoted wound healing in TSK -1 mice.
New text:
In summary , investigations of the anti- fibrotic efficacy  of sGC stimulators riociguat and 
BAY 41-2272, another sGC compound, showed that these agents act dose-dependentl y:
reduced collagen production in human dermal fibroblasts  
reduced fibroblast -to-myofibro blast differentiation of human dermal fibroblasts
prevented TGF -ß-induced skin fibrosis in vivo
prevented skin fibrosis in bleomy cin model
reduced established skin fibrosis in genetic TSK- 1 model
promoted wound healing in TSK -1 mice.
2 Study objectives
Old text:
The secondary  objectives of this study  are to assess the efficacy  of treatment with riociguat 
administered TID as compared with placebo in terms of: 
Efficacy :
oNeed for Escape Therap y (see definition in Section 6.9)
New text:
The secondary  objectives of this study  are to assess the efficacy  of treatment with riociguat 
administered TID as compared with placebo in terms of: 
Efficacy :
oNeed for Rescue Therapy  (see definition in Section 6.9)
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  95of 167
3. Investigators and other study perso nnel
Old text:
Sponsor’s medical expert:
Name:  
Address: Bayer Healthcare UK
Strawberry  Hill
Newbury , RG14 1JA
United Kingdom
Phone: 
New text:
Sponsor’s medical expert:
Name:
Address: Bayer Healthcare Company  Ltd
Bayer Center, 
No.27, Dong San Huan North Road, Chao yang District, 
Beijing, 100020, China
Tel: 
Fax: 
4.1.2 Main treatment phase (Week 0 -Week 52)
Old text:
Maintenance period (Visits 7 to 12)
The overall duration of the main treatment phase is 52 weeks, including the dose titration 
period.  At the end of the dose titration period (Week 10) the patient’s maintenance dose will 
be determined using the treatment algorithm above.  No further increase in dose will be 
allowed.  The established dose will then be taken as the “optimal dose” to be administered for 
the remaining duration of the main treatment phase (up to Week 52).
Dose reductions for safety  reasons (eg, in case of any  treatment -emergent adverse event [AE]) 
are allowed, but a subsequent dose increase during the maintenance period is not permitted.
From Week 26 (Visit 10), patients will have the opportunity  to add “ escape therap y”, 
consisting of immunosuppressant drugs, to their rando mized study  medication if they  meet 
certain criteria for worsening skin or pulmonary  disease.  Please refer to Section 6.9 for 
further details.
New text:
Maintenance period (Visits 7 to 12)
The overall duration of the main treatment phase is 52 weeks, inc luding the dose titration 
period.  At the end of the dose titration period (Week 10) the patient’s maintenance dose will 
be determined using the treatment algorithm above.  No further increase in dose will be 
PPD
PPD
PPD
PPD
PPD
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  96of 167
allowed.  The established dose will then be tak en as the “optimal dose” to be administered for 
the remaining duration of the main treatment phase (up to Week 52).
Dose reductions for safety  reasons (eg, in case of any  treatment -emergent adverse event [AE]) 
are allowed, but a subsequent dose increase du ring the maintenance period is not permitted.
From Week 26 (Visit 10), patients will have the opportunity  to add “ rescue therap y”, 
consisting of immunosuppressant drugs, to their randomized study  medication if they  meet 
certain criteria for worsening skin or pulmonary  disease.  Please refer to Section 6.9 for 
further details.
4.1.4 Termination visit and safety follow -up 
Old text:
....
If the patient discontinues study  participation prematurely  during the main treatment phase 
(Week 0 –Week 52) he/she will be invited to come for limited assessments (mRSS, FVC, 
DL COand patient -reported outcomes [PROs]) at Week 12, Week 26, Week 39, and Week 52, 
depending on the timing of withdrawal.  The collection of these assessments is important for 
endpoint anal ysis whi ch considers all assessments post baseline up to Week 52.
New text:
...
If the patient discontinues study  drug prematurel y during the main treatment phase (Week 0 –
Week 52) he/she will be invited to come for limited assessments (mRSS, FVC, DL COand 
patien t-reported outcomes [PROs]) at Week 12, Week 26, Week 39, and Week 52, depending 
on the timing of withdrawal.  The collection of these assessments is important for endpoint 
analysis which considers all assessments post baseline up to Week 52.
5.1.2 Exclusion criteria
Old text:
2.Hepatic -related criteria
Hepatic insufficiency  classified as Child -Pugh C (see Appendix 14.1 for 
classification table)
3.Renal -related criteria
Estimated glomerular filtration rate (eGFR) < 15 mL /min/1.73m2(Modification of 
Diet in Renal Disease [MDRD] formula) or on dialy sis at the screening visit
oBecause the MDRD formula is thought to cause significant bias for 
Japanese patients, the equation for Japanese patients is: 
194 x serum creatinine (mg/dL) -1.094 x Age -0.287 x 0.739 (if female).
7.Prior and concomitant therap y
Treatment with methotrexate, cy clophosphamide, hy droxychloroquine, 
cyclosporine A, azathioprine, my cophenolate mofetil, rapam ycin, colchicine, 
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  97of 167
D-penicillamine, or intravenous immunoglobulin w ithin 4 weeks before the 
screening visit
New text:
2.Hepatic -related criteria
Hepatic insufficiency  classified as Child -Pugh C (see Appendix 14.1 for 
classification table)
oPatients with isolated AST or ALT >3xULN or bilirubin >2xUL N can be 
included in the t rial under the condition of additional monitoring during the 
trial (see section 7.6.2)
3.Renal -related criteria
Estimated glomerular filtration rate (eGFR) < 15 mL /min/1.73m2(Modification of 
Diet in Renal Disease [MDRD] formula) or on dialy sis at the screen ing visit. 
Patients entering the trial with eGFR 15- 29 mL/min/1.73m2will be undergo 
additional monitoring of renal function (see section 7.6.2)
oBecause the MDRD formula is thought to cause significant bias for 
Japanese patients, the equation for Japanese patients is: 
194 x serum creatinine (mg/dL) -1.094 x Age -0.287 x 0.739 (if female).
7.Prior and concomitant therap y
Treatment with methotrexate, cy clophosphamide, hy droxychloroquine, 
cyclosporine A, azathioprine, my cophenolate mofetil, rapam ycin, colchicin e, 
D-penicillamine, tacrolimus, mizoribine or intravenous immunoglobulin within 
4 weeks before the screening visit
5.2.1 Withdrawal
Old text:
Patients must be withdrawn from the stud y for the following reasons:
If treatment is interrupted for > 3 consecutive days during the dose titration period of 
the main treatment phase
Patients may be withdrawn from the stud y for the following reasons:
At the specific request of the sponsor and in liaison with the investigator (eg, safet y 
concerns)
A relative decline in FVC % predicted b y ≥10% (eg, a change of FVC from 60% to 
54%) or a relative decline in FVC % predicted between 5 to < 10% with associated 
relative decline in DL CO%predicted b y ≥15%, provided that the decline in FVC 
results in FVC <75% of predicted (confirmed b y repeat pulmonary  function testing 
within 1 month). Please refer to Section 6.9 for the option of adding escape therap y.
An absolute increase in mRSS by  > 5 units and ≥ 25% (Please refer to Section 6.9 for 
the option of adding escape therapy), life-threatening or organ -threatening event 
attributable to SSc (such as renal crisis, digital gangrene, development of new PAH on 
right heart catheterization) or not attributable to SSc.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  98of 167
A patient who, for an y reason (eg, failure to satisfy  the se lection criteria), terminates the study  
before the time point used for the definition of “dropout” (see below) is regarded a “screening 
failure”.  Restarting the defined set of screening procedures to enable the “screening failure” 
patient’s participation at a later time point is not allowed.
One re -assessment of laboratory  parameters is allowed during the screening phase to re- assess 
the eligibility  of patients.
A patient who discontinues study  participation prematurely  for any  reason is defined as a 
“drop out” if the patient has already  been randomized.
Any randomized patient removed from the trial should undergo the assessments at the 
termination visit.  The patient will remain under medical supervision until discharge or 
transfer is medically  acceptable a nd will complete the 30 -day safet y follow -up period.
If the patient discontinues study  participation prematurely  during the main treatment phase 
(Week 0 –Week 52) he/she will be invited to come for limited assessments (mRSS, FVC, 
DL COand patient -reported outcomes [PROs]) at Week 12, Week 26, Week 39, and Week 52, 
depending on the timing of withdrawal.  This will be in addition to the termination visit 
assessments (see Section 7.1.2.8), provided that the patient does not object to collection of 
study  data after withdrawal of consent.  If the discontinuation occurs before Visit 8 
(Week 14), the skin biopsy  and blood samples for biomarkers are to be collected.
New text:
Patients must be withdrawn from the stud y for the following reasons:
If treatment is inter rupted for > 3 consecutive days (9 doses) during the dose titration 
period of the main treatment phase
Patients may be withdrawn from the stud y for the following reasons:
At the specific request of the sponsor and in liaison with the investigator (eg, safe ty 
concerns)
A relative decline in FVC % predicted b y ≥10% (eg, a change of FVC from 60% to 
54%) or a relative decline in FVC % predicted between 5 to < 10% with associated 
relative decline in DL CO%predicted b y ≥15%, provided that the decline in FVC 
results in FVC <75% of predicted (confirmed b y repeat pulmonary  function testing 
within 1 month). Please refer to Section 6.9 for the option of adding rescue therapy .
An absolute increase in mRSS by  > 5 units and ≥ 25% (Please refer to Section 6.9 for 
the op tion of adding rescue therap y), life-threatening or organ -threatening event 
attributable to SSc (such as renal crisis, digital gangrene, development of new PAH on 
right heart catheterization) or not attributable to SSc.
A patient who, for an y reason (eg, failure to satisfy  the selection criteria), terminates the study  
before the time point used for the definition of “dropout” (see below) is regarded a “screening 
failure”.  Restarting the defined set of screening procedures to enable the “screening failure” 
patient’s participation at a later time point is not allowed.
One re -assessment of laboratory  parameters is allowed during the screening phase to re- assess 
the eligibility  of patients.
A patient who discontinues study  participation prematurely  for any  reas on is defined as a 
“dropout” if the patient has alread y been randomized.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  99of 167
Any randomized patient removed from the trial should undergo the assessments at the 
termination visit.  The patient will remain under medical supervision until discharge or 
transfer i s medically  acceptable and will complete the 30 -day safet y follow -up period.
If the patient discontinues study  drug prematurel y during the main treatment phase (Week 0 –
Week 52) he/she will be invited to come for limited assessments (mRSS, FVC, DL COand 
patient -reported outcomes [PROs]) at Week 12, Week 26, Week 39, and Week 52, depending 
on the timing of withdrawal.  This will be in addition to the termination visit assessments (see 
Section 7.1.2.8), provided that the patient does not object to collection of study  data after 
withdrawal of consent.  If the discontinuation occurs before Visit 8 (Week 14), the skin 
biopsy  and blood samples for biomarkers are to be collected.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  100of 167
6.9 Prior and concomitant medications
Old text:
Table 6-2Prohibited prior and concomitant therapy
Therapy Timeframe 
Chlorambucil, bone marrow transplantation, or total lymphoid irradiation Any previous therapya
Rituximab or other anti -CD20 antibodies Within 6 m onths prior to 
the screening visita
Infliximab, certolizumab, golimumab, adalimumab, abatacept, 
leflunomide or tocilizumabWithin 8 weeks prior to the 
screening visita
Methotrexate, cyclophosphamide, hydroxychloroquine, cy closporine A, 
azathioprine, m ycophenolate mofetil, rapam ycin, colchicine, D 
penicillamine, or intravenous immunoglobulinWithin 4 weeks prior to the 
screening visita
Etanercept Within 2 weeks prior to the 
screening visita
Anakinra Within 1 week prior to the 
screening visita
Nitrates or NO donors (such as am yl nitrate) in any form, including 
topical; phosphodiesterase (PDE) 5 (PDE5) inhibitors (such as 
sildenafil, tadalafil, vardenafil); and nonspecific PDE5 inhibitors 
(theophylline, dipyridamole)Concomitant therapy with 
study drug
Prostacyclin analogs (oral beraprost for digital ulcers / R aynaud’s 
disease and short -term / intermittent therapy of up to 21 days 
with intravenous prostacyclin analogs for digital / vascular lesions is 
allowed)Concomitant therapy with 
study drug
aConcomitant use of these treatments with study medication is also prohibited, except for certain 
agents from Week 26 onwards; please see “ Escape Therapy” below.  
Other medications and considerations (detailed information can be found in the current IB)
Pre-and concomitant treatment with the proton pump inhibito r omeprazole (40 mg 
once dail y) reduced riociguat mean area under the plasma concentration versus time 
curve (AUC) b y 26% and mean maximum plasma concentration (C max) by 35%.  This 
is not considered clinically  relevant.
Co-administration of the antacid alu minum hy droxide / magnesium hy droxide reduced 
riociguat mean AUC b y 34% and mean C maxby 56%.  Antacids should be taken at 
least 1 hour after riociguat.
Plasma concentrations in smokers are reduced b y 5060% compared with 
nonsmokers.  A dose reduction shou ld be considered in patients who stop smoking 
whilst participating in the study .
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  101of 167
Escape therapy
From Week 26 (Visit 10), patients with the following will have the opportunity  to add rescue 
therap y to their randomized study  medication.  “Escape therapy ” is defined as treatment with 
an immunosuppressant drug, under the following situations:
Worsening of skin disease (defined as > 5 units and ≥ 25% increase in mRSS), or
Relative decline in FVC % predicted b y ≥ 10%, or relative decline in FVC % 
predicted between ≥5% and < 10% with associated relative decline in DL CO% 
predicted b y ≥ 15%, provided that the decline in FVC results in FVC <75% of 
predicted  (confirmed b y repeat pulmonary  function testing within 1 month).
The decision to initiate rescue therap y is ba sed on investigator discretion in eligible patients.  
Rescue therap y ma y include an y of the following 4 agents:  methotrexate, mycophenolate 
mofetil, cy clophosphamide, or azathioprine. These treatments are not provided by  the 
Sponsor.
New text:
Table 6-2Prohibited prior and concomitant therapy -amended
Therapy Timeframe 
Chlorambucil, bone marrow transplantation, or total lymphoid irradiation Any previous therapya
Rituximab or other anti -CD20 antibodies Within 6 m onths prior to 
the screening visita
Infliximab, certolizumab, golimumab, adalimumab, abatacept, 
leflunomide or tocilizumabWithin 8 weeks prior to the 
screening visita
Methotrexate, cyclophosphamide, hydroxychloroquine, cy closporine A, 
azathioprine, m ycophenolate mofetil, rapam ycin, colch icine, D 
penicillamine, tacrolimus, mizoribine or intravenous immunoglobulinWithin 4 weeks prior to the 
screening visita
Etanercept Within 2 weeks prior to the 
screening visita
Anakinra Within 1 week prior to the 
screening visita
Nitrates or NO donors (such as am yl nitrate) in any form, including 
topical; phosphodiesterase (PDE) 5 (PDE5) inhibitors (such as 
sildenafil, tadalafil, vardenafil); and nonspecific PDE5 inhibitors 
(theophylline, dipyridamole)Concomitant therapy with 
study drug
Prostacyclin analogs (oral beraprost for digital ulcers / Raynaud’s 
disease and short -term / intermittent therapy of up to 21 days 
with intravenous prostacyclin analogs for digital / vascular lesions is 
allowed)Concomitant therapy with 
study drug
aConcomitant use of these treatments with study medication is also prohibited, except for certain 
agents from Week 26 onwards; please see “ Rescue Therapy” below.  
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  102of 167
Other medications and considerations (detailed information can be found in the current IB)
Pre-and concomitant treatment with the proton pump inhibitor omeprazole (40 mg 
once dail y) reduced riociguat mean area under the plasma concentration versus time 
curve (AUC) b y 26% and mean maximum plasma concentration (C max) by 35%.  This 
is not considered clinic ally relevant.
Co-administration of the antacid aluminum hy droxide / magnesium hy droxide reduced 
riociguat mean AUC b y 34% and mean C maxby 56%.  Antacids should be taken at 
least 1 hour after riociguat.
Plasma concentrations in smokers are reduced b y 5060% compared with 
nonsmokers.  For this reason, it is highly  recommended to strongl y advise patients to 
stop smoking while taking this medication .  A dose reduction should be considered in 
patients who stop smoking whilst participating in the study .
Rescue therapy
From Week 26 (Visit 10), patients with the following will have the opportunity  to add rescue 
therap y to their randomized study  medication. “ Rescue therapy ” is defined as treatment with 
an immunosuppressant drug, under the following situations:
Worsening of skin disease (defined as > 5 units and ≥ 25% increase in mRSS), or
Relative decline in FVC % predicted b y ≥ 10%, or relative decline in FVC % 
predicted between ≥5% and < 10% with associated relative decline in DL CO% 
predicted b y ≥ 15%, provided that the decline in FVC results in FVC <75% of 
predicted  (confirmed b y repeat pulmonary  function testing within 1 month).
The decision to initiate rescue therap y is based on investigator discretion in eligible patients.  
Rescue therap y ma y include an y of the following 4 agents:  methotrexate, my cophenolate 
mofetil, cy clophosphamide, or azathioprine. These treatments are not provided by  the 
Sponsor.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  103of 167
7.1.1 Tabulated overview
Old text:
Table 7-1 Schedule of evaluations
Scr Main Treatment Phase  (Double -blind) Long- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension 
PeriodSafety  
Follow -up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364 
±14378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
±1430 + 5
Written informed consent X
Inclusion / exclusion criteria
X X
Demographic dataX
Medical and surgical history
X X
Other history (alcohol)X
Smoking historyX X X X X X
Height and weightc
X X X X X X X X
Physical examinationX X X X X X X X
mRSS X X X X X X X
Assessment of Raynaud’s 
attacks XdXeXfXe
Digital ulcer net burden
assessment X X X X X X X X X X X X X X X X X X X X
Tender & swollen joint countX X Xg
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  104of 167
Table 7-1 Schedule of evaluations
Scr Main Treatment Phase  (Double -blind) Long- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension 
PeriodSafety  
Follow -up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364 
±14378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
±1430 + 5
Vital signs (BP, HR)h
X X X X X X X X X X X X X X X X X X X X X
Vital signs post -dose 
(BP, HR)i,j XiXjXi
Blood sample for safetykX X X X X X X X X
Blood sample for PK XlXmXmXmXmXmXnXlXmXmXmXmXm
Blood sample for biomarkers X X Xr
Blood sample for 
Autoantibody screenX
Pregnancy test (if 
applicable)o X X X X X X X X X X X X
12-lead ECGp
X X X X X X X X X
Pulmonary function testsq
X X X X X X X
Skin biopsyX X Xr
Questionnairess
X X X X X X X
Patient’s and physician’s 
global assessmentX X X Xg
Patient interference with skin X X X Xg
Tendon Friction Rubst
X X
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  105of 167
Table 7-1 Schedule of evaluations
Scr Main Treatment Phase  (Double -blind) Long- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension 
PeriodSafety  
Follow -up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364 
±14378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
±1430 + 5
Randomization (IxRS)X
Dispensation of study drugX X X X X X X X X X X X X X X X X X
Drug accountability X X X X X X X X X X X X X X X X X X
Adverse events recordingX X X X X X X X X X X X X X X X X X X X X
Prior and concomitant 
therapy X X X X X X X X X X X X X X X X X X X X X
Survival statusX
Abbreviations:  BP = blood pressure; ECG = electrocardiogram; TV = Termination Visit; SFU =30-Day Safety Follow -up (30 [+5] days after the last 
dose of study drug); HR = heart rate; IxRS = telephone -based or web -based response system; mRSS = modified Rodnan skin score; 
PK=pharmacokinetics; q 12 wk = every 12 weeks; Scr = Screening.
Note:  Day 0 (Visit 1) is the baseline visit.
aVisit 12 ( Week 52) is the last visit in the Maintenance Period of the Main Treatment phase and the first (baseline) visit in the Long- term Extension 
phase.
bTo be performed as soon as possible after withdrawal of study medication.  
cHeight to be measured only at the screening visit
dPatient to be provided with 7 -day diary, to complete daily for 7 consecutive days leading up to Visit 1 
e Patient and physician assessment of Raynaud’s disease (see Section 7.6.12 )
fPatient to be provided with 7 -day diary, to complete daily for 7 consecutive days leading up to Visit 8.
gMust not be performed if TV is after V12.
h Blood pressure and heart rate will be measured at all visits with the patient in a sitting position, after the patient has be en at rest for at least 5 
minutes.  The same arm is always used for these measurements (see Section 7.6.5 ).
i Vital signs to be measured within 20 minutes prior to each post-dose PK sampling (see Table 7–2)
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  106of 167
Table 7-1 Schedule of evaluations
Scr Main Treatment Phase  (Double -blind) Long- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension 
PeriodSafety  
Follow -up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364 
±14378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
±1430 + 5
jVital signs to be measured within 20 minutes prior to PK sampling (see Table 7–2)
kCoagulation tests to be performed at a local laboratory
lSamples for PK to be taken 1 –2 hours and 3 –4 hours after the morning dose of study medication (see Table 7–2)
mSample for PK to be ta ken up to 1 hour before the morning dose of study medication (trough) (see Table 7–3)
n Samples for PK to be taken up to 1 hour before the morning dos e of study medication (trough) and 2 –3 hours after the morning dose of study 
medication (peak) (see Table 7–4)
oFor women of childbearing potential only. Serum pregnancy test is required only at screening; pregnancy testing (urine) will be done every 
4weeks and should continue until 30 days after the last dose of study drug. W hen pregnancy testing coincides with a visit, the test should be 
performed at the site, but otherwise should be performed at home. 
pStandard ECG (12 -lead ECG) will be recorded with the patient in the supine position, after the patient has been at rest for at least 5 minutes (see 
Section 7.6.7 ).
q Pulmonary function tests include forced vital capacity (FV C)and diffusion capacity of the lung for carbon monoxide (DL CO).
rMust be done at a TV if this visit occurs before Visit 8.
s Questionnaires include Scleroderma Health Assessment Questionnaire (SHAQ), Short Form 36 (SF-36), Patient -Reported Outcomes 
Measurement Information System (PROMIS) -29, and University of California, Los Angeles, Scleroderma Clinical Trial Consortium 
Gastroi ntestinal Scale (UCLA SCTC GIT) 2.0.
t Assessment of the presence or absence of tendon friction rubs
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  107of 167
New text:
Table 7-1 Schedule of evaluations -amended
Scr Main Treatment Phase  (Double -blind) Long- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension 
PeriodSafety  
Follow -up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364 
±14378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
±1430 + 5
Written informed consent X
Inclusion / exclusion criteria
X X
Demographic dataX
Medical and surgical history
X X
Other history (alcohol)X
Smoking historyX X X X X X
Height and weightc
X X X X X X X X
Physical examinationX X X X X X X X
mRSS X X X X X X X
Assessment of Raynaud’s 
attacks XdXeXfXe
Digital ulcer net burden
assessment X X X X X X X X X X X X X X X X X X X X
Tender & swollen joint countX X Xg
Vital signs (BP, HR)h
X X X X X X X X X X X X X X X X X X X X X
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  108of 167
Table 7-1 Schedule of evaluations -amended
Scr Main Treatment Phase  (Double -blind) Long- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension 
PeriodSafety  
Follow -up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364 
±14378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
±1430 + 5
Vital signs post -dose 
(BP, HR)i,j XiXjXi
Blood sample for safetyk, uX X XuXuXuXuX X X X X X X X
Blood sample for PK XlXmXmXmXmXmXnXlXmXmXmXmXm
Blood sample for biomarkers X X Xr
Blood sample for 
Autoantibody screenX
Pregnancy test (if 
applicable)o X X X X X X X X X X X X
12-lead ECGp
X X X X X X X X X
Pulmonary function testsq
X X X X X X X
Skin biopsyX X Xr
Questionnairess
X X X X X X X
Patient’s and physician’s 
global assessmentX X X Xg
Patient interference with skin X X X Xg
Tendon Friction Rubst
X X
Randomization (IxRS)X
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  109of 167
Table 7-1 Schedule of evaluations -amended
Scr Main Treatment Phase  (Double -blind) Long- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension 
PeriodSafety  
Follow -up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364 
±14378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
±1430 + 5
Dispensation of study drugX X X X X X X X X X X X X X X X X X
Drug accountability X X X X X X X X X X X X X X X X X X
Adverse events recordingX X X X X X X X X X X X X X X X X X X X X
Prior and concomitant 
therapy X X X X X X X X X X X X X X X X X X X X X
Survival statusX
Abbreviations:  BP = blood pressure; ECG = electrocardiogram; TV = Termination Visit; SFU =30-Day Safety Follow -up (30 [+5] days after the last 
dose of study drug); HR = heart rate; IxRS = telephone -based or web -based response system; mRSS = modified Rodnan skin score; 
PK=pharmacokinetics; q 12 wk = every 12 weeks; Scr = Screening.
Note:  Day 0 (Visit 1) is the baseline visit.
aVisit 12 ( Week 52) is the last visit in the Maintenance Period of the Main Treatment phase and the first (baseline) visit in the Long- term Extension 
phase.
bTo be performed as soon as possible after withdrawal of study medication.  
cHeight to be measured only at the screening visit
dPatient to be provided with 7 -day diary, to complete daily for 7 consecutive days leading up to Visit 1 
e Patient and physician assessment of Raynaud’s disease (see Section 7.6.12 )
fPatient to be provided with 7 -day diary, to complete daily for 7 consecutive days leading up to Visit 8.
gMust not be performed if TV is after V12.
h Blood pressure and heart rate will be measured at all visits with the patient in a sitting position, after the patient has been at rest for at least 5 
minutes.  The same arm is always used for these measurements (see Section 7.6.5 ).
i Vital signs to be measured within 20 minutes prior to each post-dose PK sampling (see Table 7–2)
jVital signs to be measured within 20 minutes prior to PK sampling (see Table 7–2)
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  110of 167
Table 7-1 Schedule of evaluations -amended
Scr Main Treatment Phase  (Double -blind) Long- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension 
PeriodSafety  
Follow -up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364 
±14378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
±1430 + 5
kCoagulation tests to be performed at a local laboratory
lSamples for PK to be taken 1 – 2 hours and 3 –4 hours after the morning dose of study medication (see Table 7–2)
mSample for PK to be taken up to 1 hour bef ore the morning dose of study medication (trough) ( see Table 7–3)
n Samples for PK to be taken up to 1 hour before the morning dose of study medicatio n (trough) and 2 –3 hours after the morning dose of study 
medication (peak) (see Table 7–4)
o For women of childbearing potential only. Serum pregnancy test is required only at screening; pregnancy testing (urine) will be done every 
4weeks and should continue until 30 days after the last dose of study drug. W hen pregnancy testing coincides with a visit, the test should be 
performed at the site, but otherwise should be performed at home. 
pStandard ECG (12 -lead ECG) will be recorded with the patient in the supine position, after the patient has been at rest for at least 5 minutes (see 
Section 7.6.7 ).
q Pulmonary function tests include forced vital capacity (FV C)and diffusion capacity of the lung for carbon monoxide (DL CO).
rMust be done at a TV if this visi t occurs before Visit 8.
s Questionnaires include Scleroderma Health Assessment Questionnaire (SHAQ), Short Form 36 (SF-36), Patient -Reported Outcomes 
Measurement Information System (PROMIS) -29, and University of California, Los Angeles, Scleroderma Clinic al Trial Consortium 
Gastrointestinal Scale (UCLA SCTC GIT) 2.0.
t Assessment of the presence or absence of tendon friction rubs
u     Additional monitoring may apply for patients with impaired renal and liver function at Visit 2, 3, 4, 5 as needed (see sec tion 7.6.2)
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  111of 167
7.1.2.3 Visits 2 through to 6 -Main treatment phase – Dose -titration period 
Old text :
At these study  visits, the patient should attend the clinic without having taken the morning 
dose of study  medication.
During the dose titration period of the main tre atment phase, the following assessments will 
be performed according to the Schedule of evaluations (Section 7.1.1):
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position, after the patient has been at 
rest for at least 5 minutes.  The same arm is always used for these measurements (see 
Section 7.6.5).
Digital ulcer net burden assessment (see Section 7.6.10)
Recording and assessment of AEs (see Section 7.5)
Blood samp
les for safet y Visit 6 (see Section 7.6.2)
Blood sample for PK up to 1 hour before the morning dose of stud y medication (see 
Section 7.4)
Pregnancy  test (urine) for all women of childbearing potential (Visit 3 and Visit 5) 
(see Section 7.6.1)
Concomitant t herap y
Dose titration according to the titration algorithm (see Section 4.1.2)
Dispensation of study  drug and drug accountability
New text :
At these study  visits, the patient should attend the clinic without having taken the morning 
dose of study  medication.
During the dose titration period of the main treatment phase, the following assessments will 
be performed according to the Schedule of evaluations (Section 7.1.1):
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position, after the patient has been at 
rest for at least 5 minutes.  The same arm is always used for these measurements (see 
Section 7.6.5).
Digital ulcer net burden assessment (see Section 7.6.10)
Recording and assessment of AEs (see Section 7.5)
Blood samples for additional safet y for patients with impaired renal and liver function 
at Visit 2, 3, 4, 5 as needed (see Section 7.6.2)
Blood samples for safet y Visit 6 (see Section 7.6.2)
Blood sample for PK up to 1 hour before the morning dose of stud y medication (see 
Section 7.4)
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  112of 167
Pregnancy  test (urine) for all women of childbearing potential (Visit 3 and Visit 5) 
(see Section 7.6.1)
Concomitant therap y
Dose titration according to the titration algorit hm (see Section 4.1.2)
Dispensation of study  drug and drug accountability
7.1.2.8 Termination visit
Old text:
The termination visit will be performed if the patient is withdrawn from study  medication for 
any reason except death or lost to follow -up, and s hould occur as soon as possible after the 
patient receives his/her last dose of study  drug.  Assessments and procedures at this visit 
include the following:
Questionnaires (see Section 7.6.13)
Smoking history
Physical examination, including weight
Vital si gns (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position, after the patient has been at 
rest for at least 5 minutes.  The same arm is always used for these measurements (see 
Section 7.6.5)
mRSS (see Section 7.6.6)
Digital ulcer net burden assessment (see Section 7.6.10)
Patient’s and phy sician’s global assessment (see Section 7.6.15)
Patient interference with skin assessment (see Section 7.6.16)
Assessment for the presence or absence of tendon friction rubs (see Section 7.6.17)
New text:
The termination visit will be performed if the patient is withdrawn from study  medication for 
any reason except death or lost to follow -up, and should occur as soon as possible after the 
patie nt receives his/her last dose of study  drug.  Assessments and procedures at this visit 
include the following:
Questionnaires (see Section 7.6.13)
Smoking history
Physical examination, including weight
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position, after the patient has been at 
rest for at least 5 minutes.  The same arm is always used for these measurement s (see 
Section 7.6.5)
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  113of 167
mRSS (see Section 7.6.6)
Digital ulcer net burden assessment (see Section 7.6.10 )
Tender and swollen joint count assessment (not needed after V12, see Section 7.6.14)
Patient’s and phy sician’s global assessment ( not needed after V12 , see Section 7.6.15)
Patient interference with skin assessment ( not needed after V12 , see Section 7.6.16)
7.1.2.10 Premature discontinuation of study drug treatment
Old text :
In the event of premature discontinuation of study  drug treatment, patients must undergo the 
same procedures as outlined for the termination visit (Section 7.1.2.8) and then undergo 
evaluation at the safet y follow -up visit, 30 (+5) day s later (Section 7.1.2.9).
The reason for premature discontinuation of study  drug treatment or earl y withdrawal from 
the study  must be recorded in the eCRF (please refer to Section 5.2).
If the patient discontinues study  participation prematurely  during the main treatment phase 
(Week 0 – Week 52) he/she will be invited to come for limited assessments (mRSS , FVC, 
DL COand PROs) at Week 12, Week 26, Week 39 and Week 52, depending on the timing of 
withdrawal.  This will be in addition to the termination visit assessments (see Section 7.1.2.8), 
provided that the patient does not object to collection of study  data after withdrawal of 
consent.  If the discontinuation occurs before Visit 8 (Week 14), a skin biopsy  will also be 
performed.
New text:
In the event of premature discontinuation of study  drug treatment, patients must undergo the 
same procedures as outline d for the termination visit (Section 7.1.2.8) and then undergo 
evaluation at the safet y follow -up visit, 30 (+5) day s later (Section 7.1.2.9).
The reason for premature discontinuation of study  drug treatment or earl y withdrawal from 
the study  must be recorded in the eCRF (please refer to Section 5.2).
If the patient discontinues study  drug prematurel y during the main treatment phase (Week 0 –
Week 52) he/she will be invited to come for limited assessments (mRSS, FVC, DL COand 
PROs) at Week 12, Week 26, Week 39 and Week 52, depending on the timing of withdrawal.  
This will be in addition to the termination visit assessments (see Section 7.1.2.8), provided 
that the patient does not object to collection of study  data after withdrawal of consent.  If the 
discontinuation occurs before Visit 8 (Week 14), a skin biopsy  will also be performed.
7.6.2 Laboratory parameters
Old text:
The following safet y laboratory  parameters will be anal yzed in a central laboratory  (apart 
from coagulation tests, which will be analyzed at a local laboratory ) at the screening visit 
(Visit 0), Visit 1 (Day  0), Visit 6 (Week 10), Visit 11 (Week 39), Visit 12 (Week 52), Visit 17 
(Week 62), every  12 weeks during the Open- label extension period, termination visit, and 
safet y follow-up visit:
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  114of 167
Hematology : WBC differential count, ery throcy tes, hemoglobin, hematocrit and 
platelets
Coagulation tests: activated partial thromboplastin time (aPTT) and international 
normalized ratio (INR) (to be performed at a local laboratory )
Clinical chemist ry: aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), alkaline phosphatase (AP), gamma glutamy l transferase (GGT), glutamate 
dehy drogenase (GLDH) , CK, sodium, potassium, magnesium, calcium, phosphate, 
creatinine, urea, uric acid, total bilirubin, total protein, serum albumin.
At latest, at the end of the study  when all planned anal yses are completed, all blood samples 
will be destroyed.  The name and address for the central laboratory  service provider can be 
found in the documentation suppli ed by  the vendor.
Note:   One re -assessment of laboratory  parameters is allowed during the screening phase to 
re-assess the eligibility  of patients.
New text:
The following safet y laboratory  parameters will be anal yzed in a central laboratory  (apart 
from co agulation tests, which will be anal yzed at a local laboratory ) at the screening visit 
(Visit 0), Visit 1 (Day  0), Visit 6 (Week 10), 
Visit 10 ( Week 26) , Visit 11 (Week 39), Visit 12 
(Week 52), Visit 17 (Week 62), every  12 weeks during the Open- label extension period, 
termination visit, and safety follow -up visit:
Hematology : WBC differential count, ery throcy tes, hemoglobin, hematocrit and 
platelets
Coagulation tests: activated partial thromboplastin time (aPTT) and international 
normalized ratio (INR) (to b e performed at a local laboratory )
Clinical chemistry : aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), alkaline phosphatase (AP), gamma glutamy l transferase (GGT), CK, sodium, 
potassium, magnesium, calcium, phosphate, creatinine, urea, ur ic acid, total bilirubin, 
total protein, serum albumin.
Patients with isolated AST or ALT >3xULN or bilirubin >2xUL N at screening and /or
baseline will have additional anal ysis of coagulation tests, AST, ALT, AP, GGT, total 
bilirubin and serum albumin until normalization and/ or stabilization at Visit 2 (Day 14), Visit 
3 (Day  28), Visit 4 (Day 42), Visit 5 (Day  56), as needed.  Worsening of the parameters in the 
order of 2 -fold from baseline values will be considered clinically  significant [22] and 
additiona l diagnostic procedures may  be requested.
Patients entering the trial with eGFR 15- 29 mL/min/1.73m2will be undergo additional serum 
creatinine and eGFR calculation until normalization and/ or stabilization at Visit 2 (Day  14), 
Visit 3 (Day  28), Visit 4 (D ay 42), and Visit 5 (Day  56), as needed.  A decrease in eGFR 
equal or greater than 5ml/min/1.73m2in these patients (eGFR 15 -29 ml/min/1.73m2) during 
the study  or a reduction of 25% or more in 12 months will be considered clinically  significant 
[23,24].
Atlatest, at the end of the study  when all planned anal yses are completed, all blood samples 
will be destroyed.  The name and address for the central laboratory  service provider can be 
found in the documentation supplied by  the vendor.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  115of 167
Note:   One re -assessm ent of laboratory  parameters is allowed during the screening phase to 
re-assess the eligibility  of patients.
8.2 Analysis sets
Old text:
Efficacy  and safet y analyses will be performed in patients valid for the full anal ysis set (FAS).  
This is defined as all patients randomized and treated with study  medication.  I nvestigators 
will be instructed not to make the call to the I xRS sy stem until they  are certain the patient is 
valid to be treated with study  medication, on the day  that study  medication is to sta rt.  In that 
way, we expect all patients who are randomized also to be treated, so the FAS population 
would then be consistent with the full intent -to-treat (ITT) definition.
For the primary  and secondary  exploratory  efficacy  and safet y endpoints, as a supportive 
analysis, a per protocol set (PPS) will also be defined, including patients who meet the major 
inclusion and exclusion criteria at randomization that may  affect efficacy , who are not taking 
excluded concomitant medications during the study  that could have an effect on efficacy  (not 
including escape medication after Week 26), have the mRSS assessed at baseline and at least 
once during the main treatment phase and who are at least 80% compliant with study  
medication.  A full definition of valid for PPS will be given in the SAP.
New text:
Efficacy  and safet y analyses will be performed in patients valid for the full anal ysis set (FAS).  
This is defined as all patients randomized and treated with study  medication.  I nvestigators 
will be instructed not to make the call to the I xRS sy stem until they  are certain the patient is 
valid to be treated with study  medication, on the day  that study  medication is to start.  I n that 
way, we expect all patients who are randomized also to be treated, so the FAS populatio n 
would then be consistent with the full intent -to-treat (ITT) definition.
For the primary  and secondary  exploratory  efficacy  and safet y endpoints, as a supportive 
analysis, a per protocol set (PPS) will also be defined, including patients who meet the maj or 
inclusion and exclusion criteria at randomization that may  affect efficacy , who are not taking 
excluded concomitant medications during the study  that could have an effect on efficacy  (not 
including rescue medication after Week 26), have the mRSS assesse d at baseline and at least 
once during the main treatment phase and who are at least 80% compliant with study  
medication.  A full definition of valid for PPS will be given in the SAP.
12 Reference list
New text:
22. Regev A, Seeff LB, Merz M, Ormarsdottir S, Aithal GP, Gallivan J, Watkins PB. 
Causality  Assessment for Suspected DILI During Clinical Phases of Drug 
Development. Drug Saf (2014) 37 (Suppl 1):S47–S56.
23. NICE clinical guideline 182 “Chronic kidney  disease: early identification and 
management of chronic kidney  disease in adults in primary  and secondary  care”, 
issued in July  2014 (guidance.nice.org.uk/cg182).
24. MacGregor MS and Taal MW. Clinical Practice Guidelines - Detection, Monitoring 
and Care of Patie nts with CKD. UK renal association, 5th edition, 2011 
(www.renal.org/guidelines).
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  116of 167
39. Steen VD and Medsger TA. L ong-Term Outcomes of Scleroderma Renal Crisis. Ann 
Intern Med. 2000;133:600 -603.
40. Shanmugam VK and Steen VD. Renal disease in scleroderma: an update on 
evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol. 
2012 November ; 24(6): 669 –676.
14.2 Definition of Systemic Sclerosis Renal Crisis
Old text:
The definition of s ystemic sclerosis hy pertensive renal crisis is independent of whether or not 
concomitant antihypertensive medications are used.
...
At least 1 of the following 5 features:
1.Serum Creatinine: increase of ≥ 50% above baseline*
2.Proteinuria: ≥ 2+ by  dipstick confirmed by  protein: creatinine ratio > ULN
3.Hema turia: ≥ 2+ b y dipstick or > 10 RBCs (red blood cells) /HPF (high power field)
(without menstruation)
4.Thrombocy topenia: < 100,000 platelets/mm3
5.Hemoly sis: by  blood smear or increased reticulocyte count
*Historical baseline creatinine of the patient
New te xt:
Scleroderma renal crisis is defined as the new onset of severe h ypertension associated with a 
rapid increase in serum creatinine concentration, microangiopathic hemoly tic anemia, or both 
[39]. Systemic sclerosis renal crisis usually  manifests with acu te onset of moderate -to-severe 
‘accelerated’ h ypertension and oliguric renal failure [40] .
The definition of s ystemic sclerosis hy pertensive renal crisis is independent of whether or not 
concomitant antihypertensive medications are used.
...
At least 1 of the following 5 features:
1.Serum Creatinine: increase of ≥ 50% above baseline*
2.Proteinuria: ≥ 2+ by  dipstick confirmed by  protein: creatinine ratio > ULN
3.Hematuria: ≥ 2+ b y dipstick or > 10 RBCs/H igh Power Field [HPF] (without 
menstruation)
4.Thro mbocy topenia: < 100,000 platelets/mm3
5.Hemoly sis: by  blood smear or increased reticulocyte count
*Historical baseline creatinine of the patient
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  117of 167
13.2 Amendment 4
Amendment 4 was approved on 24 FEB 2016 .
13.2.1 Overview of changes to the study
With this amendment, the list of secondary  endpoints was changed to include a hierarch y of
testing. The chosen key  secondary  endpoint is the CRI SS and the other endpoints in the 
hierarch y are components of this endpoint. Since 2008, researchers at 4sclero derma centers in 
the US (United States) with the participation of the Scleroderma Clinical Trial Consortium 
(SCTC) have been developing a combined response index known as CRI SS based on 
prospective, data
-driven, consensus building techniques [42] . The resu lt of this effort was 
given approval b y the American Colleague of Rheumatology (ACR [
41]). The use of CRI SS 
in clinical trials is believed to greatl y facilitate the interpretation of results and assess the 
impact of a pharmacological agent on overall disea se activit y or severit y.
Based on feedback from the US Food and Drug Administration, the protocol was adjusted to 
clearl y differentiate between withdrawal from the study (ie, withdrawal of informed consent) 
or discontinuation of study  treatment (with conti nued data collection). This change mainl y 
affected Section 5.2, but wording was also adapted in several other sections.
Further changes to the protocol , eg, based on feedback from investigators, included:
Clarification that at Visit 6 no further dose incre ase is possible.
Addition of a clearer definition for d cSS
cdisease criterion to inclusion criterion 4.
Addition of local hemoglobin measurements to visits with limited assessments.
Clarification of the timing of the vital status check for patients who pre maturely  
discontinue study medication before Week 52.
Correction of inconsistencies.
Correction of t ypographical errors and minor editorial changes are not specified in the list of 
changes below. New text is display ed as underlined; text that was deleted is presented as 
strike -through text.
13.2.2 Changes to the protocol text
General change
In several sections of the protocol , the term “withdrawal” was replaced b y “discontinuation/
discontinuation of study  medication ” if it did not refer to withdrawal of informed consent.
Individual changes are marked by footnotes in the body of the protocol, but due to the high 
number of changes, not all are provided in the list of changes below.
2. Study objectives -amended
Old text:
Efficacy :
omRSS progression rate (defined as increase in mRSS by  > 5 units and ≥ 25% 
from baseline) and mRSS regression rate (defined as decrease in mRSS by  
> 5units and ≥ 25% from baseline)
oPatient’s andphysician’s global assessment 
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  118of 167
oHRQoL  using Short Form 36 (SF -36) and the Scleroderma Health Assessment 
Questionnaire (SHAQ)
oDigital ulcer net burden (defined as total number of ulcers at time point minus 
number of ulcers at baseline) and proportion of patients who do not develop 
new ulcers
oChange in FVC (forced vital capacit y) % predicted and per cent DL CO(carbon 
monoxide diffusing capacity) % predicted
oCombined Response I ndex for Sy stemic Sclerosis (CRI SS) 
oNeed for Rescue Therapy  (see definition in Section 6.9)
New text:
Efficacy :
oKey secondary  objective
American College of Rheumatology  Combined Response Index for 
Systemic Sclerosis (CRISS)
oFurther secondary  objectives
Health Assessment Questionnaire disability  index (HAQ -DI) domain 
(separatel y from the Scleroderma Health Assessment Questionnaire 
[SHAQ ] as part of the calculation of the CRI SS alg orithm)
Patient’s global assessment 
Physician’s global assessment
Change in FVC (forced vital capacit y) % predicted
4.1.2 Main treatment phase (Week 0 to Week 52) –amended
Old text:
To maintain blinding of the treatment arms, patients randomized to the placebo group will 
undergo sham titration from Visit 1 onwards during the dose- titration period according to the 
rules of the dose titration scheme.
New text:
To maintain blinding of the treatment arms, patients randomized to the placebo group will 
undergo sham titration from Visit 1 onwards during the dose -titration period according to the 
rules of the dose titration scheme. At Visit 6, the last visit of the Titration Phase, no further 
increase in study  medication will be possible (see Figure 4-1).
4.1.4Dose Interruptions
Old text:
Interruptions of an y length in the open- label extension period: treatment can be 
restarted at the discretion of the investigator at 0.5 mg TID lower than the last dose.
New text:
Interruptions in the open- label extension period : 
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  119of 167
o≤28 day s:treatment can be restarted at the discretion of the investigator at 
0.5mg TID lower than the last dose.
o>28days: discontinue the patient from stud y medication.
4.1.5Termination visit and safety follow -up visit - amended
Old text:
If the patient discontinues study  drug prematurel y during the main treatment phase (Week 0 –
Week 52) he/she will be invited to come for limited assessments (mRSS, FVC, DL COand 
PROs) at Week 12, Week 26, Week 39 and Week 52, depending on the timing of withdrawal .
New text:
If the patient discontinues study  drug prematurel y during the main treatment phase (Week 0 –
Week 52) he/she will be invited to come for limited assessments (mRSS, pulmonary function 
test [FVC and DL COincluding hemoglobin measurement at the lo cal laboratory ],and patient 
reported outcome [PROs]) at Week 12, Week 26, Week 39 and Week 52, depending on the 
timing of discontinuation .
5.1.1 Inclusion criteria
Old text:
4. dcSSc according to the LeRoy  criteria[3]
New text:
4. dcSSc according to the LeRoy  criteria[3], ie, skin fibrosis proximal to the elbows and 
knees in addition to acral fibrosis
5.1.2 Exclusion Criteria - amended
Old text:
5. Pulmonary -related criteria
Diagnosed PAH as determined by  right heart catheterization
New text:
5. Pulmonary -related criteria
Diagnosed pulmonary  hypertension as determined by  right heart catheterization
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  120of 167
5.2.1 Withdrawal -amended
Old text:
Patients must be withdrawn from the stud y for the following reasons:
At their own request or at the req uest of their legally  acceptable representative at an y 
time during the study and without giving reasons, a patient may decline to participate 
further.  The patient will not suffer an y disadvantage as a result.
If, in the investigator's opinion, continuation of the study  would be harmful to the 
patient's well -being
Occurrence of AEs or intercurrent diseases which the investigator judges unacceptable 
for continuation of participation in the study
Occurrence of adverse drug reactions, which in the i nvestigator’s opinion have a 
negative impact on the patient’s individual risk- benefit ratio.  (Investigators are 
obliged to reassess the patient’s individual risk-benefit ratio on a continuous basis.  
Factors such as anticipated treatment effect, progressi on of underl ying disease, 
occurrence of side effects, and alternative treatment options must be considered.)
Non-compliance with the conditions for the trial or instructions by  the investigator
If treatment is interrupted for > 3 consecutive days (9 doses)144during the dose 
titration period of the main treatment phase
If treatment is interrupted for > 14 consecutive days during the maintenance period of 
the main treatment phase or the dose -titration period of the long- term extension phase
In case of pregnancy  or breast feeding.
In case a female patient of childbearing potential is not compliant with 4 -weekl y 
pregnancy  testing or with contraceptive measures.
Participation in another clinical trial.  Participation in observational registries is 
allowed.
In case no further dose reduction is possible and the patient does not tolerate the 
lowest possible dosage (0.5 mg TID) of stud y drug
Patients may be withdrawn from the study for the following reasons:
At the specific request of the sponsor and in liaison with the investigator (eg, safet y 
concerns)
A relative decline in FVC % predicted b y ≥10% (eg, a change of FVC from 60% to 
54%) or a relative decline in FVC % predicted between 5 to < 10% with associated 
relative decline in DL CO%predicted b y ≥15%, pro vided that the decline in FVC 
results in FVC <75% of predicted (confirmed b y repeat pulmonary  function testing 
within 1 month). Please refer to Section 6.9for the option of adding rescue145therap y.
                                                
144Per Amendment 1
145Per Amendment 1
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  121of 167
An absolute increase in mRSS by  > 5 units and ≥ 25% (Pleas e refer to Section 6.9for 
the option of adding rescue146therap y), life-threatening or organ -threatening event 
attributable to SSc (such as renal crisis, digital gangrene, development of new PAH on 
right heart catheterization) or not attributable to SSc.
A patient who, for an y reason (eg, failure to satisfy  the selection criteria), terminates the study  
before the time point used for the definition of “dropout” (see below) is regarded a “screening 
failure”.  Restarting the defined set of screening procedures to enable the “screening failure” 
patient’s participation at a later time point is not allowed.
[…]
If the patient discontinues study  drug147prematurel y during the main treatment phase (Week 0 
–Week 52) he/she will be invited to come for limited assessment s (mRSS, FVC, DL COand 
patient -reported outcomes [PROs]) at Week 12, Week 26, Week 39, and Week 52, depending 
on the timing of withdrawal .  
[…]
A patient may  withdraw from further participation in the study  and, unless he/she signs an 
objection form , the following information should be obtained and documented in the eCRF:
Vital status
Outcome of SAEs
Efficacy  endpoints at Weeks 12, 26, 39, and 52 (depending on timing of withdrawal )
The information should be collected in the eCRF until the safety  follow -up visit 30 (+5) days 
after the last intake of study  drug.  Serious adverse events that occur within 30 (+5) days after 
the last dose of study  drug will be followed up until resolution, if possible.
For patients who object to further release of information, v ital status only  should be obtained.  
The measures taken for follow up must be documented in the site medical record.  
New text:
5.2.1.1 Withdrawal from the study
Patients must be withdrawn from the stud y for the following reasons: 
At their own request or at the request of their legally  acceptable representative at an y 
time during the study and without giving reasons, a patient may decline to participate 
further (withdrawal from study ).  The patient will not suffer an y disadvantage a s a 
result. 
Participation in another clinical trial after Visit 12.  Participation in observational 
registries is allowed.
5.2.1.2 Discontinuation of study medication
                                                
146Per Amendment 1
147Per Amendment 1
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  122of 167
Patients must be discontinued from the stud y medication for the following reasons:
If, in the investigator's opinion, continuation of the study  would be harmful to the 
patient's well -being
Occurrence of AEs or intercurrent diseases which the investigator judges unacceptable 
for continuation of participation in the study
Occurrence of adverse drug reactions, which in the investigator’s opinion have a 
negative impact on the patient’s individual risk- benefit ratio.  (Investigators are 
obliged to reassess the patient’s individual risk-benefit ratio on a continuous basis.  
Factors such as anticipated treatment effect, progression of underl ying disease, 
occurrence of side effects, and alternative treatment options must be considered.)
Non-compliance with the conditions for the trial or instructions by  the investigator
Iftreatment is interrupted for > 3 consecutive days (9 doses) during the dose titration 
period of the main treatment phase
Iftreatment is interrupted for > 14 consecutive day s during the maintenance period of 
the main treatment phase or the dose -titration period of the long- term extension phase
If treatment is interrupted for >28 day s during the open-label extension period (of the 
long-term extension phase)
In case of pregnancy  or breast feeding.
In case a female patient of childbearing potential is not compliant with 4 -weekl y 
pregnancy  testing or with contraceptive measures.
Participation in another clinical trial.  Participation in observational registries is 
allowed.
In case no further dose reduction is possible and the patient does not tolerate the 
lowest possible dosage (0.5 mg TID) o f study  drug
Patients may be discontinued from the stud ymedication for the following reasons:
At the specific request of the sponsor and in liaison with the investigator (eg, safet y 
concerns)
A relative decline in FVC % predicted b y ≥10% (eg, a change of FVC from 60% to 
54%) or a relative decline in FVC % predicted between 5 to < 10% with associated 
relative decline in DL CO%predicted b y ≥15%, provided that the decline in FVC 
results in FVC <75% of predicted (confirmed b y repeat pulmonary  function testing 
within 1 month). Please refer to Section 6.9for the option of adding rescue therap y.
An absolute increase in mRSS by  > 5 units and ≥ 25% (Please refer to Section 6.9for 
the option of adding rescue therap y), life-threatening or organ -threatening event 
attributable to SSc (such as renal crisis, digital gangrene, development of new PAH on 
right heart catheterization) or not attributable to SSc.
5.2.1.3 Handling of withdrawals or discontinuation s from study medication
A patient who, for an y reason (eg, failure to satisfy  the selection criteria), terminates the study  
before the time point used for the definition of “dropout” (see below) is regarded a “screening 
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  123of 167
failure”.  Restarting the defined se t of screening procedures to enable the “screening failure” 
patient’s participation at a later time point is not allowed.
[…]
If the patient discontinues study  drug  prematurel y during the main treatment phase (Week 0 –
Week 52) he/she will be invited to c ome for limited assessments (mRSS, pulmonary function 
test [FVC and DL COincluding hemoglobin measurement at the local laboratory ],and PROs) 
at Week 12, Week 26, Week 39 and Week 52, depending on the timing of discontinuation .
[…]
A patient may  withdraw f rom further participation in the study  and, unless he/she objects to 
further data collection , the following information should be obtained and documented in the 
eCRF:
Vital status (at Week 52)
Outcome of SAEs
Efficacy  endpoints at Weeks 12, 26, 39, and 52 (depending on timing of 
discontinuation of study  medication )
The information should be collected in the eCRF until the safety  follow -up visit 30 (+5) days 
after the last intake of study  drug.  Serious adverse events that occur within 30 (+5) days after 
thelast dose of study  drug will be followed up until resolution, if possible.
If patients refuse to be contacted via telephone (eg, patient objects to further release of 
information or are lost to follow -up), every  effort should be made to obtain vital status (dead 
or alive) information at Week 52 through consultation of public databases, wherever allowed 
by local regulations. 
5.2.2 Replacement
Old text:
There will be no replacement of randomized patients who withdraw from the study .
New text:
There will be no replacement of randomized patients who withdraw from the study  or 
prematurel y discontinue study  medication .
6.4.1 Selection of doses in the study
Old text:
The respective single doses of riociguat should be taken at least 6 hours apart. 
New text:
The intervals between drug intake should be 6 to 8 hours.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  124of 167
6.5 Blinding -amended
Old text:
Any patient withdrawn from the trial will remain under medical supervision until discharge or 
transfer is medically  acceptable.  Patients who withdraw should take part at the termination 
visit (refer to Section 7.1.2.8 ) and the safet y follow -up visit (refer to Section 7.1.2.9).
New text:
Any patient who discontinues study  medication will remain under medical supervision until 
discharge or transfer is medicall y acceptable.  Patients who withdraw from the study  or 
discontinue study  medication should take part at the termination visit (refer to Section 7.1.2.8) 
and the safety  follow -up visit (refer to Section 7.1.2.9 ).
7.1.1 Tabulated overview - amended
Old text:
Not applicable. A new footnote was added for the Main Treatment Phase to the schedule of 
events in Table 7.1.
The visit window for V12 was changed. Original visit window: ±14 days. 
New text:
v All patients who discontinue study  drug prematurely  during the Main Treatment Phase 
(Week 0 – Week 52) will be invited to come for limited assessments (see Sections 
7.1.2.10 and 7.6.2).
New visit window for V12: - 14 to +2 day s.
7.1.2.10 Premature discontinuation of study drug treatment -amended
Old text:
If the patient discontinues study  drug prematurel y during the main treatment phase (Week 0 –
Week 52) he/she will be invited to come for limited assessments (mRSS, FVC, DL COand 
PROs) at Week 12, Week 26, Week 39 and Week 52, depending on the timing of withdrawal .
New text:
If the patient disc ontinues study  drug  prematurel y during the main treatment phase (Week 0 –
Week 52) he/she will be invited to come for limited assessments (mRSS, pulmonary function 
test [FVC and DL COincluding hemoglobin measurement at the local laboratory ],and PROs) 
at Week 12, Week 26, Week 39 and Week 52, depending on the timing of discontinuation .
7.3 Efficacy -amended
Old text:
Secondary efficacy outcome measures
mRSS progression rate (defined as increase in mRSS by  > 5 units and > 25% from 
baseline) and mRSS regression rate (defined as decrease in mRSS by  > 5 units and 
>25% from baseline)
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  125of 167
Patient’s andphysician’s global assessment 
HRQoL  using SF -36 and the SHAQ
Digital ulcer net burd en (defined as total number of ulcers at time point minus number 
of ulcers at baseline) and proportion of patients who do not develop new ulcers
Change in FVC (forced vital capacit y) % predicted and DL CO(carbon monoxide 
diffusing capacity ) % predicted
Combined Response I ndex for Sy stemic Sclerosis ( CRISS), consisting of five 
variables: mRSS, FVC % predicted, ph ysician and patient global assessments, and 
HAQ- DI score (from SHAQ patient reported outcome)
Need for Rescue Therapy  (see definition in Section 6.9)
[…]
Other exploratory measures:
All-cause Mortality
Gastrointestinal invo lvement as assessed b y University of California, Los Angeles, 
Scleroderma Clinical Trial Consortium Gastrointestinal Scale (UCLA SCTC GI T) 2.0 
instrument
Patient- Reported Outcomes Measurement Information Sy stem (PROMIS) -29 (subset 
of patients)
Patient inte rference with skin 
Presence or absence of tendon friction rubs
Pain VAS
Change in BMI
Joint involvement using tender and swollen joint counts
New items for Ray naud’s response index excluding items included in secondary  
outcome measures
oPatient and phy sician assessment of Ray naud's phenomenon; pain, numbness, 
and tingling during a Raynaud's phenomenon attack; Ray naud’s condition 
score, average number of attacks/day ; and duration of attacks
New text:
Secondary efficacy outcome measures
Key secondary  endpoint :
CRISS, consisting of five variables: mRSS, FVC % predicted, ph ysician and patient 
global assessments, and HAQ- DI score (from SHAQ patient reported outcome)
Further secondary  endpoints:
HAQ- DI domain (separately  from the SHAQ as part of the calculation of the CRI SS 
algorithm).
Patient’s global assessment
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  126of 167
Physician’s global assessment
Change in FVC (forced vital capacit y) % predicted
[…]
Other exploratory measures148:
mRSS progression rate (defined as increase in mRSS by  > 5 units and > 25% from 
baseline) and mRSS regression rate (defined as decrease in mRSS by  > 5 units and 
>25% from baseline)
HRQoL  using SF -36 and the SHAQ.
Digital ulcer net burd en (defined as total number of ulcers at time point minus number 
of ulcers at baseline) and proportion of patients who do not develop new ulcers
Change in DL CO(carbon monoxide diffusing capacity ) % predicted
Need for Rescue Therapy  (see definition in Section 6.9)
All-cause Mortality
Gastrointestinal involvement as assessed b y University of California, Los Angeles, 
Scleroderma Clinical Trial Consortium Gastrointestinal Scale (UCLA SCTC GI T) 2.0 
instrument
Patient- Reported Outcomes Measurement Information Sy stem (PROMIS) -29 (subset 
of patients)
Patient interference with skin 
Presence or absence of tendon friction rubs
Pain VAS
Change in BMI
Joint involvement using tender and swollen joint counts
New items for Ray naud’s response index excluding items included in secondary  
outcome measures
oPatient and phy sician assessment of Ray naud's phenomenon; pain, numbness, 
and ting ling during a Raynaud's phenomenon attack; Ray naud’s condition 
score, average number of attacks/day ; and duration of attacks
7.6.2 Laboratory parameters - amended
Old text:
Hematology : WBC differential count, ery throcy tes, hemoglobin, hematocrit and 
platelets
                                                
148Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  127of 167
New text:
Hematology : WBC differential count, ery throcy tes, hemoglobin, hematocrit and 
platelets
The hemoglobin value required for the pulmonary function tests performed at visits 
with limited assessments (see Section 7.1.2.10 ) will be measured at the local 
laboratory .The hemoglobin value will be entered in the eCRF and used for the 
calculation of predicted DL COonly.
7.6.8 Pulmonary function testing
Old text:
Printouts from the analy zer must be stored in the patient file and the measured values
transferred to the eCRF.
New text:
Printouts from the analy zer must be stored in the patient file and the measured values 
transferred to the eCRF.
The hemoglobin value required for the pulmonary function tests performed at visits with 
limited assessments (see Section 7.1.2.10) will be measured at the local laboratory . The 
hemoglobin value will be entered in the eCRF and used for the calculation of predicted DL CO
only.
8.4.2 Efficacy -amended
Old text:
In the efficacy  anal yses, countries and centers will be clustered b y geographic region.  The 
decision on country  pooling will be made before unblinding.  Statistical analy ses will be 
adjusted for these countries / geographic regions.
The primary  anal ysis will be the change in mRSS from baseline to all assess ments post 
baseline up to Week 52 using mixed model repeated measures (MMRM) with baseline mRSS 
as a covariate, fixed effects treatment arm and region, the interaction effect between stud y 
visit and treatment arm, and patient specific random effects to acc ount for both heterogeneit y 
among patients and correlation among measurements taken on the same patient with an 
unstructured covariance assumption.  
[…]
As a sensitivity  anal ysis, the MMRM using the above model will also be applied to 
assessments post -baseline up to termination of study  medication or initiation of rescue 
medication.  In addition, the MMRM on all assessments will be repeated including addit ional 
effects time on rescue medication and time on study  medication.  MMRM assumes missing at 
random; mRSS by  time of patient withdrawal will be summarized and further methods using 
multiple imputation that allow for missing data not at random will be inv estigated.  Details of 
such methods will be described in the SAP.
[…]
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  128of 167
Rules for the imputation of missing values where the patient withdraws or dies for the 
univariate analy sis, null / alternative hy pothesis statements, and model statements in 
mathematica l notation will be specified in the SAP.  Two- sided 95% confidence intervals of 
treatment (riociguat compared to placebo) differences will be calculated in addition to the 
statistical significance testing.
The other secondary  and exploratory  efficacy  varia bles measured on a continuous or semi-
continuous scale will analy zed using the MMR M, ANCOVA, and stratified Wilcoxon test, as 
for the mRSS above.
The time to first mRSS progression and regression and clinical outcome parameters will be 
analyzed using the log-rank test comparing between treatment groups.
Any binary  outcomes, such as the predicted CRI SS outcome will be anal yzed using Mantel -
Haenzel weights, stratified by  region.  Also as a sensitivity  analy sis in addition to the time to 
event anal ysis, the occurrence of the events mRSS progression and regression and clinical 
outcome parameters will be anal yzed using this method.
Details on an y descriptive subgroup anal yses will be specified in the SAP.  These will include 
gender and region.
New text:
In the efficacy  anal yses, countries and centers will be clustered b y geographic region.  The 
decision on country  pooling will be made before unblinding.  Statistical analy ses will be 
adjusted for these countries / geographic regions.
8.4.2.1 Primary endpoint
The primary  anal ysis will be the change in mRSS from baseline to all assessments post 
baseline up to Week 52 using mixed model repeated measures (MMRM) with baseline mRSS 
as a covariate, fixed effects treatment arm and region, the interaction effect between st udy 
visit and treatment arm, and patient specific random effects to account for both heterogeneit y 
among patients and correlation among measurements taken on the same patient with an 
unstructured covariance assumption.
[…]
As a sensitivity  anal ysis, the MMRM using the above model will also be applied to 
assessments post -baseline up to termination of study  medication or initiation of rescue 
medication.  In addition, the MMRM on all assessments will be repeated including additional 
effects time on rescue medi cation and time on study medication.  MMRM assumes missing at 
random; mRSS by  time of patient discontinuation from study  medication will be summarized 
and further methods using multiple imputation that allow for missing data not at random will 
be investiga ted.  Details of such methods will be described in the SAP.
[…]
Rules for the imputation of missing values where the patient discontinues the study  (eg, 
withdrawal of consent or death) or study  medication for the univariate anal ysis, null / 
alternative h ypothesis statements, and model statements in mathematical notation will be 
specified in the SAP.  Two- sided 95% confidence intervals of treatment (riociguat compared 
to placebo) differences will be calculated in addition to the statistical significance test ing.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  129of 167
8.4.2.2 Secondary and exploratory endpoints
General aspects
The other secondary  and exploratory  efficacy  variables measured on a continuous or semi-
continuous scale will analy zed using the MMR M, ANCOVA, and stratified Wilcoxon test, as 
for the mRSS above.
The time to first mRSS progression and regression and clinical outcome parameters will be 
analyzed using the log -rank test comparing between treatment groups.
Any binary  outcomes, such as the predicted CRI SS outcome will be anal yzed using Mantel -
Haenzel weights, stratified by  region.  Also as a sensitivity  analy sis in addition to the time to 
event anal ysis, the occurrence of the events mRSS progression and regression and clinical 
outcome parameters will be anal yzed using this method.
Details on an y descriptive subgroup anal yses will be specified in the SAP.  These will include 
gender and region.
Hierarchical testing of secondary en dpoints
The following secondary endpoints will be tested in a hierarchical fashion at a 2 -sided 5% 
level, only  if the prim ary endpoint of mRSS is shown to be statistically  significant at a 2 -sided 
5% level.
The following order of testing will be applied:
CRISS
HAQ- DI (health assessment questionnaire -disability  index)
Patient's global assessment
Physician's global assessment
FVC % predicted
For example, if CRI SS is statistically  significant at a 2 -sided 5% level, then the HAQ -DI will 
be tested, if not the testing procedure will be stopped.  This step is repeated further down the 
list of the 5 secondary  endpoints until a non-s tatistically  significant endpoint is reached. 
These particular secondary  endpoints were chosen to be tested in this hierarchical fashion, 
because the mRSS and the above additional, secondary  variables were considered to have the 
greatest face validity  whe n designing the CRISS [41].
American College of Rheumatology Combined Response Index for Systemic Sclerosis
Application of CRI SS algorithm in a randomized clinical trial is a 2 -step process.  Firstl y, 
evaluate if patients have met the criterion for not -improved.  If yes, these patients are assigned 
a probability  score of 0.0.  For the remaining patients, calculate the probability  based on 
change in 5 measures: mRSS, FVC %, HAQ- DI, patient ’sglobal assessment, and phy sician's 
global assessment, where each me asure has a probability  score between 0 and 1 [41].
In Step 1, a patient is clinically  evaluated to determine whether the patient has improved or 
not.  Expert consensus on the definition of a patient who is not improved during a trial is the 
following:
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  130of 167
A patient is considered not improved and is assigned a probabilit y score of improving equal to 
0.0, irrespective of improvement on other core items, if he/she develops: 
1.New scleroderma renal crisis, 
2.Decline in FVC % predicted ≥15% (relative), confirmed b y another FVC % within a 
month, high resolution computed tomograph y (HRCT) to confirm interstitial lung 
disease (if previous HRCT did not show interstitial lung disease) and FVC % 
predicted below 80% predicted (attributable toSSc), 
3.New onset of left ventricular failure (defined as ejection fraction ≤45%) or new onset 
of pulmonary  arterial hypertension requiring treatment (attributable to SS c).
If the patient is determined to exhibit improvement in Step 1 (ie, not assigned a 0.0), Step 2 
involves computing the predicted probability  of improving (a score between 0.0 and 1.0, 
inclusive) for each patient using the equation:
      .    .  ∗∆      .  ∗∆   %  .  ∗∆         .  ∗∆         .  ∗∆       
        .    .  ∗∆      .  ∗∆   %  .  ∗∆         .  ∗∆         .  ∗∆       
where ∆MRSS indicates the change in mRSS from baseline to follow-up, ∆FVCdenotes the 
change in FVC % predicted from baseline to follow -up, ∆ Pt-globindicates the change in patient 
global assessment, ∆ MD-globdenotes the change in phy sician global assessment, and ∆ HAQ- DIis 
the change in HAQ -DI.  Note that all changes are absolute changes (Time 2–Time baseline ) and 
that the phy sician’s and patient’s global assessment was measured on the Likert sc ale ranging 
from 0 to 10, where 0 = excellent, and 10 = extremely  poor.
Hence, the CRI SS is comprised of 5 variables: mRSS, FVC % predicted, patient’s global 
assessment, phy sician’s global assessment, and HAQ -DI from the SHAQ patient reported 
outcome.  Com bined, the 5 variables explained 89.3% of the variability  in the data.  
Individuall y, when used in a single -variable logistic regression model, mRSS explained 
66.3% of the variation, FVC % predicted explained 36.1% of the variation, phy sician global 
assess ment explained 24.5% of the variation, patient global assessment explained 23.7% of 
the variation, and HAQ -DI explained 28.5% of the variation.  A change in mRSS, FVC % 
predicted and HAQ -DI are strong indicators of whether a patient is likely  to be improve d or 
not. I n each scenario, a decrease of mRSS or HAQ -DI from baseline to follow -up and an 
increase in FVC % predicted corresponds to very  high probabilities of improving.  For 
patient’s global and ph ysician’s global assessment, the association between pro bability  of 
improving and change in these 2 core components is less evident.  Subjects for which the 
predicted probability  is greater or equal to 0.60 are considered improved, while subjects for 
which the predicted probability  is below 0.60 are considered not improved.  The 2 groups 
(riociguat vs. placebo) can then be compared in a 2x2 table using appropriate significance 
tests.  The predicted probabilities obtained using the CRI SS can also be assessed as a 
continuous variable and the distributions of the p robability  of improving for patients on drug 
vs. placebo can be compared using non -parametric tests [41].In this study , the CRI SS 
outcome will be anal yzed using Mantel -Haenzel weights, stratified by  region, and 
additionally , the stratified Wilcoxon test will be used as non- parametric test.
However, Step 2 assumes that there is complete data; ie, all 5 components of the CRI SS are 
fully  recorded at Week 52.  If the subject discontinues from study  drug from the study  before 
Week 52, or has one or more missin g components of the CRI SS at this visit, then a mixed 
model repeated measures (MMRM) analysis will be implemented to estimate the value or 
values for those components at Week 52. These estimates will then we used to calculate the 
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  131of 167
CRISS score at Week 52 as given in Step 2.  Subjects for which the predicted probability  is 
greater or equal to 0.60 are considered improved, while subjects for which the predicted 
probability  is below 0.60 are considered not improved. [41] Further details will be provided in 
the statistical analy sis plan.
8.6 Determination of sample size
Old text:
One of the components of secondary efficacy  measure mRSS progression is a 5 point or more 
deterioration from baseline to any  assessment in the 12 month study  period, this being 
considere d a clinicall y meaningful change [14].  
New text:
One of the components of exploratory efficacy  measure mRSS progression is a 5 point or 
more deterioration from baseline to an y assessment in the 12 month study  period, this being 
considered a clinicall y me aningful change [14].  
12. Reference list -amended
New text:
41. Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, May es MD, et al. The 
American College of Rheumatology  Provisional Composite Response I ndex for Clinical 
Trials in Earl y Diffuse Cutaneous Sy stemic Sclerosis. Arthritis Rheumatol. 2016; 68(2):299 -
311.
42. Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. 
Development of a provisional core set of response measures for clinical trials of sy stemic 
sclerosis. Ann.Rheum Dis. 2008;67(5):703 -709.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  132of 167
13.3 Amendment 5
Amendment 5 was approved on 18 Aug 2016.
13.3.1 Overview of changes to the study
This amendment was implemented to clarify  that the benefit
-risk balance for the population in 
this study  (patients with dcSSc) remains po sitive, despite the potential safety  issue that has 
been reported in a stud y in patients with PH -IIP leading to earl y termination of th e concerned
study . The benefit - risk assessment for patients with dcSSc was re- evaluated by  the DMC in 
3meetings and was confirmed to remain positive. 
Furthermore, the sample size determination in Section 8.6 was adapted to reflect 
The change in key  secondary  efficacy  endpoint to CRI SS (implemented with 
amendment 4).
Appropriate ranges for the significan celevels and numbe r of patients required. 
When scientific advice was initially  sought from the Food and Drug Administration ( FDA )
and European Medicines Agency  (EMA ) during the set -up of this study , a one -sided 
significance level of 5%, equivalent to a two -sided significan
ce level of 10%, was proposed, 
resulting in a total sample size of 102 patients. If such a significance level was achieved, 
together with a clinicall y significant effect on the mRSS, then this was considered a potential 
criterion for efficacy to proceed wi th the drug to Phase III studies. To make the study  more 
robust, the final protocol specified a two -sided significance level of 5%, resulting in a total 
sample size of 128 patients. 
Additionally , the time point of the CRI SS assessment was clarified to be Week 52. The 
original term “follow -up”, as mentioned in Section 8.4.2.2, was taken from the paper 
describing the derivation of the CRI SS score [41]. This was not referring to a specif ic visit, 
but a post -baseline follow -up assessment of a patient to be able to calculate the CRI SS. 
Week 52 has now been specified, this being the planned final visit in the main treatment 
phase, and to avoid the interpretation that this might have been the post-treatment Safet y 
Follow -up visit.
As of 01 July  2016, Bay er HealthCare AG merged with Bay er AG. Thereb y, Ba yer 
HealthCare AG 
ceased to exist and Bay er AG became its legal successor and automatically  
took over all of the Bay er HealthCare AG’s rights, obligations and liabilities by  law, 
including the sponsorship for clinical studies currently  sponsored by  Bayer HealthCare AG.
The sponsorship information for this study  was changed on the title page.
Additionally , the sponsor for US territory  was added. Bayer HealthCare 
Pharmaceuticals Inc. is and has been the sponsor for the US territory  for this study  as 
set forth in FDA Investigational New Drug ( IND) form 1571. The reference on the 
protocol was incomplete in this regard.
Further changes to the protocol included the following clarifications and additions:
Update of permitted concomitant medication during the long- term extension phase.
Update of allowed rescue therap y.
Clarification that biomarker anal yses will be reported separatel y.
Addition of description of unblinding process for biomarker and PK anal ysis.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  133of 167
Clarification of sampling time points for blood samples for PK anal ysis and 
documentation requirements.
Addition of analy sisof PK data in relationship of exposure parameters with treatment 
effects.
Change in time point for first data cleaning andreporting .
Clarification for adverse event reporting regarding conditions of SSc .
Clarification of the wording for exclusion criterion 5.
Addition of one criterion for discontinuation of the study  medication in case patients 
develop renal disease andhepatic insufficiency in alignment with exclusion criteria 2 
and 3 .
Addition of the patient’s and phy sician’s global assessment to the visits with limited 
assessments to ensure that all required variabl es are available at Week 52 for the 
analysis of the CRI SS.
Correction of v
isit window for Visit 18.
Clarification of allowed dose interruptions in the open -label extension period.
Correction of t ypographical errors and minor editorial changes are not speci fied in the list of 
changes below. New text is display ed as underlined; text that was deleted is presented as 
strike -through text.
13.3.2 Changes to the protocol text
General change
Due to the change in the sponsor details, the header was adapted in the whole doc ument: the 
old logo was deleted and replaced by the new logo.
Title page - amended
Old text:
Sponsor: Bayer HealthCare AG,  D- 51368 Leverkusen,  Germany
New text:
Sponsor:Non-US: Bayer AG,  D -51368 Leverkusen,  Germany
US territory: Bayer Healthcare Pharmaceuticals Inc., 
100Bayer Boulevard, P.O. Box 915, 
Whippany NJ 07981 -0915, USA
Synopsis –Number of patients
Old text:
130 randomized patients.
New text:
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  134of 167
Up to a pproximately 130 randomized patients.
1.3 Benefit-risk assessment –amended
Old text:
[Not applicable. New text added in the end of the section.]
New text:
Recently , a potential safety  issue has been reported for patients with pulmonary  hypertension 
associated with idiopathic interstitial pneumonias (PH- IIP) and, therefore, the benefit -risk 
assessment for this indication has changed from positive to unfavorab le. Following the data 
monitoring committee (DMC) recommendation, the study treatment has been terminated. 
Also per DMC recommendation patients are continuing in a safet y follow-up for 4 months 
after stud y drug discontinuation and the study is expected to close in September 2016. 
A careful review, assessment and anal ysis will be done by  the sponsor with unblinded and 
clean data originating from clinical study  13605 (RI SE-IIP; final clinical study report 
expected in 2017). Information of health care profess ionals (via Dear Healthcare Professional 
Letter), label updates and an update of the risk management plan have been initiated in 
July 2016 in collaboration with the European Medicines Agency  as well as national 
competent authorities.
The benefit -risk profi le for conditions being studied in ongoing clinical studies also has been 
carefully  re-evaluated. In the case of the present study  in the dcSSc indication, 2 ad-hoc 
meetings of the DMC for this study  took place, on 23 MAY 2016 and on 25 MAY 2016, 
followed by  a third meeting on 15 AUG 2016. The DMC concluded that this study  may  
continue without amendment or modification. Overall, the benefit -risk balance for this 
indication remains positive.
2. Study objectives -amended
Old text:
oKey secondary  objective:
American College of Rheumatology Combined Response Index for 
Systemic Sclerosis (CRISS)
New text:
oKey secondary  objective:
American College of Rheumatology  Combined Response Index for 
Systemic Sclerosis (CRISS) at Week 52 .
4.1 Design overview
Old text:
In this multinational, multicenter, randomized (1:1), double -blind, placebo -controlled, 
parallel -group stud y, a total of approximately 200 patients are planned for enrollment in order 
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  135of 167
to randomize approximately  130 patients to study  drug treatment (approximat ely 65 patients 
to the riociguat group and 65 to the placebo group).
New text:
In this multinational, multicenter, randomized (1:1), double- blind, placebo -controlled, 
parallel -group stud y, a total of approximately 200 patients are planned for enrollment in order 
to randomize up to approximately  130 patients to study  drug treatment (a pproximately  65 
patients to the riociguat group and 65 to the placebo group).
4.1.4 Dose Interruptions - amended
Old text:
o≤28 day s: treatment can be restarted at the discretion of the investigator at 
0.5mg TID lower than the last dose.
o>28days: discontinue the patient from stud y medication.
New text:
o>13 and ≤28 consecutive days: treatment can be restarted at the discretion of 
the investigator at 0.5 mg TID lower than the last dose.
o>28consecutive days: discontinue the patient from study  medicat ion.
4.1.5 Termination visit and safety follow -up visit - amended
Old text:
If the patient discontinues study  drug  prematurel y during the main treatment phase (Week 0 –
Week 52) he/she will be invited to come for limited assessments (mRSS, pulmonary  func tion 
test [FVC and DL COincluding hemoglobin measurement at the local laboratory ], andpatient -
reported outcomes [PROs]) at Week 12, Week 26, Week 39, and Week 52, depending on the 
timing of discontinuation .  
New text:
If the patient discontinues study  drug prematurel y during the main treatment phase (Week 0 –
Week 52) he/she will be invited to come for limited assessments (mRSS, pulmonary  function 
test [FVC and DL COincluding hemoglobin measurement at the local laboratory ], patient
-
reported outcomes [PRO s], and patient’s and physician’s global assessment) at Week 12, 
Week 26, Week 39, and Week 52, depending on the timing of discontinuation.  
5.1.2 Exclusion Criteria - amended
Old text:
5. Pulmonary -related criteria
• Diagnosed pulmonary  hypertension  as determined by  right heart 
catheterization  
New text:
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  136of 167
Pulmonary -related criteria
• Any form of pulmonary  hypertension as determined by  right heart 
catheterization  
5.2.1.2 Discontinuation of study medication 
Old text:
Patients must be discontinued from the stud y medication for the following reasons:
[…]
Occurrence of adverse drug reactions, which in the investigator’s opinion have a 
negative impact on the patient’s individual risk- benefit ratio.  (Investigators are 
obliged to re assess the patient’s individual risk -benefit ratio on a continuous basis.  
Factors such as anticipated treatment effect, progression of underl ying disease, 
occurrence of side effects, and alternative treatment options must be considered.)
[…]
If treatment is interrupted for >28 days during the open-label extension period (of the 
long-term extension phase)
New text:
Patients must be discontinued from the stud y medication for the following reasons:
[…]
Occurrence of adverse drug reactions, which in the invest igator’s opinion have a 
negative impact on the patient’s individual risk- benefit ratio.  (Investigators are 
obliged to reassess the patient’s individual risk-benefit ratio on a continuous basis.  
Factors such as anticipated treatment effect, progression of underl ying disease, 
occurrence of side effects, and alternative treatment options must be considered.)
If a subject, during the course of the stud y, develops 
a)renal disease that leads to eGFR <15/mL/min/1.73m2, 
b)hepatic insufficiency  classified as Child- Pugh C .  
[…]
If treatment is interrupted for >28 consecutive days during the open- label extension 
period (of the long- term extension phase)
5.2.1.3 Handling of withdrawals or discontinuations from study medication
Old text:
If the patient discontinues study  drug prematurel y during the main treatment phase (Week 0 –
Week 52) he/she will be invited to come for limited assessments (mRSS, pulmonary  function 
test [FVC and DL COincluding hemoglobin measurement at the local laboratory ] , andPROs) 
at Week 12, Week 26, Week 39, and Week 52, depending on the timing of discontinuation.  
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  137of 167
New text:
If the patient discontinues study  drug prematurel y during the main treatment phase (We ek 0 –
Week 52) he/she will be invited to come for limited assessments (mRSS, pulmonary  function 
test [FVC and DL COincluding hemoglobin measurement at the local laboratory ], PROs, and 
patient’s and ph ysician’s global assessment) at Week 12, Week 26, Week 39, and Week 52, 
depending on the timing of discontinuation.  
6.5 Blinding -amended
Old text:
[Not applicable. New text added.]
New text:
Appropriate measures will be taken to maintain blinding of the stud y team while PK and 
biomarker anal yses are ongoi ng. Data with a potential to unblind (eg, plasma concentrations) 
are not to be handled b y or shown to the study  team members and will only be uploaded into 
the clinical database after official unblinding. The process of data flow will be documented 
separat ely (see also Section 7.4 and Section 7.6.3.).
Statistical analy sis as described in the SAP will be done after database lock and authorization 
of data release according to standard operating procedures.
6.9 Prior and concomitant therapy –amended
Old text :
[…] These treatments will also be allowed as new- onset during the study at the discretion of 
the investigator to treat SSc- specific adverse events (eg, Raynaud’s phenomena, joint 
inflammation, new onset renal crisis).
[…]
Table 6 -2 Prohibited prior and concomitant therapy -amended
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  138of 167
Therapy Timeframe 
Chlorambucil, bone marrow transplantation, or total lymphoid irradiation Any previous therapya
Rituximab or other anti -CD20 antibodies Within 6 m onths prior to 
the screening visita
Infliximab, certolizumab, golimumab, adalimumab, abatacept, 
leflunomide or tocilizumabWithin 8 weeks prior to the 
screening visita,
Methotrexate, cyclophosphamide, hydroxychloroquine, cy closporine A, 
azathioprine, m ycophenolate mofetil, rapam ycin, colchicine, D 
penicillamine, tacrolimus, mizoribine or intravenous immunoglobulinWithin 4 weeks prior to the 
screening visita,
Etanercept Within 2 weeks prior to the 
screening visita,
Anakinra Within 1 week prior to the 
screening visita
Nitrates or NO donors (such as amyl nitrate) in any form, including 
topical; phosphodiesterase (PDE) 5 (PDE5) inhibitors (such as 
sildenafil, tadalafil, vardenafil); and nonspecific PDE5 inhibitors 
(theophylline, dipyridamole)Concomitant therapy with 
study drug
Prostacyclin analogs ( oral beraprost for digital ulcers / Raynaud’s 
disease and short- term / intermittent therapy of up to 21 days 
with intravenous prostacyclin analogs for digital / vascular lesions is 
allowed)Concomitant therapy with 
study drug 
aConcomitant use of these treatments with study medication is also prohibited, except for certain 
agents from Week 26 onwards; please see “Rescue Therapy” below.  
Rescue therapy
[…] The decision to initiate rescue therap y is based on investigator discret ion in eligible 
patients.  Rescue therap y may include an y of the following 4 agents:  methotrexate, 
mycophenolate mofetil, cy clophosphamide, or azathioprine. These treatments are not 
provided b y the Sponsor.
New text:
[…] These treatments will also be allowed as new -onset during the study at the discretion of 
the investigator to treat SSc- specific adverse events (eg, Raynaud’s phenomena, joint 
inflammation, new onset renal crisis).
During the long -term extension phase (ie, after completion of all effica cy-and safet y-related 
procedures at Visit 12), except for the contraindicated nitrates or NO donors and PDE5 
inhibitors, the addition of any other concomitant medication is at the discretion of the 
investigator.
[….]
Table 6-2 Prohibited prior and concomi tant therapy -amended
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  139of 167
Therapy Timeframe 
Chlorambucil, bone marrow transplantation, or total lymphoid irradiation Any previous therapya, b
Rituximab or other anti -CD20 antibodies Within 6 m onths prior to 
the screening visita, b
Infliximab, certolizumab, golimumab, adalimumab, abatacept, 
leflunomide or tocilizumabWithin 8 weeks prior to the 
screening visita, b
Methotrexate, cyclophosphamide, hydroxychloroquine, cy closporine A, 
azathioprine, m ycophenolate mofetil, rapam ycin, colchicine, D 
penicillamine, tacrolimus, mizoribine or intravenous immunoglobulinWithin 4 weeks prior to the 
screening visita, b
Etanercept Within 2 weeks prior to the 
screening visita,b
Anakinra Within 1 week prior to the 
screening visita,b
Nitrates or NO donors (such as am yl nitrate) in any form, including 
topical; phosphodiesterase (PDE) 5 (PDE5) inhibitors (such as 
sildenafil, tadalafil, vardenafil); and nonspecific PDE5 inhibitors 
(theophylline, dipyridamole)Concomitant therapy with 
study drug
Prostacyclin analogs (oral beraprost for digital ulcers / Raynaud’s 
disease and short- term / intermittent therapy of up to 21 days 
with intravenous prostacyclin analogs for digital / vascular lesions is 
allowed)Concomitant therapy with 
study drug 
aConcomitant use of these treatments with study medication is also prohibited, except for certain 
agents from Week 26 onwards; please see “Rescue Therapy” below.  
bConcomitant use of these medications will be allowed during the long -term extension phase
Rescue therapy
[…] The decision to initiate rescue therap y is based on investigator discretion in eligible 
patients.  Rescue therap y may include an y of the following 4 agents:  methotrexate, 
mycophenolate mofetil, cy clophosphamide, or azathioprine.
Worse ning of inflammatory  joint disease or my ositis.  
Rescue therap y can be initiated at investigator’s discretion in eligible patients. In addition to 
the 4 agents methotrexate, my cophenolate mofetil, cy clophosphamide, or azathioprine, 
hydroxychloroquine will be allowed for the treatment of inflammatory  joint disease and 
myositis.
These treatments are not provided b y the Sponsor.
7.1.1 Tabulated overview - amended
The visit window for Visit 18 was changed from ±14 days to ±2 days in the schedule of events 
(Table 7 -1). The visit windows for all following visits (Vn) remains unchanged.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  140of 167
7.1.2.10 Premature discontinuation of study drug treatment -amended
Old text:
If the patient discontinues study  drug prematurel y during the main treatment phase (Week 0 –
Week 52) he/she will be invited to come for limited assessments (mRSS, pulmonary  function 
test [FVC and DL COincluding hemoglobin measurement at the local laboratory ] , andPROs) 
at Week 12, Week 26, Week 39, and Week 52, depending on the timing of discontinuation.  
New text:
If the patient discontinues study  drug prematurel y during the main treatment phase (Week 0 –
Week 52) he/she will be invited to come for limited assessments (mRSS, pulmonary  function 
test [FVC and DL COincluding hemoglobin measurement at the local laboratory ], PROs, and 
patient’s and ph ysician’s global assessment) at Week 12, Week 26, Week 39, and Week 52, 
depending on the timing of discontinuation.  
7.3 Efficacy -amended
Old text:
Key secondary  endpoint:
CRISS, consisting of five variables: mRSS, FVC % predicted, ph ysician and patient 
global assessments, and HAQ
-DI score (from SHAQ patient reported outcome)
New text:
Key secondary  endpoint:
CRISSat Week 52 , consisting of five variables: mRSS, FVC % predicted, phy sician 
and patient global assessments, and HAQ -DI score (from SHAQ patient reported 
outcome)
7.4 Pharmacokinetics / pharmacodynamics
Old text:
At these study  visits the patients should present themselves to the hospital without taking the 
morning dose of study  medication. The trough PK sample should alway s be obtained at up to 
1 hour before administration of the morning dose of study  medication.
It is essential that the exact time of b lood sampling and time of dose administration of the 3 
preceding doses of stud y medication are documented accuratel y in the eCRF.
For investigation of exposure behavior, plasma concentrations of BAY63 -2521 and its 
metabolite (M1) will be determined at the times given below using a sparse sampling 
approach in all participating patients. 
[…]
Plasma concentration time points will be compared to the available plasma concentration 
profiles in health y volunteers and selected patient populations.
[…]
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  141of 167
Pharmacokine tic (PK) samples will be analy zed under the responsibility  of the Bay er 
HealthCare Bioanaly tics Laboratory , Bay er Pharma AG, GDD -GED -DMPK Bioanal ytics, 
42096 Wuppertal, Germany .
New text:
At these study  visits the patients should present themselves to the hospital without taking the 
morning dose of study  medication. The trough PK sample should alway s be obtained at up to 
1 hour before administration of the morning dose of study  medication and approximately  5to 
15hours after the evening dose .
It is essential that the exact time of blood sampling and time of dose administration of the 
3preceding doses of study  medication are documented accuratel y in the eCRF. For samples 
taken before riocig uat administration, also the time of the first dose taken at the visit needs to 
be documented.
For investigation of exposure behavior, plasma concentrations of BAY63 -2521 and its 
metabolite (M1) will be determined at the times given below using a sparse sa mpling 
approach in all participating patients. If the investigator decides to take additional PK 
samples, those may  be used for PK analy sis as well.
[…]
Plasma concentration time points will be compared to the available plasma concentration 
profiles in hea lthy volunteers and selected patient populations. Pharmacokinetic and 
exposure -response anal ysis might be performed using population approaches (popPK and 
popPK/PD, eg, b y non -linear mixed effect modeling). Anal ysis and report will be done under 
separate c over. This evaluation might be started prior to database lock. If this is applicable, 
appropriate measures will be taken to maintain blinding of the stud y team , eg, data will be 
stored separatel y, and members of the stud y team will neither have access to the 
randomization list nor to individual data .
[…]
Pharmacokinetic (PK) samples will be analy zed under the responsibility  of the Bay er 
HealthCare Bioanaly tics Laboratory , Bay er Pharma AG, GDD -GED -DMPK Bioanal ytics, 
42096 Wuppertal, Germany . The bioanal yst will be unblinded and have access to the 
randomization list. 
7.5.1.1 Definitions 
Old text:
Conditions that started or deteriorated after signing of informed consent will be 
documented as AEs.
New text:
Conditions that started or deteriora ted after signing of informed consent will be 
documented as AEs. This includes any  conditions related to the underl ying disease .
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  142of 167
7.6.2 Laboratory parameters - amended
Old text:
Patients with isolated AST or ALT >3xULN or bilirubin >2xUL N at screening and/ or 
baseline will have additional anal ysis of coagulation tests, AST, ALT, AP, GGT, total 
bilirubin and serum albumin until normalization and/ or stabilization at Visit 2 (Day  14), Visit 
3 (Day  28), Visit 4 (Day 42), Visit 5 (Day  56), as needed.  Worsening of the parameters in the 
order of 2 -fold from baseline values will be considered clinically  significant [22] and 
additional diagnostic procedures may be requested.
Patients entering the trial with eGFR 15- 29 mL/min/1.73m2will be undergo additional serum 
creatinine and eGFR calculation until normalization and/ or stabilization at Visit 2 (Day  14), 
Visit 3 (Day  28), Visit 4 (Day  42), and Visit 5 (Day  56), as needed.  A decrease in eGFR 
equal or greater than 5ml/min/1.73m2in these patients (eGFR 15 -29 ml/min /1.73m2) during 
the study  or a reduction of 25% or more in 12 months will be considered clinically  significant 
[23,24].
New text:
Patients with isolated AST or ALT >3xULN or bilirubin > 2xUL N at screening and/or 
baseline will have additional anal ysis of coagulation tests, AST, ALT, AP, GGT, total 
bilirubin and serum albumin until normalization and/ or stabilization at Visit 2 (Day  14), Visit 
3 (Day  28), Visit 4 (Day 42), Visit 5 (Day  56), as needed. Worsening of the parameters in the 
order of 2 -fold from baseline values will be considered clinically  significant [22] and 
additional diagnostic procedures may  be requested. See Section 5.2.1.2 for discontinuation 
criteria related to liver function.
Patients entering the trial with eGFR 15- 29 mL/min/1.73m2will be undergo additional serum 
creatinine and eGFR calculation until normalization and/ or stabilization at Visit 2 (Day  14), 
Visit 3 (Day  28), Visit 4 (Day  42), and Visit 5 (Day  56), as nee ded.  A decrease in eGFR 
equal or greater than 5ml/min/1.73m2in these patients (eGFR 15 -29 ml/min/1.73m2) during 
the study  or a reduction of 25% or more in 12 months will be considered clinically  significant 
[23,24]. See Section 5.2.1.2 for discontinuation criteria related to eGFR values .
7.6.3 Exploratory Biomarkers 
Old text:
[Not applicable. New text added in the end of the section.]
New text:
The evaluation of biomarkers might be started prior to database lock; if this is applicable, 
appropriate measu res will be taken to maintain blinding of the stud y team (see also Section 
6.5 and Section 7.4) .  
The results of the biomarker anal ysis will be reported separatel y to the clinical study report.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  143of 167
7.6.15 Patient’s and physician’s global assessment
Old text:
Frequency : Visit 1 (Day  0), Visit 10 (Week 26) and Visit 12 (Week 52) andtermination visit 
(not needed after V12).
New text:
Frequency : Visit 1 (Day  0), Visit 10 (Week 26) and Visit 12 (Week 52) ,termination visit (not 
needed after V12) , and visits with limited assessments .
8.4.2.2 Secondary and exploratory endpoints
Old text:
American College of Rheumatology Combined Response Index for Systemic Sclerosis
Application of CRI SS algorithm in a randomized clinical trial is a 2 -step process.  
[…]
If the pati ent is determined to exhibit improvement in Step 1 (ie, not assigned a 0.0), Step 2 
involves computing the predicted probability  of improving (a score between 0.0 and 1.0, 
inclusive) for each patient using the equation:
      .    .  ∗∆      .  ∗∆   %  .  ∗∆         .  ∗∆         .  ∗∆       
        .    .  ∗∆      .  ∗∆   %  .  ∗∆         .  ∗∆         .  ∗∆       
where ∆MRSS indicates the change in mRSS from baseline to follow -up, ∆FVCdenotes the 
change in FVC % predicted from baseline to follow -up, ∆Pt-globindicates the change in patient 
global assessment, ∆MD-globdenotes the change in phy sician global assessment, and ∆ HAQ- DIis 
the change in HAQ -DI.
[…]
In each scenario, a decrease of mRSS or HAQ -DI from baseline to follow -upand an increase 
in FVC % predicted corresponds to very  high probabilities of improving.
New text:
American College of Rheumatology Combined Response Index for Systemic Sclerosis
The key  secondary endpoint will be the CRI SSat Week 52.
Application of CRI SS algorithm in a randomized clinical trial is a 2 -step process.  
[…]
If the patient is determined to exhibit improvement in Step 1 (ie, not assigned a 0.0), Step 2 
involves computing the predicted probability  of improving (a score between 0.0 and 1.0, 
inclusive) for each patient using the equation:
      .    .  ∗∆      .  ∗∆   %  .  ∗∆         .  ∗∆         .  ∗∆       
        .    .  ∗∆      .  ∗∆   %  .  ∗∆         .  ∗∆         .  ∗∆       
where ∆MRSS indicates the change in mRSS from baseline to Week 52, ∆ FVCdenotes the 
change in FVC % predicted from baseline to Week 52 , ∆Pt-globindicates the change in patient 
global assessment, ∆MD-globdenotes the change in phy sician global assessment, and ∆ HAQ- DIis 
the change in HAQ -DI.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  144of 167
[…]
In each scenario, a decrease of mRSS or HAQ- DI from baseline to Week 52 and an increase 
in FVC % predicted corresponds to very  high probabilities of improving.
8.5 Planned interim analyses
Old text:
The main treatment phase will be unblinded for data anal ysis when the last patient completes 
the dose -titration period of the long- term extension phase and the database for the main 
treatment phase is declared clean, wh ichever occurs last.
The first safety  update will be performed on the long -term extension phase when the last 
patient completes the dose -titration period after the first 10 weeks of this phase .  
New text:
The main treatment phase will be unblinded for dat a anal ysis when the last patient completes 
the main treatment phase (Visit 12) and the database for the main treatment phase is declared 
clean, whichever occurs last.
The first safety  update will be performed on the long -term extension phase when the last 
patient completes 24 weeks of treatment (Visit 19) .
8.6 Determination of sample size 
Old text:
The primary  efficacy  estimand in this study  will be change in mRSS from baseline to 
Week 52.  Assuming a standard deviation of 8 points, a power of80% and a two -sided 
significance level of 5%, with a 1:1 randomization, then to detect a placebo -adjusted 
difference of 4 points, 64 patients in each treatment group, a total of 128 patients, would be 
required to be valid for the ITT analy sis.  Allowing f or up to two patients randomized and not 
treated, a total of 130 randomized patients are planned.
For the secondary  efficacy  measure based on the mRSS progression rate, if the sample size is 
fixed at 128 patients with a 1:1 randomization, then with an even t rate on placebo of 20% and 
on riociguat of 4% (a relative risk reduction of 80%), the stud y has a power of 71% to detect 
this as statistically  significant at a two- sided p ≤ 0.05.
Sources of these sample size and power calculations are nQuery  version 7.0, module s
MTT0-1 and PTT2-1.
New text:
The primary  efficacy  estimand in this study  will be change in mRSS from baseline to 
Week 52. Assuming a standard deviation of 8 points, a power between 70% and 80% and a 
two-sided significance level of 5% with a 1:1 r andomization, then to detect a placebo -adjusted 
difference of 4 points, between 51 and 64 patients in each treatment group, a total of 102 to
128patients, would be required to be valid for the ITT anal ysis(see Table 8 –2). Allowing for 
up to two patients randomized and not treated, approximately 130 randomized patients are 
planned.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  145of 167
Table 8 -2 Power calculations: power varying from 70% to 80% in 2% stages
N per group 51 53 56 58 61 64
Total N 102 106 112 116 122 128
Power (%) 70 72 74 76 78 80
N =number of patients
Sources of these sample size and power calculations are nQuery  version 7.0, module MTT0-1.
9.3 Data processing
Old text:
For data coding (eg, AEs, medication), internationally  recognized and accepted dictionaries 
will be used. After its initial release for biometrical analy sis, the clinical database is planned 
to be re -opened for the inclusion of the following additional data: eg,PK data, antibody  data.
New text:
For data coding (eg, AEs, medication), internationally  recognized and accepted dictionaries 
will be used. After its initial release for biometrical analy sis, the clinical database is planned 
to be re -opened for the inclusion of the following additional dat a: eg, PK data, biomarker
data.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  146of 167
13.4 Amendment 6
Amendment 6 was approved on 02 MAY 2017.
13.4.1 Overview of changes to the study
This amendment was implemented based on therecommendation of the data monitoring 
committee (DMC) after review of the safet y anal ysis on 0 1 MAR 2017. Due to increased 
complaints of both palpitations and dizziness in subjects with interstitial lung disease (ILD) 
noted by  the DMC, the assessment of orthostatic changes in blood pressure and heart rate as 
well as the measurement of oxy gen satura tion (using forehead pulse oximetry ) were added to 
the protocol assessments for all subjects . As recruitment for this study  was alread y completed, 
the new assessments will not be implemented starting with the screening visit, but only  for 
study  visits, whi ch will be performed after implementation of this amendment.
Additionally , an error in the description of the units provided in exclusion criterion 6 was 
corrected.
Correction of t ypographical errors and minor editorial changes are not specified in the lis t of 
changes below. New text is display ed as underlined; text that was deleted is presented as 
strike -through text.
13.4.2 Changes to the protocol text
4.1.2 Main treatment phase (Week 0 to Week 52) –amended
Old text:
Dose titration algorithm
The study  medication dose for the next titration step will be determined every  2weeks 
according to the patient’s well
-being and the peripheral s ystolic blood pressure (SBP) 
measured at trough before intake of the morning according to the following algorit hm (dose 
titration scheme):
If SBP is ≥ 95 mmHg and the patient has no signs or sy mptoms of hy potension, the 
dosage should be increased by  0.5mg TID. 
If SBP is < 95mmHg, the dosage should be maintained provided the patient does not 
show an y signs or s ymptoms of hy potension.
If SBP is < 95mmHg, and the patient exhibits signs or sy mptoms of hy potension, the 
current dosage should be decreased b y 0.5 mg TID.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  147of 167
New text:
Dose titration algorithm
The study  medication dose for the next titration step will be determined every  2weeks 
according to the patient’s well-being and the peripheral s ystolic blood pressure (SBP) 
measured at trough before intake of the morning dose as well as based on any  of the 
2measurements (supine or sitting) performed 2 hours after d ose intake to assess orthostatic 
changes according to the following algorithm (dose titration scheme):
If SBP is ≥ 95 mmHg and the patient has no signs or sy mptoms of hy potension, the 
dosage should be increased by  0.5mg TID. 
If SBP is < 95mmHg, the dosage should be maintained provided the patient does not 
show an y signs or s ymptoms of hy potension.
If SBP is < 95mmHg, and the patient exhibits signs or sy mptoms of hy potension, the 
current dosage should be decreased b y 0.5 mg TID.
5.1.2 Exclusion Criteria -amended
Old text:
6. Laboratory  examinations
Patients with:  hemoglobin <9.0 g/dL, white blood cell (WBC) count <3000/mm3
(<3× 109/L), platelet count <100,000/mm3(<3× 109/L)
New text:
6. Laboratory  examinations
Patients with:  hemoglobin <9.0 g/dL, white blood cell (WBC) count <3000/mm3
(<3× 109/L), platelet count <100,000/mm3(<100× 109/L)
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  148of 167
7.1.1 Tabulated overview - amended
Old text:
Table 7–1 Schedule of evaluations -amended
Scr Main Treatment Phase  (Double -blind) vLong- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension PeriodSafety  Follow -
up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364
-14
to +2378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
V18 ± 2
Vn ± 1430 +5
Written informed consent X
Inclusion / exclusion criteria
X X
Demographic dataX
Medical and surgical history
X X
Other history (alcohol)X
Smoking historyX X X X X X
Height and weightc
X X X X X X X X
Physical examinationX X X X X X X X
mRSS X X X X X X X
Assessment of Raynaud’s 
attacks XdXeXfXe
Digital ulcer net burden
assessment X X X X X X X X X X X X X X X X X X X X
Tender & swollen joint countX X Xg
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  149of 167
Table 7–1 Schedule of evaluations -amended
Scr Main Treatment Phase  (Double -blind) vLong- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension PeriodSafety  Follow -
up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364
-14
to +2378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
V18 ± 2
Vn ± 1430 +5
Vital signs (BP, HR)hX X X X X X X X X X X X X X X X X X X X X
Vital signs post -dose 
(BP, HR)i,j XiXjXi
Blood sample for safetyk, uX X XuXuXuXuX X X X X X X X
Blood sample for PK XlXmXmXmXmXmXnXlXmXmXmXmXm
Blood sample for biomarkers X X Xr
Blood sample for 
Autoantibody screenX
Pregnancy test (if 
applicable)o X X X X X X X X X X X X
12-lead ECGp
X X X X X X X X X
Pulmonary function testsq
X X X X X X X
Skin biopsyX X Xr
Questionnairess
X X X X X X X
Patient’s and physician’s 
global assessmentX X X Xg
Patient interference with skin X X X Xg
Tendon Friction Rubst
X X
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  150of 167
Table 7–1 Schedule of evaluations -amended
Scr Main Treatment Phase  (Double -blind) vLong- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension PeriodSafety  Follow -
up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364
-14
to +2378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
V18 ± 2
Vn ± 1430 +5
Randomization (IxRS)X
Dispensation of study drugX X X X X X X X X X X X X X X X X X
Drug accountability X X X X X X X X X X X X X X X X X X
Adverse events recordingX X X X X X X X X X X X X X X X X X X X X
Prior and concomitant 
therapy X X X X X X X X X X X X X X X X X X X X X
Survival statusX
Abbreviations:  BP = blood pressure; ECG = electrocardiogram; TV = Termination Visit; SFU =30-Day Safety Follow -up (30 [+5] days after the last dose of study drug); HR = heart rate; IxRS = 
telephone -based or web -based response system; mRSS = modified Rodnan skin score; PK =pharmacokinetics; q 12 wk = every 12 weeks; Scr = Screening.
Note:  Day 0 (Visit 1) is the baseline visit.
a Visit 12 ( Week 52) is the last visit in the Maintenance Period of the Main Treatment phase and the first (baseline) visit in the Long -term Extension phase.
b To be performed as soon as possible after discontinuation of study medication.  
c Height to be measured only at the screening visit
d Patient to be provided with 7 -day diary, to complete daily for 7 consecutive days leading up to Visit 1 
e Patient and physician assessment of Raynaud’s disease (see Section 7.6.12 )
f Patient to be provided with 7 -day diary, to complete daily for 7 consecutive days leading up to Visit 8.
g Must not be performed if TV is after V12.
h Blood pressure and heart rate will be measured at all visits with the patient in a sitting position, after the patient has been at rest for at least 5 minutes.  The same arm is always used for th ese 
measurements (see Section 7.6.5 ).
i Vital signs to be measured within 20 minutes prior to each post -dose PK sampling ( see Table 7–2)
j Vital signs to be measured within 20 minutes prior to PK sampling (see Table 7–2)
k Coagulation tests to be performed at a local laboratory
l Samples for PK to be taken 1 –2 hours and 3 –4 hours after the morning dose of study medication ( see Table 7–2)
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  151of 167
m Sample for PK to be taken up to 1 hour before the morning dose of study medication (trough) (see Table 7–3)
n Samples for PK to be taken up to 1 hour before the morning dose of study medication (trough) and 2 –3 hours after the morning dose of study medication (peak) 
(see Table 7–4)
o For women of childbearing potential only. Serum pregnancy test is required only at screening; pregnancy testing (urine) will be done every 4 weeks and should continue until 30 days after the 
last dose of study drug. When pregnan cy testing coincides with a visit, the test should be performed at the site, but otherwise should be performed at home. 
p Standard ECG (12 -lead ECG) will be recorded with the patient in the supine position, after the patient has been at rest for at least 5 minutes (see Section 7.6.7 ).
q Pulmonary function tests include forced vital capacity (FV C)and diffusion capacity of the lung for carbon monoxide (DLCO).
r Must be done at a TV if this visit occurs before Visit 8.
s Questionnaires include Scleroderma Health Assessment Questionnaire (SHAQ), Short Form 36 (SF -36), Patient -Reported Outcomes Measurement Information System (PROMIS) -29, and 
University of California, Los Angeles, Scleroderma Clinical Trial Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0.
t Assessment of the presence or absence of tendon friction rubs
u     Additional monitoring may apply for patients with impaired renal and liver fun ction at Visit 2, 3, 4, 5 as needed (see Section 7.6.2 )149
v All patients who discontinue study drug prematurely during the main treatment phase (Week 0 –Week 52) will be invited to come for limited assessments (see Sections 7.1.2.10 and 7.6.2 ).150
                                                
149Per Amendment 1
150Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  152of 167
New text:
Table 7 –1 Schedule of evaluations -amended
Scr Main Treatment Phase  (Double -blind) vLong- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension PeriodSafety  Follow -
up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364
-14
to +2378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
V18 ± 2
Vn ± 1430 +5
Written informed consent X
Inclusion / exclusion criteria
X X
Demographic dataX
Medical and surgical history
X X
Other history (alcohol)X
Smoking historyX X X X X X
Height and weightc
X X X X X X X X
Physical examinationX X X X X X X X
mRSS X X X X X X X
Assessment of Raynaud’s 
attacks XdXeXfXe
Digital ulcer net burden
assessment X X X X X X X X X X X X X X X X X X X X
Tender & swollen joint countX X Xg
Oximetryw
X X X X X X X X X X X X
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  153of 167
Table 7 –1 Schedule of evaluations -amended
Scr Main Treatment Phase  (Double -blind) vLong- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension PeriodSafety  Follow -
up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364
-14
to +2378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
V18 ± 2
Vn ± 1430 +5
Vital signs (BP, HR)hX X X X X X X X X X X X X X X X X X X X X
Vital signs post -dose 
(BP, HR)i,j XiXjXi
BP and HR for assessment 
of orthostatic changesx X X X X X X X
Blood sample for safetyk, u
X X XuXuXuXuX X X X X X X X
Blood sample for PK XlXmXmXmXmXmXnXlXmXmXmXmXm
Blood sample for biomarkers X X Xr
Blood sample for 
Autoantibody screenX
Pregnancy test (if 
applicable)o X X X X X X X X X X X X
12-lead ECGp
X X X X X X X X X
Pulmonary function testsq
X X X X X X X
Skin biopsyX X Xr
Questionnairess
X X X X X X X
Patient’s and physician’s 
global assessmentX X X Xg
Patient interference with skin X X X Xg
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  154of 167
Table 7 –1 Schedule of evaluations -amended
Scr Main Treatment Phase  (Double -blind) vLong- term Extension Phase  
Scr 
PhaseDose -Titration Period Maintenance Period Dose -Titration PeriodOpen -label 
Extension PeriodSafety  Follow -
up
Visit V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12aV13 V14 V15 V16 V17 V18 –Vn
(q 12 wk)TVbSFU
Week -2 0 2 4 6 8 10 12 14 20 26 39 52 54 56 58 60 62 64 –n 
Day -14
to
-10 14 
± 228 
± 242 
± 256 
± 270 
± 284 
± 298 
± 2140 
± 2182 
± 2273 
±14364
-14
to +2378 
± 2392 
± 2406 
± 2420 
± 2434 
± 2448 –(n+84)
V18 ± 2
Vn ± 1430 +5
Tendon Friction Rubst
X X
Randomization (IxRS)X
Dispensation of study drugX X X X X X X X X X X X X X X X X X
Drug accountability X X X X X X X X X X X X X X X X X X
Adverse events recordingX X X X X X X X X X X X X X X X X X X X X
Prior and concomitant 
therapy X X X X X X X X X X X X X X X X X X X X X
Survival statusX
Abbreviations:  BP = blood pressure; ECG = electrocardiogram; TV = Termination Visit; SFU =30-Day Safety Follow -up (30 [+5] days after the last dose of study drug); HR = heart rate; IxRS = 
telephone -based or web -based response system; mRSS = modified Rodnan skin score; PK =pharmacokinetics; q 12 wk = every 12 weeks; Scr = Screening.
Note:  Day 0 (Visit 1) is the baseline visit.
a Visit 12 ( Week 52) is the last visit in the Maintenance Period of the Main Treatment phase and the first (baseline) visit in the Long -term Extension phase.
b To be performed as soon as possible after discontinuation of study medication.  
c Height to be measured only at the screening visit
d Patient to be provided with 7 -day diary, to complete daily for 7 consecutive days leading up to Visit 1 
e Patient and ph ysician assessment of Raynaud’s disease (see Section 7.6.12 )
f Patient to be provided with 7 -day diary, to complete daily for 7 consecutive days le ading up to Visit 8.
g Must not be performed if TV is after V12.
h Blood pressure and heart rate will be measured at all visits with the patient in a sitting position, after the patient has be en at rest for at least 5 minutes.  The same arm is always used for these 
measurements (see Section 7.6.5 ).
i Vital signs to be measured within 20 minutes prior to each post -dose PK sampling ( see Table 7–2)
j Vital signs to be measured within 20 minutes prior to PK sampling (see Table 7–2)
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  155of 167
k Coagulation tests to be performed at a local laboratory
l Samples for PK to be taken 1 –2 hours and 3 –4 hours after the morning dose of study medication (see Table 7–2)
m Sample for PK to be taken up to 1 hour before the morning dose of study medication (trough) (see Table 7–3)
n Samples for PK to be taken up to 1 hour before the morning dose of study medication (trough) and 2 –3 hours after the morning dose of study medication (peak) 
(see Table 7–4)
o For women of childbearing potential only. Serum pregnancy test is required only at screening; pregnancy testing (urine) will be done every 4 weeks and should co ntinue until 30 days after the 
last dose of study drug. When pregnancy testing coincides with a visit, the test should be performed at the site, but otherwi se should be performed at home. 
p Standard ECG (12 -lead ECG) will be recorded with the patient in the supine position, after the patient has been at rest for at least 5 minutes (see Section 7.6.7 ).
q Pulmonary function tests include forced vital capacity (FV C)and diffusion capacity of the lung for carbon monoxide ( DLCO).
r Must be done at a TV if this visit occurs before Visit 8.
s Questionnaires include Scleroderma Health Assessment Questionnaire (SHAQ), Short Form 36 (SF -36), Patient -Reported Outcomes Measurement Information System (PROMIS) -29, and 
University of California, Los Angeles, Scleroderma Clinical Trial Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0.
t Assessment of the presence or absence of tendon friction rubs
u     Additiona l monitoring may apply for patients with impaired renal and liver function at Visit 2, 3, 4, 5 as needed (see Section 7.6.2 )151
v All patients who di scontinue study drug prematurely during the main treatment phase ( Week 0 –Week 52) will be invited to come for limited assessments (see Sections 7.1.2.10 and 7.6.2 ).152
w Oxygen saturation will be measured using forehead pulse oximetry. At visits with blood samples for PK and blood pressure measurements for the assessment of orthostatic changes , post -dose 
measurements will be performed in addition to pre -dose measurements (see Section 7.6.18 , Table 7–2, Table 7–3, Table 7–4)
x Measure supine and sitting blood pressure and heart rate to check for orthostatic changes approximately 2 hours after intake of study medi cation. (see Section 7.6.5 , Table 7–2, Table 7–3, 
Table 7–4).
                                                
151Per Amendment 1
152Per Amendment 4
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  156of 167
7.1.1 Tabulated overview - amended
Oldtext:
Pharmacokinetics sampling flow charts
Profile day (Visit 1 and Visit 12)
1 2 hours after administration of the morning dose of study  medication
3 –4 hours after administration of the morning dose of study  medication
Table 7 –2:  Profile Day PK Sampling (Visit 1 and Visit 12)
Visit 1 and Visit 12 (profile days) Cycle of procedures
Order of 
proceduresStarting point of procedures Time interval (h) 00 00 1 –2 h 3 –4 h
Blood pressure, heart rate X
Administration of morning dose of study 
medication X
Blood pressure, heart rate (within 20 minutes 
prior to PK sample)X
Blood sample for PK X
Blood pressure, heart rate (within 20 minutes 
prior to PK sample)X
Blood sample for PK X
Abbreviations:  h = hours; PK = pharmacokinetic.
Visits 2 to 6 and Visits 13 to 17
Up to 1 hour before administration of the morning dose of study  medication (trough)
Table 7 –3:  PK Sampling (Visits 2 –6 and Visits 13 –17)
Visit 2 to Visit 6 and Visit 13 to Visit 17 Cycle of procedures
Order of 
proceduresStarting point of procedures Time interval (h) 1 h 00 00 00
Blood sample for PK X
Blood pressure, heart rate X
Administration of morning dose of study medication X
Abbreviations:  h = hours; PK = pharmacokinetic.
Visit 11
Up to 1 hour before administration of morning dose of study  medication (trough)
2 3hours after administration of morning dose of study  medication (peak)
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  157of 167
Table 7 –4 PK Sampling (Visit 11)
Visit 11 Cycle of procedures
Order of 
proceduresStarting point of procedures Time interval (h) 1 h 00 00 00 2 –3 h
Blood sample for PK X
Blood pressure, heart rate X
Administration of morning dose of study 
medication X
Blood pressure, heart rate (within 20 minutes 
prior to PK sampling)X
Blood sample for PK X
Abbreviations:  h = hour; PK = pharmacokinetics.
New text:
Pharmacokinetics sampling flow charts
Profile day (Visit 1 and Visit 12)
2 hours after administration of the morning dose of study  medication
3 –4 hours after administration of the morning dose of study  medication
Table 7 –2 Profile Day PK Sampling (Visit 1 and Visit 12)153
Visit 1 and Visit 12 (profile days) Cycle of procedures
Order of 
proceduresStarting point of procedures Time interval (h) 00 001:45 –2 h2h 3 –4 h
At Visit 12 only: oxygen saturation using 
forehead pulse oximetryX
Blood pressure, heart rate X
Administration of morning dose of study 
medication X
At Visit 12 only: oxygen saturation using 
forehead pulse oximetryXa
Blood pressure, heart rate ; at Visit 12 only: 
supine and sitting position Xa
Blood sample for PK X
Blood pressure, heart rate (within 20 minutes 
prior to PK sample)X
Blood sample for PK X
a At Visit 12 only: measure oxygen saturation, blood pressure and heart rate in supine and sitting 
position (see Section 7.6.5 and Section 7.6.18).
Abbreviations:  h = hours; PK = pharmacokinetic.
Visits 2 to 6 and Visits 13 to 17
Up to 1 hour before administration of the morning dose of study  medication (trough)
                                                
153Per Amendment 6
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  158of 167
Table 7 -3 PK Sampling (Visits 2 –6 and Visits 13 –17)
Visit 2 to Visit 6 and Visit 13 to Visit 17 Cycle of procedures
Order of 
proceduresStarting point of procedures Time interval (h) 1 h 00 00 00 2h
Blood sample for PK X
Visit 13 -17 only: ox ygen saturation using forehead 
pulse oximetryX
Blood pressure, heart rate X
Administration of morning dose of study medication X
Visit 13 -17 only: ox ygen saturation using forehead 
pulse oximetryX
Visits 13 -17 only: Blood pressure, heart rate in 
supine and sitting positionX
Abbreviations:  h = hours; PK = pharmacokinetic.
Visit 11
Up to 1 hour before administration of morning dose of study  medication (trough)
2 hours after administration of morning dose of study  medication (peak)
Table 7 –4 PK Sampling (Visit 11)154
Visit 11 Cycle of procedures
Order of 
proceduresStarting point of procedures Time interval (h) 1 h 00 00 00 1:45- 2 h 2 h
Blood sample for PK X
Oxygen saturation using forehead pulse 
oximetryX
Blood pressure, heart rate X
Administration of morning dose of study 
medication X
Oxygen saturation using forehead pulse 
oximetry  Xa
Blood pressure, heart rate in supine and sitting 
position Xa
Blood sample for PK X
aMeasure oxygen saturation, blood pressure and heart rate in supine and sitting position (see 
Section 7.6.5 and Section 7.6.18).
Abbreviations:  h = hour; PK = pharmacokinetics.
                                                
154Per Amendment 6
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  159of 167
7.1.2.4 Visits 7 through to 11 –Main treatment phas e -Maintenance period
Old text:
[…]
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position, after the patient has been at 
rest for at least 5 minutes.  The same arm is always used for these measurements (See 
Section 7.6.5)
[…]
New te xt:
[…]
Oxygen saturation measurement using forehead pulse oximetry at Visits 9 and 10 
only. At Visit 11 only , oxy gen saturation will be measured before and after intake of 
study  drug ( see Section 7.6.18, Table 7 –2, Table 7 –3, and Table 7 –4)
Vital signs (b lood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position, after the patient has been at 
rest for at least 5 minutes.  The same arm is always used for these measurements (See 
Section 7.6.5)
Assessment of orthostatic changes: measure blood pressure and heart rate in supine 
position and sitting position approximately  2 h after intake of stud y drug (Visit 11 
only, see Section 7.6.5).
[…]
7.1.2.5 Visit 12 (Week 52)
Old text:
[…]
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position, after the patient has been at 
rest for at least 5 minutes.  The same arm is always used for these measurements (See
Section 7.6.5)
[…]
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  160of 167
New text:
[…]
Oxygen saturation will be measured before and after intake of study  drug (see 
Section 7.6.18, Table 7 –2, Table 7 –3, and Table 7 –4)
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position, after the patient has been at 
rest for at least 5 minutes.  The same arm is always used for these measurements (See 
Section 7.6.5)
Assessment of orthostatic changes: measure blood pressure and heart rate in supine 
position and sitting position approximately  2 h after intake of stud y drug (see 
Section 7.6.5).
[…]
7.1.2.6 Visits 13 through to 17 –Long -term extension phase -Dose -titration 
period 
Old text:
[…]
Vital signs (blood pressure and he art rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position, after the patient has been at 
rest for at least 5 minutes.  The same arm is always used for these measurements (See 
Section 7.6.5)
[…]
New text:
[…]
Oxygen saturation will be measured before and after intake of stud y drug (see Section 
7.6.18, Table 7 –2, Table 7 –3, and Table 7 –4)
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the pat ient in a sitting position, after the patient has been at 
rest for at least 5 minutes.  The same arm is always used for these measurements (See 
Section 7.6.5)
Assessment of orthostatic changes: measure blood pressure and heart rate in supine 
position and s itting position approximately  2 h after intake of stud y drug (see 
Section 7.6.5).
[…]
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  161of 167
7.1.2.7 Visits 18 through Visit n (every 12 weeks) –Long -term extension 
phase – Open- label extension period 
7.1.2.8 Termination Visit
7.1.2.9 Safety follow -up visit 
The following change applies to all sections mentioned above.
Old text:
[…]
Vital signs (blood pressure and heart rate).  Blood pressure and heart rate will be 
measured at all visits with the patient in a sitting position, after the patient has been at 
rest for at least 5 minutes.  The same arm is always used for these measurements (See 
Section 7.6.5)
[…]
New text:
[…]
Oxygen saturation measurement using forehead pulse oximetry  (see Section 7.6.18).
Vital signs (blood pressure and heart rate).  Blood press ure and heart rate will be 
measured at all visits with the patient in a sitting position, after the patient has been at 
rest for at least 5 minutes.  The same arm is always used for these measurements (See 
Section 7.6.5)
[…]
7.4 Pharmacokinetics / pharma codynamics –amended
Old text:
Profile day (Visit 1 and Visit 12)
1 2 hours after administration of the morning dose of study  medication
3 –4 hours after administration of the morning dose of study  medication
Visits 2 through to 6 and Visits 13 through to 17
Up to 1 hour before administration of morning dose of study  medication (trough)
Visit 11
Up to 1 hour before administration of morning dose of study  medication (trough)
2 3hours after administration of morning dose of study  medication (peak)
New text:
Profile day (Visit 1 and Visit 12)
2 hours after administration of the morning dose of study  medication
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  162of 167
3 –4 hours after administration of the morning dose of study  medication
Visits 2 through to 6 and Visits 13 through to 17
Up to 1 hour before administration of morning dose of study  medication (trough)
Visit 11
Up to 1 hour before administration of morning dose of study  medication (trough)
2 hours after administration of morning dose of study  medication (peak)
7.6.5 Blood pressure and heart rate measurement
New text was added in the end of the section.
New text:
Assessment of orthostatic changes 
To assess orthostatic changes, blood pressure and heart rate will be measured with the patient 
in a supine position, after the patient has rested for 5 minutes. Immediatel y thereafter, the 
patient should sit up and blood pressure and heart rate will be mea sured after the patient has 
rested for 2 minutes.
These measurements should be performed approximately  2 hours after study  medication 
intake.
Frequency : Visit 11 (Week 39), Visit 12 (Week 52), during the dose -titration period of the 
long-term extension phase (Visits 13 to 17).
7.6.18 Oxygen saturation measurement using forehead pulse oximetry 
Section was newly inserted with Amendment 6.
New text:
Oxygen saturation measurements will be performed in all subjects using non -invasive 
forehead pulse oximetry  expressing the SpO2 (peripheral ox ygen saturation) percentage. At 
visits with blood pressure measurements to assess orthostatic changes, ox ygen saturation will 
be measured pre -dose and post -dose (see Table 7 –2, Table 7 –3, and Table 7 –4). At all other 
visits, ox ygen saturation will be measured pre -dose only . 
If the patient receives supplemental ox ygen, the amount [L /min] will be recorded in the 
eCRF.
Frequency : Visit 9 (Week 20), Visit 10 (Week 26), Visit 11 (Week 39), Visit 12 (Week 52), 
Visits 13 to 17 (Week 54 to 62), Visit 18 to Visit n (Open- label Extension Period), 
Termination Visit, and 30- day Safet y Follow -up.
8.4.3 Safety 
Old text:
[…]
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  163of 167
Descriptive anal ysis of vital and their changes from baseline will be performed by  treatment 
group and visit.
New text:
[…]
Descriptive anal ysis of vital signs and their changes from baseline will be performed b y 
treatment group and visit. Descriptive statistics of pulse oximetry  and blood pressure/heart 
rate measurements for the assessm ent of orthostatic changes will be performed by treatment 
group and visit .
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  164of 167
13.5 Amendment 7
Amendment 7is presented using a different approach to the previous amendments of this 
protocol . The rationale for changes in this amendment and all affected sections ar e provided 
in the “Protocol Amendment Summary  of Changes Table” at the beginning of this document 
directly  before the Table of Contents .The old/new text section detail ing the changes 
compared to the last global CSP version has been replace d with a document edited intrack 
change mode showing all changes, this document is available on request.
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  165of 167
14. Appendices
14.1 Child -Pugh Classification of Liver Disease
Factor +1 +2 +3
Bilirubin (mg/dL) < 2 2 – 3 > 3
Albumin (g/dL) > 3.5 2.8 – 3.5 < 2.8
International Normalized 
Ratio< 1.7 1.7 – 2.3 > 2.3
Ascites None Mild Moderate / Severe
Encephalopathy NoneGrade I –IIor 
medically controlledGrade III –IV or 
poorly controlled
Child- Pugh Class A B C
Points 56 7 – 9 10 15
Source:  Pugh RN, Murray -Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the 
oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646 -649.[38]
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  166of 167
14.2 Definition of Sy stemic Sclerosis Renal Crisis -amended
Scleroderma renal crisis is defined as the new onset of severe h ypertension associated with a 
rapid increase in serum creatinine concentration, microangiopathic hemoly tic anemia, or both 
[39]155. Systemic sclerosis renal crisis usually  manifests with acute onset of moderate- to-
severe ‘accelerated’ h ypertension and oliguric renal failure [40].
The definition of s ystemic sclerosis hy pertensive renal crisis is independent of whether or not 
concomitant antihypertensive medications are used.
History  of new -onset hypertension, based on any  of the following (measurements repeated 
and confirmed at least 2 hours apart within 3 day s of first event- associated observation, with a 
change from baseline*). As a reminder, renal crisis is defined as meeting the first 4 sign s:
1. S ystolic blood pressure (SBP) ≥ 140 mmHg
2.Diastolic blood pressure (DBP) ≥ 90 mmHg
3.Rise in SBP ≥ 30 mmHg compared to baseline
4.Rise in DBP ≥ 20 mmHg compared to baseline
*Historical baseline blood pressure of the patient
AND
At least 1 of the following 5 features:
1.Serum Creatinine: increase of ≥ 50% above baseline*
2.Proteinuria: ≥ 2+ by  dipstick confirmed by  protein: creatinine ratio > ULN
3.Hematuria: ≥ 2+ b y dipstick or > 10 RBCs/H igh Power Field (HPF)(without 
menstruation)
4.Thrombocy topenia: < 100,000 pl atelets/mm3
5.Hemoly sis: by  blood smear or increased reticulocyte count
*Historical baseline creatinine of the patient
                                                
155References 39 and 40 added per Amendment 1
Integrated Clinical Study Protocol
No. BAY 63-2521 / 16277
17 APR 2018 Version 6.0 Page:  167of 167
14.3 Tender and Swollen Joint Count Assessment Form
TENDER & SWOLLEN JOI NT COUNT ASSESSMENTS
Left Right
Swollen Tender Swollen Tender
Shoulder
Elbow
Wrist
MCP 1
         2
         3
         4
         5
PIP   1
         2
         3
         4
         5
Knee
Subtotal
TOTAL Swollen Tender
0 = Absent     1 = Present     9 = Replaced/N.A.*
*Injected joints will not be assessed for a period of one month (30 days) and will be documented as 
“Replaced/N.A.”